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Chelating diphosphine ligands have been prepared for two main applications: cytotoxic 
Ru complexes and organopalladium alkylation catalysts. By applying rational design ideas 
to the ligand targets, the desired properties of the resulting metal complexes have been 
achieved. 
Ruthenium diphosphine complexes derived from [RuCl(DMSO-S)2(cis-tach)]Cl (2.1) have 
been synthesised and assessed as cytotoxic agents by physical inorganic measurements, in 
vitro assays, and imaging techniques. The structures of the diphosphine ligand backbone 
and metallacycle size both have a significant influence on cytotoxicity. Therefore, 
diphosphines have been specifically designed to be capable of interacting with DNA by 
intercalation. Complexes with flexible aliphatic backbones (2.7-2.8) or planar aromatic 
backbones (2.17-2.19) are the most active, and we have demonstrated cytotoxicity may be 
the result of multiple mechanisms.  
The diphosphine bis((diphenylphosphino)methyl)glycine L3.1 is a versatile amide coupling 
partner with a variety of aryl and alkyl amines, producing fluorescent ligand conjugates. 
In addition, L3.1 forms a Ru chelate complex [RuCl(cis-tach)(L3.1)]Cl (3.1) which serves as 
a Ru precursor to fluorescent complex conjugates by coupling of the carboxylic acid 
functional group. The photophysical properties of the resulting diphosphine ligands and 
Ru complex conjugates have been assessed, and the methodology has been applied to 
other fluorescent, therapeutic agents. The cytotoxicity of a pyrene complex conjugate 
[RuCl(cis-tach)(L3.2)]Cl (3.3) has been investigated in collaboration with the University of 
York and compared to (cis-tach)Ru complexes 2.17-2.19. Changing from an all-carbon 
backbone to a PCNCP backbone does not have a detrimental effect on cytotoxicity and 
provides a useful point of derivatisation for metal diphosphine drug conjugates. 
A series of primary, secondary, and tertiary 1-pyrenylphosphines L4.1-L4.3 has been 
synthesised. The luminescence and air stability properties of these ligands and their 
associated (arene)Ru complexes have been investigated and it was found that phosphine 
oxidation increases fluorescence quantum yield, whereas Ru coordination dramatically 
quenches emission. The resistance to air-oxidation of 1-pyrenylphosphines has been 
explored experimentally and by computational studies on the phosphine radical cations. 
A series of aminophosphine pincer ligands L5.1-L5.9 have been synthesised and their 
derived organopalladium complexes with both symmetric (5,5- and 6,6-) and non-
symmetric (5,6-) metallacycles were prepared. The ligands that form non-symmetric 
metallacycles have been shown to have a dramatic impact on the Pd coordination 
chemistry. When applied as catalysts in allylic alkylation reactions, the larger 5,6- and 6,6-
metallacycles show superior catalytic activity to the widely studied 5,5-metallacyclic 
systems. By optimising the reaction, we have found organopalladium catalysts that 
perform allylation of dimethylmalonate with high activity and excellent linear selectivity 
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2 
This thesis describes discoveries in the applications of metal-phosphine complexes in two 
quite different areas of research: chemotherapy and homogeneous catalysis. For this 
reason, this Introduction contains elements for both of these aspects to provide context 
for the experimental results given in subsequent chapters. 
There is a consistent drive to improve the safety and efficacy of cancer treatments and 
make them available to as many patients as possible. In 2018, there were 17 million new 
cases of cancer worldwide, which is predicted to rise to 28 million per year by 2040.1 To 
help address this issue, industry and academia are developing metal-based 
chemotherapeutics with various modes of action to overcome the problems associated 
with the toxic side effects and emerging resistance that are prevalent in cancer treatment 
today.  
There is currently an imperative to develop sustainable production processes for bulk and 
fine chemicals and catalysis will undoubtably have a pivotal role to play in achieving this 
objective. For over half a century, phosphorus(III) ligands have been central to the 
development of metal complex catalysts for a plethora of chemical transformations. Four 
Nobel Prizes in chemistry have been awarded for innovations in which phosphorus(III) 
ligands have played a significant part in their success: in 2001 (Knowles and Noyori) for 
asymmetric hydrogenation;2 in 2005 (Chauvin, Grubbs and Schrock) for olefin metathesis 
methods;3,4 in 2010 (Heck, Negishi and Suzuki) for Pd-catalysed cross-coupling;5,6 and in 
2016 (Sauvage, Stoddart and Feringa) for molecular machines.7,8 This impressive record 
of success is partly due to the tunability of phosphorus(III) ligands, whereby the 
stereoelectronic properties can be modulated to tailor the ligand by judicious choice of P-
substituents.  
There are important examples of metal complexes of P(III) ligands used in medicine 
including clinically approved pharmaceuticals (Figure 1.1). One of the most widely used 
radioisotopes in modern medicine is 99mTc, known as the “Workhorse of Diagnostic 
Nuclear Medicine”.9 Myoview is an important heart imaging agent, based on a [99mTcO2] 
core with two coordinated tetrafosmin diphosphine ligands. This bidentate P(III) ligand 
has been specifically selected to confer the required lipophilicity and bioavailability that 
makes Myoview so effective in myocardial perfusion imaging.10 
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Figure 1.1. Chemical structures of phosphine containing pharmaceuticals. 
Auranofin is a Au(I) compound that received FDA approval for the treatment of 
rheumatoid arthritis in 1985. Following the clinical success of auranofin, the development 
of Au–phosphine complexes for therapeutic applications, including anti-cancer agents, 
has accelerated. Auranofin is a key candidate for drug repurposing and has since been 
investigated for its activity against leukaemia, ovarian cancer, and microbial infections.11  
1.1 Metals in medicine 
1.1.1 Cytotoxic Pt complexes 
Since its serendipitous discovery in 1965 by Rosenberg, cisplatin has become one of the 
most broadly administered chemotherapeutics.12 Following the success of cisplatin, 
second and third generation Pt therapies (carboplatin and oxaliplatin respectively) have 
been developed with six derivatives in total gaining clinical approval worldwide (see 
Figure 1.2).13–16 Around 50% of all cancer patients who require chemotherapy receive at 
least one form of Pt-based therapy.17 Due to its consistent and widespread use, coupled 
with high toxicity (cisplatin cannot differentiate between cancerous cells and non-
cancerous cells), Pt-based therapy can be considered a palliative treatment for many types 
of cancer, rather than a cure.18 While the development of Pt-based therapies remains an 
active area of research, the continued use of these drugs is constrained by dose-limiting 
side effects, such as nephrotoxicity, neurotoxicity, and ototoxicity, due to a lack of 
selectivity for cancer cells.19 For example, it has been reported that between 40–80% of 
all adults and 50% of children treated with cisplatin develop permanent hearing loss.20 
Another disadvantage for the persistent use of cisplatin is the propensity for cancers to 
mutate and acquire resistance. 
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Figure 1.2. Chemical structures of clinically approved Pt complexes. 
The mechanism of action for cisplatin is widely believed to be as follows (Figure 1.3).21,22 
First, introduction of cisplatin into the blood stream occurs via intravenous 
administration. The chloride concentration in the blood is high (100 mM) and hence 
aquation of the Pt–Cl bond is suppressed. It is then understood that cisplatin is 
transported into the cell by passive and facilitated diffusion. Once inside the cell, the lower 
chloride concentration (20 mM) allows aquation of one, or both Pt–Cl bonds. 
Deprotonation of the Pt–OH2 complex to give the less reactive Pt–OH species can 
occur.23 Another important deactivation mechanism involves S-coordination of 
glutathione (GSH), increased expression of which is associated with cisplatin resistance.19 
Overall, only a small percentage of the administered Pt reaches its target: the cell nucleus. 
Once inside the nucleus, the mono-aqua species cis-[PtCl(NH3)2(OH2)]
+ is substituted at 
the site of the coordinated water ligand by a DNA base, primarily at the N7 site of guanine 
residues.24 Once the DNA is platinated, substitution of the labile chloride ligand with a 
second DNA base forms the active Pt-DNA metallacycle, with intrastrand 1,2-d(GG) 
cross-linking predominating. Although duplex DNA platination is thought to be the 
primary mode of action, most of the Pt does not end up bound to DNA and the 
remainder are likely a major cause of the cytotoxicity through binding to other cellular 
targets.  
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Figure 1.3. Primary mechanism of cell death by covalently binding to DNA via 
intrastrand 1,2-d(GG) cross-linking.  
The emergence of Pt-resistant cancers has necessitated the development of alternative 
therapies. Generally, resistance mechanisms fall into one of two categories: (i) those that 
limit the formation of Pt-DNA adducts; or (ii) those that prevent cancer cell death 
following Pt-DNA adduct formation. For comprehensive reviews of metal based 
anticancer agents, see the work of Bonsignore, Capellá and McFarland.25–27 The use of 
different metals will enable the development of anti-cancer agents that present alternative 
modes of action and diverse interactions with biomolecules, and therefore, may overcome 
the limitations of Pt-based therapy.9 The next section details the most widely studied non-
Pt, metal-based anticancer compounds: cytotoxic Ru complexes.  
1.1.2 Cytotoxic Ru complexes 
The first ruthenium complex tested for its anti-tumour properties was a ruthenium 
analogue of cisplatin, fac-[RuCl3(NH3)3] (1.1, Figure 1.4).
28 The compound was found to 
inhibit cell division in E. coli which served as an initial proof-of-concept for the activity. 
Further development of this compound was halted due to its poor aqueous solubility and 
attention was directed towards ionic compounds with more halide ligands to improve 
aqueous solubility.29 
The results of the initial phase I/II clinical trials of NAMI-A (1.2) were reported by Leijen 
et al. in 2015.30 Following this, Keppler et al. published the synthesis and activity of 
indazolium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (KP1019, 1.3) and the 
more aqueous-soluble sodium salt (NKP-1339, 1.4).31 The phase I clinical trials were 
successfully completed and noted very promising anticancer activities with low general 
toxicity and very limited adverse side effects. One useful feature of Ru(III) complexes 1.2-
Chapter 1. Introduction 
6 
1.4 is that they are chemically inert and can be reduced to their more cytotoxic Ru(II) 
analogues in the hypoxic environment of tumour cells. This ‘activation-by-reduction’ 
approach has been exploited as a drug delivery method.28,32 
 
Figure 1.4. Chemical structures of early Ru anti-cancer agents. 
Many studies have explored transport of Ru in vivo, thought to be facilitated by Fe 
transporters. Due to the similarities that Ru shares with Fe because of its position in the 
periodic table, Ru readily binds to nitrogen and sulfur donors and can therefore be 
transported by serum albumin and transferrin proteins. As the surface of cancer cells have 
a high concentration of transferrin receptors, Ru compounds target cancer cells and 
bypass non-cancer cells leading to a clear increase in selectivity and reduced toxicity.31,33,34 
The field of inorganic chemotherapeutics is constantly developing compounds with 
increased anti-tumour activity and reduced side-effects. Broadly, the cytotoxic Ru 
complexes that are under development today can be divided into three categories: (i) Ru–
arene complexes; (ii) Ru half-sandwich complexes; (iii) Ru–polypyridyl complexes. All 
three of these categories of complexes are discussed below.  
1.1.2.1 Ru–arene complexes 
Organoruthenium complexes containing a facially capping arene ligand have been widely 
researched, notably by the groups of Sadler and Dyson, as well as many others.35,36 In 2001, 
the first examples investigated for their anticancer activity by Dyson et al. contained an η6-
p-cymene ligand which provided a robust hydrophobic face to the molecule, and a 1,3,5-
triaza-7-phospha-tricyclo-[3.3.1.1]decane (PTA) ligand to provide good aqueous solubility 
(1.5).37 Due to their modular synthesis, many variants (>30) of these so-called RAPTA 
(Ruthenium-Arene-PTA) complexes 1.5 have been tested and they constitute one of the 
most promising classes of ruthenium anti-cancer drugs currently progressing through 
clinical trials.33,38 Gasser et al. recently reported light-activated RAPTA derivatives bearing 
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azido ligands.39 In aqueous conditions, the complexes are inert, but under irradiation (λ = 
450 nm), slowly release the azido ligand, at which point an increase in toxicity in human 
cervical carcinoma (HeLa) cells under light exposure was observed. 
Concurrently, Sadler et al. reported on the tumour growth inhibition by a series of 
ruthenium biphenyl complexes with a chelating diamine ligands, (RAen complexes, such 
as 1.6, Figure 1.5).40,41 
 
Figure 1.5. Original (arene)Ru complexes studied by Dyson and Sadler. 
Loss of the arene ligand has been observed in some RAPTA complexes, although the 
contribution of this to the activity has not been elaborated.33,42 While these complexes can 
covalently bind to DNA, studies have shown that the main mechanisms of cytotoxicity 
involve interactions with proteins, in a similar manner to NAMI-A (1.2).38,43–45 
Larrosa and co-workers have recently investigated an (η6-p-cymene)Ru arylation catalyst. 
It was shown that at elevated temperatures (80 °C) the bound η6-arene ligand 
decoordinates rapidly and through a series of kinetics experiments it was found that free 
p-cymene inhibits the directed arylation catalysis.46 This observation makes it feasible that 
η6-arene dissociation at physiological temperature takes place to some degree. 
1.1.2.2 Half-sandwich organoruthenium complexes 
Based on the established cytotoxic properties of the above (arene)Ru complexes, Alessio 
et al. studied structure-activity relationships (SARs) to establish whether the η6-arene 
ligand is essential for biological activity. They focused on complexes where the arene 
ligand was replaced with a neutral 6-electron donor such as 1,4,7-trithiacyclononane 
([9]aneS3, 1.7) and 1,4,7-triazacyclononane ([9]aneN3, 1.8) (Figure 1.6). The compounds 
bearing a [9]aneS3 and chloride ligand 1.7 showed moderate activity in vitro against breast 
carcinoma (MDA-MB-231), for NN = 1,2-diaminoethane (IC50 = 80 µM) and NN = 1,2-
diaminocyclohexane (IC50 = 124 µM). These N-ligand complexes were around 10 times 
less active than the analogous (arene)Ru complex (1.6, IC50 = 10 µM).
47,48 
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Figure 1.6. Chemical structures of representative Ru complexes of [9]aneS3 and [9]aneN3, 
Alessio et al.48 
Despite this reduced activity compared to (arene)Ru complex 1.6, it was argued that the 
features required for cytotoxicity are still present in some of these complexes: (i) a Ru–Cl 
bond that can undergo rapid aquation, and (ii) the ability for the chelating ligand NH2 
groups to form hydrogen bonds that could stabilise interactions with biomolecules. The 
complexes with [9]aneN3 that retained one DMSO ligand in the coordination sphere were 
found to be inactive up to the concentrations tested (IC50 > 300 µM).
48 
1.1.2.3 Ru–polypyridyl complexes 
Cytotoxic Ru–polypyridyl complexes have been developed due to their favourable DNA 
binding and photophysical properties. The field has been the subject of many recent 
reviews.18,26,49,50 Most studies on metal-based chemotherapeutics have concentrated on 
irreversible DNA binding (see Section 1.1.1). Many Ru–polypyridyl complexes are of 
interest due to their ability to reversibly bind DNA via three main mechanisms: (i) 
intercalation of the planar aromatic ligands in between DNA base pairs, (ii) binding of the 
complex within the major or minor groove of the DNA double helix, and (iii) external 
binding of positively charged drugs to the negatively charged phosphate backbone.51 
Alessio et al. reported Ru–terpyridine complexes 1.9 that adopt a meridional configuration 
and found a correlation between lipophilicity and potency (Figure 1.7). The aquation rate 
constants for these complexes (2.0 – 9.7 ×10–3 s–1) did not correlate with the Ru–Cl bond 
lengths, possibly indicating some degree of an associative interchange (Ia) pathway for 
aquation. This mechanism has also been suggested for [(arene)RuCl(en)]+ complexes, 
such as 1.6.50 The rate constants for aquation of the Pt–Cl bonds in cisplatin are of the 
order of ~10–5 s–1, notably slower than for 1.9.50,52 The (Ph-tpy)Ru complexes (1.9) can 
interact with DNA, both by covalent binding and by intercalation (Figure 1.8). For these 
derivatives, binding to calf thymus (CT)-DNA was found to be moderate to strong, as 
indicated by the binding constants determined (Kb ~ 10
3 – 105 M–1). 
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Figure 1.7. Chemical structures of representative Ru–polypyridyl complexes. 
The main mode of action studied for polypyridyl complexes is DNA intercalation, which 
was initially reported by the groups of Barton and Sauvage for [Ru(bpy)2(DPPZ)]
2+ 
(DPPZ = dipyrido[3,2-a:2',3'-c]phenazine).53–55 Complexes of the type depicted in Figure 
1.7 (1.10) were shown to have a high binding affinity for DNA (binding constants, Kb ~ 
106 M–1).56,57 They also display luminescence upon addition of DNA due to the highly 
conjugated ligand structures. The increase in luminescence emission intensity from these 
complexes is only observed after DNA addition; thus, the term ‘light-switch effect’ was 
coined for complexes of this type. Ru–polypyridyl complexes have been developed for 
use in photodynamic therapy (PDT) and photochemotherapy (PCT).26,58–63  
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Figure 1.8. Representation of the different binding modes of 1.9 with DNA, adapted 
from reference 50. 
The first of this class of compounds to enter human clinical trials was TLD1433 (1.11) 
which contains a terthienyl chromophore.26 In 2020, the company that produce TLD1433, 
Theralase Technology, were granted FDA approval for a Fast-Track Phase II clinical trial 
in non-muscle invasive bladder cancer (NMIBC).64 A Fast-Track Designation can lead to 
accelerated approval and priority review; therefore, if the trial meets the criteria, TLD1433 
could become the first patient-specific Ru-based PDT to gain FDA approval. Moreover, 
it would be the first clinically approved Ru-based chemotherapy agent.  
In a recent development, Theralase Technology have commenced research at the in vitro, 
preclinical stage, utilising Photodynamic Compounds (PDC), specifically TLD1433 for 
vaccine development against SARS-CoV-2.65 If the initial in vitro, and subsequent small 
animal in vivo studies are successful, Theralase could commence human clinical studies in 
2021, using TLD1433 to tackle coronavirus. This highlights the power of drug 
repurposing in the fight against infectious diseases. Complexes, such as TLD1433 (1.12), 
where the metal acts as a central scaffold to which active ligands are conjugated and 
ancillary ligands are used to modulate cellular uptake warrant further study. 
1.2 Ruthenium cis-tach complexes 
With most cytotoxic Ru drug candidates comprising either arene or polypyridyl ligands, 
there is a wide scope for investigating purely coordination, heteroleptic complexes. There 
is literature precedent for using the neutral tridentate ligand cis,cis-1,3,5-
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triaminocyclohexane (cis-tach) as a facially capping ligand for various metal centres. There 
are three main reasons for using cis-tach as a facially capping ligand for biological 
applications: (i) the amine groups improve the water solubility of the metal complexes 
and may aid binding by forming hydrogen bonds with biomolecules; (ii) the amine groups 
are good σ-donors and therefore have a large trans effect; (iii) the cyclohexane ring 
provides a hydrophobic face to the complex, giving steric protection to the hydrophilic 
metal centre.  
1.2.1 Synthesis of cis-tach complexes 
The synthesis of cis-tach from cis,cis-1,3,5-cyclohexanetricarboxylic acid, originally 
reported by Brechbiel et al., and later by Cronin and co-workers involves formation of the 
tris(benzylcarbamate) as the Curtius rearrangement product.66,67 The carbamate groups are 
cleaved by hydrobromic acid to give cis-tach.3HBr. The free amine ligand is obtained as a 
hygroscopic, crystalline solid by treatment of cis-tach.3HBr with an anion exchange resin 
followed by purification by sublimation (Scheme 1.1).  
 
Scheme 1.1. Synthesis of cis-tach.66,67 
When in solution, the cyclohexane ring of the cis-tach ligand adopts a conformation that 
makes all the amine substituents equatorial. When cis-tach is treated with suitable metal 
precursors, it can undergo a ring-flip, whereupon the amine substituents are all in an axial 
position and the metal centre becomes one of the vertices of an adamantane-type 
structure (Scheme 1.2). The cis-tach provides a robust platform for the synthesis of 
chemically diverse metallodrugs. A report has highlighted the lack of 3D complexity in 
pharmaceuticals (e.g., C(sp3)-rich molecules).68 Recently, a library of metal-based 
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fragments has been developed that cover a larger region of 3D chemical space than purely 
organic compounds.69 
The amine groups of cis-tach are readily functionalised by condensation with aldehydes, 
resulting in tridentate imine ligands (Scheme 1.2).70,71 The imine substituents can contain 
coordinating groups (such as pyridyl, see Scheme 1.3) generating a hexadentate ligand or 
the groups may be non-coordinating (see examples from Cronin and Walton, Figure 1.9). 
 
Scheme 1.2. Coordination of cis-tach to a metal centre and condensation with aldehydes 
to form a tridentate imine ligand. 
1.2.2 Coordination chemistry of cis-tach 
The versatility of cis-tach has enabled the synthesis of many mononuclear complexes 
containing different metal ions (Figure 1.9). The first metal cis-tach complexes took the 
form [M(cis-tach)2]
n+ (M = Ni, Co, Rh, 1.12) and were analogues of organometallic 
sandwich complexes.72 Following these initial discoveries, Erickson et al. reported a 6-
coordinate Pt(IV) complex bearing a coordinated bipyridine and cis-tach ligand (1.13).73 
The acid dissociation properties of the NH2 groups of the cis-tach ligand were studied but 
activity against cancer cells was not explored. 
A Cu(I) complex bearing the unusual cis,cis-1,3,5-tris(2-fluoro-6-
(trifluoromethyl)benzylideneamino)cyclohexane ligand (1.14) was reported by Wass et al. 
and was shown to reversibly bind ethylene under mild conditions.74 Several Zn, Co and 
Cu complexes with cinnamaldehyde functionalised cis-tach ligands were reported by the 
Walton75 (1.15) and Cronin67 (1.16) groups. These complexes were investigated as a model 
system for carbonic anhydrase due to the similarities between the metal coordination 
environment and the active site of the enzyme.67,75 The cytotoxicity of complexes 1.12-
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1.16 has not yet been reported. Fontaine and co-workers reported the synthesis and solid-
state characterisation of Pt(II) complexes containing phosphine-substituted cis-tach 
ligands (1.17).76 
 
Figure 1.9. Chemical structures of previously reported metal cis-tach complexes, 1.12-1.17.  
1.2.3 Cytotoxicity of cis-tach complexes 
Many cis-tach derivatives and other chelators are of interest for their cytotoxic 
properties.77–81 The tachpyr ligand 1.18 (a 2-pyridylmethylene substituted cis-tach 
derivative) has been tested against MBT2 and T24 bladder cancers as well as A549 lung 
adenocarcinoma cells. The effectiveness of these compounds is attributed to the fact that 
rapidly growing cancer cells metabolise iron faster than non-cancerous cells, and the 
tachpyr ligand can efficiently bind Fe(II) ions (Scheme 1.3).77,80 When the NH groups of 
tachpyr were substituted with methyl or ethyl groups, these derivatives could not bind 
Fe(II) ions and were found to be non-cytotoxic, consistent with iron depletion in tumour 
cells being involved in the mechanism of action.  
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Scheme 1.3. Binding of tachpyr (1.18) to Fe(II) ions in vivo. 
In 2013, Lynam et al. reported the synthesis of a new class of Ru half-sandwich complexes 
resulting from the reaction of cis-tach and cis-[RuCl2(DMSO)4] (Scheme 1.4). The labile 
complex [RuCl(DMSO-S)2(cis-tach)]Cl (1.19) is the precursor to complexes with 
commercially available bidentate amine or phosphine ligands (Scheme 1.5).82 Their study 
concerned the influence of the cis-tach and chelating ligands on features such as the Ru–
Cl bond length, and compared these to the (arene)Ru analogues. It was demonstrated that 
cis-tach is a strong σ-donor, as would be expected due to the three nitrogen donors 
coordinated to the metal.  
 
Scheme 1.4. Synthesis of [RuCl(DMSO-S)2(cis-tach)]Cl (1.19).
82 
Interestingly, it was found that reaction of 1.19 with diamines yielded dicationic complexes 
retaining one DMSO ligand, whereas treatment of 1.19 with diphosphines gave complexes 
with a chloride ligand bound.I It was reasoned that the electron-rich Ru(cis-tach)(diphos) 
moiety may promote aquation of the Ru–Cl bond which might then result in enhanced in 
vitro activity.81,83  
 
I A similar phenomenon is observed with the [9]aneS3 and [9]aneN3 derived complexes reported by Alessio 
et al. (see Figure 1.6). 
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Scheme 1.5. Synthesis of N,N-chelate (1.20) and P,P-chelate complexes (1.21) previously 
reported (N,N- = bipyridine, phenanthroline, ethylenediamine; P,P- = dppm, dppe, dppp, 
dppb, dppv, dppbz).82 
In recently published work, we have found that the P,P-chelate complexes (1.21) are 
cytotoxic, whereas the N,N-chelate complexes (1.20) are not.84,85 For further details of the 
investigation of the anti-proliferative properties of (cis-tach)Ru complexes, see Chapter 2.  
1.3 Metallodrug conjugates 
1.3.1 Targeted therapy 
It can be advantageous to covalently conjugate a metallodrug with a biomolecule that 
confers specific targeting functionality. Multitargeted complexes have been designed to 
overcome some of the main limitations associated with Pt-based therapy. For example, 
due to the Warburg effect, cancer cells rely much more heavily on anaerobic glycolysis 
than non-cancerous cells.86–89 Therefore, many Pt(II) drugs conjugated with carbohydrates 
have been developed that target the glucose transporter (GLUT) membrane proteins 
which are overexpressed on the surface of cancer cells.90 Several Pt(II) drugs conjugated 
with biomolecules have been developed that target receptors for testosterone, estrogen, 
folate, somatostatin, epidermal growth factor (EGFR), and integrins. These complexes, 
highlighted in the recent review by Marmion et al.,87 have been specifically designed to 
overcome dose-limiting, toxic side effects and circumvent resistance, while increasing 
therapeutic efficacy. Many Pt(IV) prodrugs decorated with targeting groups are also 
known.91–93 
The first targeted Ru-based chemotherapy agents were derivatives of the biologically 
active molecule staurosporin (1.22), reported by Meggers et al.94 The Ru centre was not 
found to be biologically active and simply acted as an appropriate scaffold for the 
bioactive ligand. In another approach, the Keppler group developed Ru complexes with 
cyclin-dependent-kinase (CDK) inhibiting paullone ligands (1.23) that showed 
intercalative binding with DNA (Figure 1.10).95 Following this, many of the subsequent 
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examples of targeted cytotoxic Ru agents were based on the heavily studied (arene)Ru 
complexes reported by Sadler and Dyson (see Section 1.1.2.1). Many proteins that are 
upregulated in cancer cells have been the targets of such complexes (see Marmion et al.87).  
 
Figure 1.10. Chemical structures of Ru staurosporin derivative (R)-DW12 (1.22) and 
CDK-inhibiting Ru paullone derivative (1.23). 
Targeted conjugates of Ru polypyridyl complexes have been reported. For example, 
TLD1433 (1.11) which contains a terthienyl chromophore has been shown to be an 
effective PDT agent and is progressing through Phase II clinical trials.26,96 Recently, 
peptide-conjugated Ru(II) complexes featuring the [9]aneS3 facially capping ligand were 
reported by Metzler-Nolte et al. (Figure 1.11).97 The hexapeptide sequence neurotensin 
(RRPYIL) was conjugated to a 2-(2'-pyridyl)pyrimidine-4-carboxylic acid (cppH) ligand  
via amide bond formation to give 1.24. The stereochemical features of the complexes 
were investigated in aqueous and organic media, but unfortunately the compounds were 
found to be non-cytotoxic against colon adenocarcinoma (HT-29), breast cancer (MCF-
7) and pancreatic cancer (PT-45) cells.  
 
Figure 1.11. Chemical structure of [([9]aneS3)RuCl(cppH-RRPYIL)]+ (1.24).97 
The ability to chemically conjugate a chelating ligand, such as a diphosphine, with a 
biomolecule (or other small molecule) is desirable for applications in biological imaging, 
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therapy, and catalysis. By chemically modifying an ancillary ligand with an organic 
fluorophore, the resulting fluorescent complexes can lead to an understanding of the 
biological modes of action.98,99 The following Section gives background to luminescence 
and selected examples pertinent to bioinorganic chemistry.  
1.3.2 The role of luminescence in cancer diagnosis and therapy 
Luminescence is the emission of light from an electronically excited state by radiative 
fluorescence or phosphorescence processes, which can be illustrated by a Jablonski 
diagram (Figure 1.12). Under typical conditions the molecule is in one of its ground states 
(S0). Upon absorption of a photon (hνA), one electron may be promoted to one of its 
excited states (e.g., S0→S1). For fluorescence to occur, in accordance with Kasha’s Rule, 
the molecule relaxes to the lowest excited vibrational energy level through a non-radiative 
transition (which may include internal conversion, e.g., S2→S1) before emitting a photon 
at a longer wavelength (hνF).
100 Electrons in the S1 state can undergo intersystem crossing 
(ISC) to the first excited triplet state (T1)  which, after vibrational relaxation, will emit a 
photon via phosphorescence (hνP), typically at a longer wavelength than fluorescence. The 
emission wavelength for a fluorescent molecule is invariably at longer wavelength (lower 
energy) than the absorption wavelength due to internal conversions that take the electron 
from the excited vibrational energy level to the lowest vibrational S1 energy level.
100 
 
Figure 1.12. Jablonski diagram illustrating the main radiative decay processes following 
absorption (hνA) from a ground state (S0) to an electronically excited state (S1 or S2), 
followed by fluorescence (hνF) or phosphorescence (hνP). 
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The Stokes shift (Δνst) is the energy gap between the maximum of the lowest energy 
absorption band and the energy of the emission maximum. It is particularly important as 
the excitation and emission energies for different molecular probes can be tuned to 
different biological applications.101 The fluorescence quantum yield (ΦF) is a measure of 
the efficiency of a fluorescent molecule comparing the ratio of photons absorbed to 
photons emitted. For a perfect fluorescent system where every photon that is absorbed 
gets emitted, the ΦF = 1.
II In reality, many quenching processes are observed that erode 
the ΦF value (see 1.3.2.1). 
It should be noted that many biomolecules exhibit weak fluorescence known as 
autofluorescence.102,103 Common sources of autofluorescence are nicotinamide adenine 
dinucleotide phosphate (NADPH), collagen and other proteins that are rich in tryptophan, 
tyrosine, and phenylalanine residues. To overcome background autofluorescence, 
fluorophores with specific emission properties are often required for biological imaging 
techniques. 
1.3.2.1 Fluorescence quenching 
Molecular oxygen (O2) can quench fluorescence by colliding with the fluorescent 
molecule in solution, thus reducing the number of photons emitted from the S1 state. 
Therefore, the solution phase ΦF can be influenced by using either aerated or deaerated 
solvents. The concentration of a fluorescent sample can impact the ΦF as, at higher 
concentrations, the probability of an excited molecule colliding with a ground state 
molecule is increased.104 
An important quenching mechanism when considering fluorescent metal phosphine 
complexes is Photoinduced electron Transfer (PeT). A schematic for the PeT mechanism 
and a representative energy level diagram is shown in Figure 1.13. The PeT quenching 
mechanism is made possible by having an electron donating (or accepting) group in 
proximity to the fluorophore when it has been excited to its S1 state.
105,106 It allows 
formation of a donor-acceptor complex (D+A–, Figure 1.13) which enables a non-radiative 
decay process, thus quenching emission from the S1 state. The effect of engaging a 
phosphine lone pair (either by oxidation or metal coordination) can diminish the PeT 




II ΦF values often quoted between 0–1, or between 0–100%.  
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Figure 1.13. a) Representation of PeT quenching mechanism for organophosphines, and 
effect of oxidation and metal complexation. b) Energy level diagram for PeT process with 
electron transfer from donor (D) to acceptor (A).  
Many examples of phosphines conjugated to electron acceptor moieties are now known 
to be sensitive detectors for hydroperoxides in aqueous environments (see Section 4.1.1, 
Chapter 4). More pertinent examples of fluorescent phosphines and their metal complex 
conjugates are discussed in Chapter 4.  
1.3.2.2 Biological probes 
Fluorescence spectroscopy and microscopy are non-destructive techniques for analysing 
drug interactions with biomolecules. Molecular probes, many of which are commercially 
available, can selectively label different proteins, nucleic acids, or sub-cellular components. 
These probes work because the biomolecule of interest usually has weak autofluorescence, 
well below the intensity of the probe molecule. Therefore, using spectrophotometry or 
microscopy, the labelled regions of interest are detectable well above the background 
autofluorescence. Figure 1.14 shows the structures of commonly used DNA probes, 
where the planar aromatic fragments can interact with base pairs through non-covalent 
π-π interactions.  
The fluorescent dye ethidium bromide (EB) has been well-documented as a diagnostic 
technique for DNA intercalating small molecules.108–110 EB is a planar, cationic dye that is 
a known carcinogen due to its ability to intercalate between the base pairs of double helical 
DNA. It is weakly fluorescent in water, but upon intercalation, the fluorescence intensity 
increases around 30-fold. Therefore, an EB competition assay with a DNA-interacting 
small molecule allows for the quantitative determination of binding constants by 
fluorescence spectroscopy.  
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Figure 1.14. Chemical structures of commonly used fluorescent DNA probes. 
Metal-ligand-complexes (MLCs), for example [Ru(bpy)3]
2+, have been extensively used in 
solar energy conversion, photoredox catalysis and biomedicine.88,111 Figure 1.15 shows a 
metal-to-ligand charge transfer (MLCT) transition for [Ru(bpy)3]
2+ after excitation by a 
photon. The metal centre is oxidised, and an electron is excited to an MLCT state. After 
rapid intersystem crossing to the triplet MLCT state, the electron returns to the ground 
state and a photon is released (fluorescence). These spectral properties of MLCs have 
been exploited to study interactions with DNA, proteins, and other biomolecules (see 
Section 2.4.4, Chapter 2). The intensity of the emission from a fluorescent compound 
may increase or decrease when interacting with DNA. For example, for Ru–polypyridyl 
complexes (such as 1.10, see Figure 1.7), fluorescence is quenched in polar solvents, thus 
an increase in fluorescence intensity indicates that polar solvent molecules cannot access 
the complex, for example, if it is bound within a hydrophobic pocket inside the DNA 
helix.  
 
Figure 1.15. Energy level diagram for MLCT transition illustrated for [Ru(bpy)3]
2+, 
modified from reference 100. 
1.3.3 Fluorescent phosphine conjugates 
There is increasing interest in tracking therapeutic agents via a tethered organic 
fluorophore (or probe) molecule. The advantage of these fluorescent conjugates is that 
tracking in living cells via fluorescence microscopy without an exogenous probe molecule 
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is possible. These so called theranostic (therapeutic plus diagnostic) agents have been 
extensively reviewed.63,112,113 There are reported examples of phosphine ligands conjugated 
to many organic fluorophores that cover part of the UV-visible spectrum. Some examples 
containing pyrene, coumarin, BODIPY, fluorescein, and rhodamine are shown with their 
corresponding emission wavelengths (Figure 1.16a).114–120 It is clear from a survey of these 
fluorescent phosphine conjugates that all of them contain fluorophores with emission 
maxima between 350–600 nm, (i.e., across the blue to yellow range of the visible 
spectrum). Many organic dyes that emit at longer wavelengths (i.e., the red to near-IR 
range of the spectrum) are commercially available (for example, see the Alexa Fluor series, 





Figure 1.16. a) Fluorescence emission wavelengths of known fluorescent phosphine 
conjugates that cover part of the visible spectrum (~350–600 nm). R is a phosphine 
containing moiety, R' represents another substituent.114–120 b) Fluorescence emission 
spectra of commercially available Alexa Fluor dyes, compiled from reference 121.  
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However, to the best of our knowledge, there are currently no examples of fluorescent 
phosphine conjugates with emission maxima >600 nm. Certain phosphorus-containing 
dyes with lower energy emission properties are known, but they are all based on polycyclic 
phosphine oxide and phosphinate P(V) materials.122 Most Alexa Fluor dyes are 
constructed of a fluorescein or rhodamine core with several water solubilising groups, and 
therefore may be suitable conjugation partners for phosphines, useful for bioimaging 
techniques.  
Jacquemin et al. reported a series of coumarin conjugated triarylphosphine derivatives 1.25 
and the corresponding Ru(II), Os(II), and Au(I) complexes 1.27-1.28 (Scheme 1.6).116 The 
fluorescence quantum yields for the free ligands were typically low (ΦF = 0.03–0.05), 
primarily due to a PeT quenching mechanism with electron transfer from the phosphorus 
lone pair to the coumarin. Alkylation of the phosphine to form the methylphosphonium 
salts 1.26 significantly increased the fluorescence intensity (ΦF = 0.91–0.98), as the lone 
pair is no longer accessible.  
A similar observation was made for the Au(I) complexes (ΦF = 0.83–0.95). In contrast, 
the Ru(II) and Os(II) complexes displayed significant fluorescence quenching compared 
to the Au(I) and phosphonium derivatives (ΦF = 0.01–0.10) which was suggested to be 
due to triplet excited state deactivation pathways accessed via intersystem crossing. For 
many metal complexes, the presence of triplet metal-to-ligand-charge-transfer (3MLCT) 
states can reduce the luminescence intensity via non-radiative deactivation pathways.123 
 
Scheme 1.6. Coumarin conjugated phosphines and complexes, Jacquemin et al.116 
Chapter 1. Introduction 
23 
The cytotoxicity of the compounds 1.27-1.28 was assessed against four human cancer cell 
lines which determined that the Au(I) complexes were the most cytotoxic (IC50 ~ 25–50 
µM). The authors suggested that the brightness ratios (complex luminescence : ligand 
luminescence) for only the Au(I) complexes 1.27 made them suitable compounds to use 
as theranostic agents, but experimental confirmatory results are yet to be reported. 
1.4 Organometallic pincer complexes  
PCP-pincer ligands are monoanionic, tridentate ligands that usually bind to metal centres 
in the meridional η3-PCP-coordination mode. This rigid binding mode confers exceptional 
air-, temperature-, and moisture-stability, thus making pincer complexes robust catalysts 
under demanding conditions.124 Most PCP-pincer complexes are derived from symmetric 
ligands with one linking atom between the aryl-carbon and the phosphine donors 
resulting in two fused 5-membered metallacycles (Figure 1.17). Due to the many points 
of derivatisation available, a plethora of catalysts with discrete structures and functions 
have been reported.125 To date, one facet that has not received much attention, is 
metallacycle ring size. Very few examples of complexes with non-symmetric metallacycles 
(e.g., 5,6-) are known perhaps due to lengthy ligand syntheses or perceived lower stability 
of the organometallic complexes produced (Figure 1.17).126,127 
 
Figure 1.17. Schematic to show the properties and points of derivatisation for symmetric 
and non-symmetric PCP-pincer complexes.  
Due to the rigid metallacycles that pincer ligands can form, they can enable otherwise 
labile ligands to remain firmly bound. The rigid structure has been extensively exploited 
in asymmetric catalysis by preventing the phosphorus donor substituents from rotating, 
thus holding them in a defined geometry that can direct the orientation of a substrate at 
the active site of the catalyst.128–130 PCP-pincer complexes have been found to be active 
catalysts for many reactions, including transfer hydrogenation,131 Suzuki-Miyaura cross-
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coupling,132–134 the Heck reaction,135–137 and Sonogashira coupling,138 as well as many 
asymmetric processes, such as hydrogenation and hydrophosphination.129,130,139,140 For a 
review of the recent advances in the synthesis and applications of P-stereogenic pincer 
complexes, see Yang et al.141 
The chemistry of pincer complexes containing metallacycles larger than conventional 5-
membered metallacycles is discussed in Chapter 5.  
1.4.1 Catalytic allylic alkylation 
In 1965, Tsuji et al. reported the stoichiometric reaction between allylpalladium chloride 
dimer and the sodium salt of diethylmalonate which gave a mixture of the mono- and di-
allylation products (Scheme 1.7).142 The Trost group reported that PPh3 was an essential 
additive for difficult to alkylate substrates. Following this discovery, a large family of 
phosphine ligands (Trost ligands) have become ubiquitous for the Tsuji-Trost allylic 
alkylation reaction, enabling fine-tuning of the stereoelectronic properties of the Pd 
catalyst.143 
 
Scheme 1.7. Allylic alkylation of sodium diethylmalonate, reported by Tsuji et al.142  
The field of allylic alkylation has continued to flourish with many transition metal 
complexes discovered as highly active (and selective) catalysts. Although catalysts based 
on Ni, Pt, W, and other metals are known, Pd-based systems – often employing optically-
active ligands to effect an enantioselective transformation – have been unsurpassed in 
their utility.143 
The Pd(0)-catalysed Tsuji-Trost reaction for allylic alkylation is proposed to proceed via 
the mechanism shown in Scheme 1.8: (i) the the alkene of the allylic electrophile 
coordinates to the Pd forming an η2-propene-Pd(0) complex; (ii) oxidative addition to 
form an η3-allyl-Pd(II) complex; (iii) nucleophilic attack at either terminus of the η3-allyl-
Pd(II) intermediate to regenerate one of two isomeric η2-alkene-Pd(0) complexes; (iv) 
decomplexation from the Pd to give the linear or branched alkylation products and turn 
over the catalytic cycle. Nucleophilic attack is favoured at the least hindered terminus of 
the η3-allyl-Pd(II) intermediate (indicated with a blue circle) which, in this case, would lead 
to preferential formation of the linear alkylation product. 
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Scheme 1.8. Proposed mechanism for the Pd(0)-catalysed Tsuji-Trost allylic alkylation 
reaction.  
PCP-pincer ligands have been applied to the Pd-catalysed allylic alkylation of cinnamyl 
acetate with sodium dimethylmalonate.144 The mechanism of allylic alkylation catalysed by 
Pd(II) PCP-pincer complexes has not been conclusively established. One possible 
mechanism involves a Pd(0)/Pd(II) redox cycle where the Pd(II) pincer complex 
decomposes to give nanoparticulate heterogeneous Pd(0). This has been found to be the 
active catalyst in a range of cross-coupling reactions utilising pincer complexes.145,146 
Another possible mechanism involving a Pd(II)/Pd(IV) redox cycle could operate where 
the pincer ligand stabilises an octahedral Pd(IV) allyl intermediate, similar to the 
mechanisms for C–H acetoxylation and Heck-type cross-coupling with iodine(III) 
compounds, that have been previously reported.146,147 
In Chapter 5, a series of Pd PCP-pincer complexes with symmetric and non-symmetric 
metallacycles are reported and applied as catalysts in allylic alkylation. The influence of 
metallacycle size on Pd coordination and catalytic activity and selectivity has been studied. 
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1.5 Objectives 
The aims of the projects described in this thesis were to: 
• Synthesise (cis-tach)Ru diphosphine complexes with planar aromatic backbones. 
The anti-proliferative properties of the novel derivatives would be investigated by 
a range of physical inorganic and biological experiments.  
 
• Explore methods to chemically conjugate phosphine ligands with small organic 
fluorophores and study their coordination chemistry and luminescence properties.  
 
• Use a combination of spectroscopic and computational methods to rationalise the 
observed coordination, luminescence, and air-stability properties of novel 
pyrenylphosphines.  
 
• Investigate the effect of metallacycle ring size on the coordination properties of a 
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This chapter is based on the publication ‘Cytotoxic (cis,cis-1,3,5-
triaminocyclohexane)ruthenium(II)–diphosphine complexes; evidence for covalent 
binding and intercalation with DNA’, published in Dalton Transactions. The author of this 
thesis was the lead author of this paper and the co-authors were: A. J. Gamble, S.W. 
Arkawazi, P. H. Walton, M. C. Galan, M. P. O’Hagan, K. G. Hogg, J. L. Marrison, P. J. 
O’Toole, H. A. Sparkes, J. M. Lynam and P. G. Pringle. The project ideas originated at 
the University of York (P. H. Walton/J. M. Lynam) before the present author carried out 
further synthetic chemistry, analysis, and biological testing. A significant amount of this 
chapter is reproduced from Dalton Trans., 2020, 49, 15219–15230, however, additional 
compounds that were not evaluated as part of the publication are also included. All 
changes to the original manuscript are due to the present author.  
2.1 Introduction 
2.1.1 Cytotoxic Ru complexes 
Ruthenium complexes have potential as alternatives to platinum-based chemotherapy in 
the treatment of cancers. Compounds A-G in Figure 2.1 show the structural diversity of 
Ru complexes whose anti-cancer activity has been investigated.35 The ruthenium(III) 
complexes, NAMI-A (A) and KP1019 (B) have undergone clinical trials.30,32,148–150 More 
recently, Sadler151–155 and Dyson18,33,37,44,156,157 have reported piano-stool 
(η6-arene)ruthenium(II) compounds that are cytotoxic in vitro and in vivo. Notably, the 
chelate complex [RuCl(η6-biphenyl)(H2NCH2CH2NH2)]PF6 (C) has been shown to target 
DNA directly, with the DNA-complex adduct stabilised by hydrogen bonds between the 
diamine ligand and the O6 of guanine.158 It has been shown that [RuCl2(p-cymene)(PTA)] 
(D) is active in vivo against secondary metastases.156 In addition, due to their tunable 
photophysical properties, many Ru(II) polypyridyl complexes have been developed for 
use in photodynamic therapy (PDT) and photochemotherapy (PCT).26,39,61,159 The first 
example of this class of complexes to have entered human clinical trials was TLD1433 
(E), which contains a terthienyl chromophore.26,58  
The seminal work on the anti-cancer properties of (η6-arene)Ru complexes has spurred 
the investigation of many coordination complex analogues of organometallic piano-stool 
complexes. For example, Alessio et al. replaced the arene with [9]aneS3 to give complex F 
with minimal loss of biological activity compared to its organometallic analogues.47 
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Furthermore, Ru-diphosphine complexes such as [(κ3-tpm)RuCl(diphos)]PF6 (G) showed 
activity in vitro.160  
 
Figure 2.1. Chemical structures of cytotoxic Ru complexes. 
However, despite the variety of facially capping ligands available that could be used to 
modulate activity, this aspect of the complexes has received far less attention than 
modification of the other ancillary ligands on the metal.43,96,161 From a biological 
perspective, the narrow range of face-capping ligands that have been used limits the rate 
and extent of the substitution of the halido ligands by water. This rate is known to 
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correlate with in vitro activity,152,162,163 and expanding its range is thus a critical factor in 
maximising the clinical potential of ruthenium complexes in the treatment of cancer. 
The ligand cis-tach (cis,cis-1,3,5-triaminocyclohexane) forms face-capping complexes with 
many transition metals including ruthenium(II).75,81,82,164,165 The labile complex 
[RuCl(DMSO-S)2(cis-tach)]Cl (2.1) is the precursor to N,N-chelate complexes 2.2-2.4 and 
P,P-chelate complexes 2.5-2.10 (Scheme 2.1) that have been previously reported.82 The 
influence of the cis-tach ligand was evaluated by comparison of the structural data with 
those for (η6-arene)Ru complexes. It has previously been demonstrated74,82 that cis-tach is 
a strong σ–donor, as would be expected due to the three nitrogen atoms coordinated to 
the metal. For instance, reaction of the DMSO complex 2.1 with diamines yields dicationic 
complexes in which one coordinated DMSO is retained, whereas reaction of 2.1 with 
diphosphines gave complexes with one chlorido ligand retained (Scheme 2.1). This 
difference in behaviour was rationalised on the basis of the different bonding 
characteristics of diamines and diphosphines. The electron-rich nature of the Ru created 
by the cis-tach, is augmented by the diamine σ–donors which leads to strong π–back-
donation to the DMSO ligand, strengthening the Ru–S interaction. By contrast, 
diphosphines, which are better π–acceptors than DMSO, favour the coordination of 
chloride, which is presumed to be a π–donor. Importantly, for the use of these complexes 
as anti-cancer agents, it was reasoned that the Ru(cis-tach)(diphos) moiety may promote 
the rapid aquation of the Ru–Cl bond that might result in enhanced in vitro activity.81,83 
The ruthenium(II) precursor [RuCl(DMSO-S)2(cis-tach)]Cl (2.1) and the (cis-tach)Ru 
complexes containing N,N-chelates (2.2-2.4) and P,P-chelates (2.5-2.10) were synthesised 
by previously reported methods (Scheme 2.1).82 Our initial biological investigations 
described herein focused on these complexes.  
Notably, for the purposes of this study, the cationic Ru(II) P,P-chelates 2.5-2.10 are freely 
soluble in water up to millimolar concentrations, well in excess of that needed for therapy. 
The superior aqueous solubility of these complexes over traditional organometallic Ru 
complexes provides an advantage, in that biological studies can be performed without the 
addition of toxic, solubilising additives, such as DMSO.  
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Scheme 2.1. Synthesis of complexes 2.2-2.10.82 
In addition to their potential as effective anti-cancer agents, Ru complexes of cis-tach have 
other features that make them attractive for medicinal chemistry. For instance, the 
cationic Ru cis-tach complexes are readily prepared as chloride salts, obviating the use of 
the toxic PF6
– anion in potential pharmaceuticals.166 The NH2 groups of the cis-tach ligand 
enhance the water solubility of the complexes and, moreover, may strengthen any binding 
to DNA through hydrogen-bonding interactions, in a similar manner to the DNA binding 
with [RuCl(η6-biphenyl)(en)]PF6 (C).
152,153 Finally, the cyclohexane ring provides a 
hydrophobic face to the complex, giving steric protection to the hydrophilic metal centre.  
It is in this context that a detailed investigation of the in vitro activity of ruthenium cis-tach 
complexes has been carried out and described in this Chapter. It has been shown that a 
range of diphosphine derivatives exhibit activity against three tumour cell lines, in some 
cases with potency exceeding that of cisplatin or established anti-cancer ruthenium 
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complexes. The extended aromatic backbones of the new diphosphines L2.11-L2.13 (Figure 
2.2) are shown to allow detailed insight into the nature of the biological interactions with 
their Ru-complexes via a range of physical inorganic and biological measurements 
including UV-visible, fluorescence and NMR spectroscopy as well as label-free cellular 
imaging techniques. 
 
Figure 2.2. Chemical structures of L2.11-L2.13 designed for this work. 
2.1.2 Research aims 
It was apparent from preliminary anti-proliferative studies on (cis-tach)Ru P,P-chelate 
complexes that they are highly cytotoxic. To study the nature of this biological activity 
further, we aimed to carry out the following: 
• Design and structurally characterise diphosphine derivatives with planar aromatic 
backbones, capable of intercalative DNA binding interactions.  
• Study the kinetics of aquation and compare this to organometallic derivatives.  
• Assess the binding of the novel (cis-tach)Ru complexes to different DNA motifs 
and correlate this to the in vitro cytotoxicity observed by LiveCyte cell imaging 
techniques.  
2.2 Ligand synthesis 
The ligands L2.11-L2.13 were made by the routes shown in the following schemes. The novel 
terthiophene diphosphine L2.11 was prepared from 3',4'-dibromo-2,2':5',2''-terthiophene 
2.11, which has been reported by Yamaguchi and co-workers (Scheme 2.2).167 It was 
necessary to install the diphenylphosphine groups in L2.11 sequentially to avoid the 
formation of a complex mixture of products.  
 
Scheme 2.2. Synthesis of L2.11 via iterative lithiation/phosphination.  
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Crystals suitable for X-ray diffraction were grown by slow evaporation of a saturated 
CH2Cl2 solution of L2.11 stored at room temperature (Figure 2.3).  
 
Figure 2.3. Single crystal X-ray crystallography structure of L2.11. Hydrogen atoms have 
been omitted for clarity. Thermal ellipsoids at 50% probability level. Selected bond 
lengths (Å) and angles (°): P1–C6 1.846(2), P2–C7 1.837(2), C7–C6 1.448(3), C8–C7 
1.384(3), C5–C6 1.375(3); C7–C6–P1 118.69(15), C5–C6–P1 128.43(15). 
The P–C bonds between the diphenylphosphine groups and the central thiophene 
(1.846(2) and 1.837(2) Å) are within the normal range for previously reported thiophenyl 
phosphine ligands.107 The dihedral angles between the central thiophene ring and the two 
flanking thiophenyl groups are ~53° and ~61°, thus L2.11 crystallised with a twisted 
geometry. However, L2.11 did not exhibit atropisomerism in solution as one sharp set of 
signals in the 1H NMR spectrum was observed. If atropisomers were present, they would 
be enantiomers and therefore give one sharp singlet in the 31P{1H} NMR spectrum.  
The quinoxaline diphosphine ligand, L2.12 was prepared from 2,3-dichloroquinoxaline and 
lithium diphenylphosphide following a modified literature procedure (Scheme 2.3).168  
 
Scheme 2.3. Synthesis of L2.12. 
We sought to extend the aromatic surface area of quinoxaline diphosphine L2.12 by 
addition of fused benzo groups in the [f,h] positions. Starting from phenanthrene-9,10-
diamine 2.13, the extended quinoxaline dibromide 2.15 has been previously reported and 
is obtained from treatment of 1,4-dihydrodibenzo[f,h]quinoxaline-2,3-dione 2.14 with 
PBr3 in DMF (Scheme 2.4). Unfortunately, due to the highly insoluble nature of this 
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material, attempts to convert 2.15 to the desired diphosphine were unsuccessful. The most 
productive route to diphosphine ligand L2.13 was from its dichloro precursor (obtained 
from treatment of 1,4-dihydrodibenzo[f,h]quinoxaline-2,3-dione 2.13 with PCl3 in DMF, 
Scheme 2.4).169  
 
Scheme 2.4. Synthesis of L2.13. 
2.3 Synthesis of cytotoxic complexes 
The cationic Ru complexes 2.17-2.19 were prepared in an analogous way to 2.5-2.10 
(Scheme 2.5). The two DMSO ligands were substituted with the chelating phosphines 
(L2.11-L2.13) by reaction of 2.1 with 1.8 equivalents of each of the ligands in alcohol solvent 
(MeOH or EtOH) heated under reflux. The formation of the desired complexes typically 
took between 18–48 h and was monitored by in situ 31P{1H} NMR spectroscopy. 
 
Scheme 2.5. Preparation of (cis-tach)Ru diphosphine complexes 2.17-2.19. 
Single crystals of a salt containing 2.18 were grown following anion metathesis with NaPF6 
in methanol followed by filtration (to remove NaCl) and slow evaporation of the saturated 
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solution at room temperature. The X-ray crystal structure of [2.18]PF6 (Figure 2.4) 
demonstrates that the addition of the larger, planar aromatic quinoxaline diphosphine 
ligand L2.12 does not significantly alter the geometry of the (cis-tach)Ru complex, as shown 
by the overlap with the phenylene diphosphine (dppbenz) analogue (2.10) illustrated in 
Figure 2.4. The cis-tach ligand adopts the expected κ3-coordination mode and there are 
intramolecular interactions detected between the N(4)H2 and the centroids of the phenyl 
rings of the PPh2 groups. In addition to the lipophilic cyclohexane ring, the PPh2 groups 
provide further hydrophobicity to the complex and have the potential to interact with 
biomolecules (see below). 
  
Figure 2.4. (left) Single crystal X-ray crystallography structure of [2.18]PF6. Hydrogen 
atoms (except for the –NH2 groups) and PF6
– have been omitted for clarity. Thermal 
ellipsoids at 50% probability level. (right) Overlap of [2.18]PF6 (red) with dppbenz 
derivative [2.10]PF6 (blue). Selected bond lengths (Å) and angles (°): Ru1–Cl1 2.4335(6), 
Ru1–P1 2.2857(7), Ru1–P2 2.2654(6), Ru1–N3 2.179(2), Ru1–N4 2.130(2), Ru1–N5 
2.182(2); P2–Ru1–P1 84.43(2), N4–Ru1–Cl1 170.90(6), P1–Ru1–Cl1 90.11(2), P2–Ru1–
Cl1 93.92(2). 
In addition to complexes 2.17-2.19 which possess diphosphine ligands with all-carbon 
backbones, (cis-tach)Ru complex 2.20 was prepared from 2.1 and 
bis(diphenylphosphino)amine L2.14 (Scheme 2.6). It was hypothesised that the additional 
N–H bond of this ligand could behave in a similar way to the cis-tach N–H bonds and 
allow formation of hydrogen bonding interactions with biomolecules. Ligands containing 
a reactive functional group that can be further functionalised are discussed in Chapter 3. 
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Scheme 2.6. Preparation of (cis-tach)Ru diphosphine complex 2.20. 
In the case of 2.20, anion metathesis from chloride to hexafluorophosphate was not 
necessary and single crystals of 2.20 grew from evaporation of its concentrated solution 
in methanol at room temperature (Figure 2.5). The four-membered metallacycle has a 
diphosphine bite angle (69.6°) that is comparable, albeit slightly smaller, than the dppm 
derived (cis-tach)Ru complex 2.5 (72.3°). 
 
Figure 2.5. Single crystal X-ray crystallography structure of 2.20. Hydrogen atoms 
(except for the –NH2 groups) and Cl
– have been omitted for clarity. Thermal ellipsoids at 
50% probability level. Selected bond lengths (Å) and angles (°): Ru1–Cl1 2.4269(6), Ru1–
P1 2.2575(7), Ru1–P2 2.2437(7), P1–N4 1.686(2); P2–Ru1–P1 69.59(2), N2–Ru1–Cl1 
171.91(7), P2–N4–P1 99.41(12). 
To assess the ligand donor properties of L2.11-L2.13, dichloroplatinum(II) complexes were 
prepared by reaction of each ligand with one equivalent of [PtCl2(cod)] (Scheme 2.7). The 
isolated complexes displayed characteristically large 1JPPt coupling constants consistent 
with cis-coordination of the diphosphine. Table 2.1 gives the chemical shifts, coordination 
chemical shifts and relevant coupling constants of Ru complexes 2.17-2.20 and Pt 
complexes 2.21-2.23.  
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Scheme 2.7. Preparation of cis-[(PP)PtCl2] complexes, 2.21-2.23.  




Ligand/Complex δP / ppm
a ΔδP
b 1JPPt / Hz 
L2.11 Terthiophene (PP) –17.3 – – 
2.17 [RuCl(cis-tach)(PP)]+ 56.2 +73.5 – 
2.23 [PtCl2(PP)] 11.8 +29.1 3580 
L2.12 Quinoxaline (PP) –9.4 – – 
2.18 [RuCl(cis-tach)(PP)]+ 63.9 +73.3 – 
2.21 [PtCl2(PP)] 21.0 +30.4 3449 
L2.13 ExQuin (PP) –10.2 – – 
2.19 [RuCl(cis-tach)(PP)]+ 63.3 +73.5 – 
2.22 [PtCl2(PP)] 21.4 +31.6 3500 
L2.14 (Ph2P)2NH (PP) 43.0 – – 
2.20 [RuCl(cis-tach)(PP)]+ 64.3 +21.3 – 
aChemical shifts recorded in CDCl3 and given in ppm. 
bCoordination chemical 
shifts (ΔδP) are relative to the free ligands in CDCl3 (ΔδP = δP(complex) – 
δP(ligand)). 
In all cases, forming the 5-membered Ru metallacycles 2.17-2.19 resulted in a large ΔδP of 
~73 ppm consistent with the properties of previously reported Ru diphosphine 
complexes 2.9-2.10.82 The 4-membered Ru metallacycle 2.20 had a much smaller ΔδP of 
~21 ppm associated with the strained ring. This is similar to the 4-membered metallacycle 
derived from dppm (L2.5) which, on forming the Ru complex 2.5, gave a ΔδP ~10 ppm. 
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The coordination of L2.11-L2.13 to [PtCl2(cod)] to give 5-membered palladacycles induced 
smaller ΔδP values than the Ru analogues (~30 ppm for 2.21-2.23). The 
31P{1H} NMR 
spectra for these complexes showed singlets with Pt satellites with 1JPPt values of 3580 Hz 
(2.23), 3449 Hz (2.21), and 3500 Hz (2.22). 
Crystals of 2.21 and 2.22 were grown by slow evaporation of their saturated solutions in 
CH2Cl2 at room temperature and the structures determined by X-ray crystallography 
(Figure 2.6 and Figure 2.7). 
 
Figure 2.6. Single crystal X-ray crystallography structure of 2.21. Hydrogen atoms have 
been omitted for clarity. Thermal ellipsoids at 50% probability level. Selected bond 
lengths (Å) and angles (°): Pt1–Cl1 2.3508(6), Pt1–Cl2 2.3576(6), Pt1–P1 2.2111(6), Pt1–
P2 2.2122(6); Cl1–Pt1–Cl2 91.55(2), P1–Pt1–Cl1 89.69(2), P1–Pt1–P2 89.20(2). 
The molecular structures of both complexes feature planar 5-membered PtPCCP 
metallacycles and show the expected square planar geometry. In the solid state, the 
complex with the larger ligand backbone (2.22) displays a twist (~17°) with respect to the 
PtCl2 plane (Figure 2.7) which is not present in the parent quinoxaline complex 2.21.  




Figure 2.7. Single crystal X-ray crystallography structure of 2.22. Hydrogen atoms have 
been omitted for clarity. Thermal ellipsoids at 50% probability level. Selected bond 
lengths (Å) and angles (°): Pt1–Cl1 2.3552(6), Pt1–P1 2.2078(6), P1–C13 1.828(2); P1–
Pt1–Cl1 89.77(2), P1–Pt1–P1' 89.11(3). 
2.4 Biophysical measurements 
2.4.1 Inhibition of the proliferation of A549 and A2780 cancer cells 
The in vitro growth inhibition was determined by MTT assay in two cell lines: A549 
(human lung adenocarcinoma) and A2780 (human ovarian adenocarcinoma). The 
[Ru(DMSO)(cis-tach)(L2.2)]
+ complex (2.2) in concentrations up to 300 μM, did not inhibit 
the growth of tumour cells and was therefore considered inactive. 
Ruthenium mono-phosphine complexes containing an η6-arene ligand have previously 
been shown to be active against cancer cells.38,44,155,170–172 We have found clear 
antiproliferative activity with the P,P-chelates 2.5-2.10 (for structures see Scheme 2.1) as 
shown by the data given in Table 2.2 and Figure 2.8. The following trends can be 
discerned from the data. (1) The activity generally increases with increasing chelate ring 
size: 2.5 < 2.6 < 2.7 ≃ 2.8; complexes 2.7 and 2.8 are over twice as active as cisplatin 
against the A549 cell line and are equipotent to cisplatin against the A2780 cell line. (2) 
Complex 2.6 is over twice as active as complex 2.9 against both cell lines, although both 
2.6 and 2.9 are 5-membered chelates, the more active chelate 2.6 has a less rigid backbone. 
(3) Complex 2.10 is significantly more active (by factors of ca. 10 and 7 against the two 
cell lines) than the ostensibly similar complex 2.9. Although both 2.9 and 2.10 are rigid, 
5-membered chelates, the phenylene backbone in 2.10 will make the complex more 
lipophilic. It was also speculated that the intercalating potential of the planar aromatic 
backbone present in 2.10 may also be a contributing factor in its higher activity than 2.9. 
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Table 2.2. Biological evaluation of compounds 2.1, 2.2, 2.5-2.10 and 2.17-2.19.a 
 IC50
b (μM) 
Compound A549 A2780 
cisplatin 2.70 (0.05) 0.43 (0.01) 
2.1 > 300 > 300 
2.2 > 300 > 300 
2.5 41.7 (1.0) 12.4 (0.2) 
2.9 25.1 (0.4) 7.47 (0.17) 
2.6 9.88 (0.04) 3.39 (0.12) 
2.7 1.02 (0.03) 0.35 (0.01) 
2.8 1.15 (0.02) 0.39 (0.01) 
2.10 2.73 (0.11) 1.14 (0.04) 
2.17 1.83 ± 0.66c – 
2.18 11.81 ± 1.23c – 
2.19 5.06 ± 1.01c – 
aAntiproliferative activities were determined by MTT assay and dose response curves are 
given (Figure 2.9). The IC50 calculated as the concentration of drug required for 50% 
growth inhibition over 72 h. bCalculated as the average of triplicate experiments. 
cSubsequently determined to assess activity of the newly synthesised diphosphine ligand 
complexes, errors are calculated from 8 replicates. Standard deviations are given in 
parenthesis.  
To explore this hypothesis further, the (cis-tach)Ru complexes 2.17-2.19 containing 
diphosphines with extended aromatic surfaces: terthiophenyl diphosphine (L2.11), 
quinoxaline diphosphine (L2.12) and dibenzo[f,h]quinoxaline diphosphine (L2.13) (see 
Figure 2.2) were tested. It was postulated that these novel complexes might exhibit dual-
function cytotoxicity by covalently binding to biomolecules and by intercalation with 
DNA in a similar way to the functioning of the cytotoxic Pt complex phenanthriplatin.14,15 
If this were the case, it was reasoned that 2.17-2.19 would be expected to show higher 
activity than the first-generation (cis-tach)Ru complexes 2.5-2.10.  
We assessed the antiproliferative activity of 2.17-2.19 against A549 cells by a 72 h MTT 
assay and found that the complexes were comparable in activity to the most active P,P-
chelate complexes 2.7-2.8 with IC50 values of 1.83 ± 0.66 µM for 2.17, 11.81 ± 1.23 µM 
for 2.18, and 5.06 ± 1.01 µM for 2.19. Considering the experimental errors inherent in the 
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MTT assays, the difference between the activity of 2.17 and 2.7-2.8 is not statistically 
significant.  
Encouraged by the activities of these more lipophilic derivatives with planar aromatic 
backbones, we sought to understand their interactions with a variety of biomolecules and 
study their activity in vitro. The MTT data for complexes 2.17-2.19 (Table 2.2) 
demonstrated that their activity was comparable to the most active (cis-tach)Ru complexes. 
However, detailed time course studies using in situ cellular imaging revealed further details 
of the behaviour of the complexes and indicated that 2.17-2.19 are significantly more 
active against A549 and 293T cells when compared to cisplatin and 2.10 (see Section 2.5). 
 
Figure 2.8. Cell viability data in A549 and A2780 cells treated with cisplatin and 2.5-2.10 
to show influence of ligand backbone on cytotoxicity. Antiproliferative activities were 
determined by MTT assay and dose response curves are given in Figure 2.9. The IC50 
calculated is the concentration of drug required for 50% growth inhibition over 72 h. The 
error bars represent one standard deviation from three independent experiments. 
Two potential modes of action of the (cis-tach)Ru diphosphine complexes were 
investigated. First, aquation of the Ru–Cl bond to the labile Ru–OH2 complex followed 
by covalent interactions with nucleosides; and second, the ability of the complexes to 
interact with DNA by non-covalent interactions. 













Figure 2.9. Representative dose response curves for A549 cells treated with a) cisplatin, 
b) 2.10, c) 2.18, d) 2.17, e) 2.19. 
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2.4.2 Aquation of Ru–Cl complexes 
The aquation products of 2.6, 2.7 and 2.18 were characterised by 31P{1H} NMR 
spectroscopy and ESI-MS. The 31P{1H} NMR spectra for complexes recorded in water 
at pH 7.4 consisted of two singlet resonances, with one corresponding to the starting 
chlorido complex, and the other to the aquated (water or hydroxo) complex (Scheme 2.8). 
The assignment of each resonance was made by monitoring the changes upon addition 
of sodium chloride to the aqueous solution. The high-resolution electrospray ionization 
mass spectrometry (HR-ESI-MS) data for 2.6, 2.7 and 2.18 recorded in 75% H2O/25% 
MeOH supported the formation of the aquated complexes with the molecular ion mass 
and isotope patterns corresponding to the ion [Ru–Cl+OH]+ in all cases.  
 
Scheme 2.8. Representative aquation/anation for 2.6 and 2.7 to give 2.6' and 2.7'. 
2.4.3 Kinetics of aquation 
The kinetics of aquation and anation of the (cis-tach)Ru complexes 2.6, 2.10 and 2.18 were 
investigated by UV-visible spectroscopy and compared to [RuCl(η6-bip)(en)]+ (C in Figure 
2.1).162 The time-evolution difference spectra (ΔA) for each complex are shown in Figure 
2.10. The presence of isosbestic points in each spectrum suggests that the aquation 
process involves a single-step mechanism in the formation of the aqua derivative from 
the chlorido complex. The time dependence for the absorbance of each complex (ΔA)max 
followed first order kinetics (Figure 2.11 and Table 2.3). The first order rate constants (k) 











The rate of aquation of 2.6 at physiological temperature (310 K) corresponds to a half-
life of 33 s. Therefore, the rate of aquation is not a significant factor in the in vitro activity 
of the complex as aquation occurs rapidly in comparison to cell proliferation (typically 24 
h). 








Figure 2.10. Time-evolution of UV-visible difference spectra for the aquation of 300 μM 
of a) 2.6, b) 2.10, c) 2.18 in aqueous solution buffered at pH 7.4 (10 mM sodium 
phosphate) with 1.6% MeOD at 298 K, I ≈ 25 mM. Plots are given for minutes 1 to 9. 
ΔA = At − A0, where At = absorbance at time t and A0 = A at t = 30 s. 
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Figure 2.11. Time dependence of the absorbance (green 2.6, blue 2.10, red 2.18, (ΔA)max 
wavelength indicated by the up arrows in Figure 2.10) for each complex. Inset is an 
expansion to show the first 2000 s. 
The rate constants for the aquation of 2.6 (6.55 ± 0.06 × 10–3 s–1) and 2.7 (63.9 ± 6.0 × 
10–3 s–1) at 298 K are approximately 5 and 15 times faster than the η6-biphenyl complex 
[RuCl(η6-bip)(en)]+ (C) (1.28 × 10–3 s–1) respectively. This difference could be attributed 
to a weakening of the Ru–Cl bond, as shown by its lengthening, observed in the crystal 
structures of 2.6 (2.4431(14) Å) and 2.7 (2.4404(4) Å)82 when compared to RAen complex 
C (2.405(6) Å),158 due to the trans-effect of the nitrogen donors in the cis-tach ligand. 
Both 2.6 and 2.7 were found to be stable for the duration of a typical 72 h MTT assay 
experiment. Furthermore, over a two-week period at 37 °C, the 1H NMR spectrum of 2.6 
in 10% D2O/90% H2O did not change. Since the rate of aquation of the Ru–Cl is rapid, 
the biological activity is likely more dependent on the binding to biomolecules once this 
aquation step has taken place. Therefore, to test this hypothesis, a series of DNA binding 
experiments were carried out.  
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Table 2.3. First order rate constants and half-lives for the aquation of (cis-tach)Ru 
complexes at various temperatures, pH 7.4. 
Complex T (K) k (10–3 s–1)a t½ (s) 
2.6 288 2.09 ± 0.02 331 ± 3 
2.6 293 3.60 ± 0.08 192 ± 5 
2.6 298 6.55 ± 0.06 106 ± 1 
2.6 303 10.7 ± 0.2 65 ± 1 
2.6 310 21.0 ± 0.7 33 ± 1 
2.7 298 63.9 ± 6.0 10 ± 2 
2.10 298 2.23 ± 0.12 311 ± 17 
2.18 298 1.02 ± 0.01 679 ± 3 
aMeasurements for the aquation of 2.6, 2.7, 2.10 and 2.18 (300 µM) in aqueous solution 
buffered at pH 7.4 (10 mM sodium phosphate). 
Given the rapid rates of aquation, one likely method of causing antiproliferative effects is 
through coordination of a biomolecule to the complex at the coordination site initially 
occupied by the chloride ligand. The reported complexes share a structural feature with 
cisplatin – a nitrogen donor trans- to a chloride ligand – and thus have favourable aquation 
kinetics. As previously reported, the aquation kinetics for the Pt–Cl bonds of square 
planar Pt(II) d8 complexes are on the order of ~10–5 s–1, notably slower than the Ru–Cl 
bonds of octahedral Ru(II) d6 complexes (~10–3 s–1).50 Additionally, the amine groups of 
the cis-tach ligand are located cis- to the chloride ligand and may have a role in 
strengthening interactions with a bound molecule through hydrogen bonding. With these 
considerations, the following DNA binding experiments were carried out.  
2.4.4 Binding of Ru to CT-DNA 
The intercalating fluorescent dye ethidium bromide (EB) was used in a competition assay 
with complexes 2.6, 2.10, 2.17, 2.18, 2.19 as well as the known DNA intercalator 
[Ru(bpy)2(DPPZ)]
2+ (DPPZ = dipyrido[3,2-a:2',3'-c]phenazine) as a benchmark (Figure 
2.12).110 A solution of 50 µM calf thymus DNA (CT-DNA) and 5 µM EB ([CT-
DNA]/[EB] = 10:1) was prepared and the EB-CT-DNA adduct was subjected to titration 
with Ru complexes.  
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= 1 +  𝐾SV[𝑄] 
where I0 and I are the emission intensity in the absence and presence of quencher complex 
respectively, KSV is the Stern-Volmer quenching constant and [Q] is the quencher 
concentration.  
From these plots, the apparent binding constants (Kapp) were calculated using: KEB[EB] = 
Kapp[complex], where KEB = 1×10
7 M–1, [EB] = 5 µM, and [complex] is the concentration 
of Ru complex that gave a 50% reduction of the initial emission intensity of EB.  
 
Figure 2.12. Chemical structures of the DNA intercalating dye ethidium bromide (EB) 
and the known intercalating complex [Ru(bpy)2(DPPZ)]
2+. 
For titrations with complexes 2.17-2.19, a gradual decrease in emission was observed 
(Figure 2.13 and Figure 2.14) implying that these complexes outcompete the EB to 
interact with DNA. The same titration was performed with 2.6 and 2.10; however, no 
appreciable decrease in emission was observed for 2.6 indicating negligible intercalative 
interaction is present (Figure 2.15). For 2.10, the decrease was so small that a binding 
constant could not be calculated and therefore intercalation is not considered a viable 
mode of action for this complex (Figure 2.15).  
The binding constants (derived from Kapp = (KEB[EB])/[complex]) for 2.17, 2.18 and 2.19 
are 3.07 ± 0.07 × 105 M–1, 1.16 ± 0.04 × 10
5 M–1 and 5.11 ± 0.25 × 105 M–1 respectively 
(Figure 2.13 and Table 2.4), indicating that increasing the aromatic surface of the ligand 
backbone (2.18 to 2.19) gave a five-fold increase in binding affinity. 
These binding constants are comparable, and in some cases superior to, rigid dinuclear 
(η6-arene)Ru complexes previously reported.175 The apparent binding constant of the 
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known DNA intercalator [Ru(bpy)2(DPPZ)]
2+ was calculated as 1.75 ± 0.02 ×106 M–1, 





Figure 2.13. a) Emission spectra of CT-DNA (50 µM) and EB (5 µM) competition assay 
with 2.18 (0–112.5 µM). b) Stern-Volmer plots EB-CT-DNA vs. [Q] where Q = (cis-













Figure 2.14. Emission spectra of CT-DNA (50 µM) and EB (5 µM) competition assay 
with a) [Ru(bpy)2(DPPZ)]
2+, b) 2.17, c) 2.19. Inset: Stern-Volmer plots EB-CT-DNA vs. 
[Q] where Q = (cis-tach)Ru complex. 






Figure 2.15. Emission spectra of CT-DNA (50 µM) and EB (5 µM) competition assay 
with a) 2.6, and b) 2.10. 
 
Table 2.4. Binding (Kapp) and quenching (KSV) constants for the interaction of Ru 
complexes with CT-DNA.a 
Complex KSV (×10
3 M–1) Kapp (×10
5 M–1) 
2.17 6.13 ± 0.16 3.07 ± 0.07 
2.18 2.31 ± 0.08 1.16 ± 0.04 
2.19 10.21 ± 0.05 5.11 ± 0.25 
2.6 n/a n/a 
2.10 n/a n/a 
[Ru(bpy)2(DPPZ)]
2+ 34.97 ± 0.43 17.48 ± 0.22 
aCalculated as the average of triplicate experiments. 
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2.4.5 Binding to G-Quadruplex DNA 
The following results were obtained with the help of Dr. Michael O’Hagan as part of 
a collaborative study.85,176 
G-quadruplexes are four-stranded DNA secondary structures that form from guanine-
rich sequences (Figure 2.17). They attract particular attention as an anticancer target, 
owing to the occurrence of quadruplex-forming motifs at chromosome telomeres and 
in the promoter sequences of several oncogenes, e.g., the c-myc gene.177–179 These 
structures can adopt a variety of topologies characterised by the relative orientations 
(parallel/antiparallel) of the DNA strands in the folded structure. 180,181 Furthermore, 
the planar G-tetrads provide additional opportunities for stacking and intercalative 
interactions with complexes, since the dimensions are significantly larger than those 
of a classical Watson-Crick base pair.182 Therefore, these DNA sequences can 
hypothetically be targeted with high-selectivity in order to reduce or eliminate the off-
target effects resulting from indiscriminate binding to duplex DNA.177,182  
This therapeutic hypothesis has led to many groups designing G-quadruplex binders 
as potential anticancer agents183–186 and many metal complexes are known to bind G-
quadruplexes effectively through covalent and non-covalent interactions.187 For 
example, Liu et al. found that ruthenium polypyridyl complexes containing 4idip (4-
indoleimidazo[4,5-f][1,10]phenanthroline) ligands were able to selectively stabilise the 
human telomeric G-quadruplex structure.184,185 
As a result of the intercalating ability of 2.17-2.19 indicated by the EB assays, we 
investigated the ability of the complexes to stabilise G-quadruplex DNA and duplex 
DNA structures. The extent of stabilisation was quantified by performing a 
Fluorescence Resonance Energy Transfer (FRET) assay initially reported by De Cian 
et al.188 The change in DNA melting temperature (ΔT1/2) induced by a Ru complex 
compared to that of the oligonucleotide in the absence of complex was also used as 
an indication of the capacity of the complex to stabilise the G-quadruplex structure. 
We chose to investigate three models of G-quadruplex DNA and one of duplex DNA 
(see Figure 2.17). The human telomeric sequence (F21T) was studied in potassium- 
and sodium-containing buffer owing to the known influence of the metal ion on the 
polymorphism of this sequence.189,190 The G-quadruplex sequence found in the c-myc 
oncogene promoter (FmycT) was selected as a model of this anticancer target.  
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The results of the FRET experiments are shown in Figure 2.17 and representative 
DNA melt curves in Figure 2.16. Complexes 2.17 and 2.18 did not induce any 
appreciable stabilisation of quadruplex DNA (ΔT1/2 < 3 °C at 1 μM complex) but 2.19 
did stabilise F21T (ΔT1/2 = +7.5 ± 2.3 °C) in Na
+-containing buffer. Additionally, 2.19 
was selective for quadruplex DNA structures, stabilising the quadruplex sequence 
FmycT (ΔT1/2 = +6.2 ± 1.5 °C), whilst stabilisation of the duplex sequence F10T was 
negligible (Figure 2.17). Meanwhile, the same complex did not significantly stabilize 
F21T in K+-rich buffer (ΔT1/2 < 3 °C), suggesting that as well as G4/duplex selectivity, 
the complex can also discriminate between different G-quadruplex topologies to some 
extent. As a control, the well-known DNA intercalator complex [Ru(bpy)2(DPPZ)]
2+ 
did not significantly stabilise quadruplex DNA (ΔT1/2 = +1.6 ± 0.4 °C for F21T) or 










Figure 2.16. Representative thermal melting curves for A) F21T quadruplex (K+ 
conditions); B) F21T quadruplex (Na+ conditions); C) FmycT quadruplex (K+ 
conditions); D) F10T duplex (K+ conditions). 
The dibenzo[f,h]quinoxaline moiety in 2.19 provides a large aromatic surface that may 
selectively stabilise G-quadruplex DNA through preferential association with the large 
G-tetrads over intercalation with Watson-Crick base pairs, akin to the 4idip examples 
previously reported.184 Complex 2.19 showed stronger binding than 2.17 and 2.18 in 
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experiments with quadruplex DNA as well as with CT-DNA (see Table 2.4). This 
interesting discovery that (cis-tach)Ru complexes interact with quadruplex DNA 





Figure 2.17. a) Schematic representation of a DNA G-quadruplex. The folding of the 
oligonucleotide into a four-stranded structure creates a stacked arrangement of G-tetrads, 
each formed by the square-planar assembly of four guanine (G) residues. The overall 
topology is determined by the relative orientation of the neighbouring strands (indicated 
by arrows) and stabilized by co-ordination to metal ions (M+). b) Average ΔT1/2 for 
quadruplex (F21T and FmycT) and duplex (F10T) DNA after treatment with Ru 
complexes (1 µM). Error bars show standard deviations from four experiments. 
2.5 LiveCyte Cell Imaging 
The following experiments were carried out with the help of Dr. Karen Hogg and Dr. 
Joanne Marrison as part of a collaborative study.85,191 
The viability of A549 cells and 293T cells was assessed using LiveCyte (Phasefocus Ltd) 
label-free time-lapse microscopy.191,192 LiveCyte cell imaging does not require the cell to 
be labelled with antibodies or cellular dyes; the cells are unperturbed and the imaging 
process is not toxic to the cells; the cellular changes measured are reported with 
confidence to be associated with the presence of the compounds. Conventional light 
microscope imaging requires the cells to be labelled with a DNA binding or cytoplasmic 
dye and requires higher energy lasers, compared to the LiveCyte: both the labelling and 
the imaging light source in conventional light microscopy may be cytotoxic over 
prolonged time and needs to be considered when interpreting results. This technique 
enables quantification of the total cellular dry mass as an indicator of cell death and growth. 
For A549 and 293T cells, the effect of treatment with cisplatin and 2.19 is shown at 36 
and 72 h time-points (Figure 2.18 and Figure 2.19).  
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Figure 2.18. LiveCyte time-lapse images of A549 control cells (a) and after treatment with 
6.25 µM cisplatin (b) and 6.25 µM 2.19 (c). (d) Dry mass plot to show growth inhibition 
when treated with cisplatin, 2.10, 2.17, 2.18, 2.19 (all at 6.25 µM). 
The MTT assay is an endpoint colorimetric readout of cell viability and does not provide 
any visual characteristics of the cells state. In this preliminary study, integrated image 
analysis software (Livecyte Cell Analysis Toolbox) was used to extract real-time changes 
in morphology and dry mass of each cell over time. The summed mass of the cellular 
components excluding water was calculated and for each treated population of cells used 
as a measure of the combined growth and proliferation. For A549 cells (Figure 2.18), the 
reduction in dry mass is greatest for 2.17 and 2.19 followed by the slightly less active 
derivative 2.18 (which shows comparable results to cisplatin), and 2.10 gave the smallest 
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decrease in dry mass of those tested. This difference in dry mass reduction between 
cisplatin and 2.10 is notable as the MTT assay derived IC50 values are within error of each 
other (IC50 ≈ 2.7 µM). 














Figure 2.19. LiveCyte time-lapse images of 293T control cells (a) and after treatment with 
6.25 µM cisplatin (b) and 6.25 µM 2.19 (c). (d) Dry mass plot to show growth inhibition 
when treated with cisplatin, 2.10, 2.17, 2.18, 2.19 (all at 6.25 µM). 
For 293T cells (Figure 2.19), the reduction in dry mass is even more pronounced, with 
2.10 causing significantly less reduction than cisplatin. The other (cis-tach)Ru complexes 
2.17-2.19 caused significant cell death at a concentration of 6.25 µM, evident from the cell 
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images and dry mass curves, and this greater activity is consistent with 2.17-2.19 exhibiting 
cytotoxicity by multiple mechanisms. 
2.6 Conclusions 
In summary, the compounds presented in this Chapter are the first reported examples of 
cytotoxic ruthenium(II) cis-tach complexes. The precursor complex [RuCl(DMSO-S)2(cis-
tach)]Cl (2.1) was obtained in high yield and is a very useful precursor for the synthesis of 
a range of ruthenium(II) derivatives. Complexes 2.5-2.10 and 2.17-2.19, which contain 
chelating diphosphine ligands, are highly active in vitro against A549, A2780 and 293T 
cancer cell lines. In particular, complexes with flexible aliphatic backbones (2.7 and 2.8) 
or planar aromatic backbones (2.17-2.19) are the most cytotoxic, with activity in the A549 
cell line more than twice that of cisplatin, and activity in the A2780 cell line equipotent to 
the clinical drug. The electron rich nature of the Ru centre afforded by the cis-tach  ligand, 
coupled with favourable aquation kinetics, enables high levels of the active Ru–OH2 
complex in the cell nucleus. 
New analogues with planar aromatic backbones have been shown to intercalate strongly 
with CT-DNA models, and, in the case of 2.19 also selectively stabilise G-quadruplex 
DNA over duplex DNA. The anti-proliferative effect has been monitored by LiveCyte, 
label-free, time-lapse imaging and stark differences are observed between the phenylene 
derivative 2.10 and the extended aromatic derivatives (2.17 and 2.19). Overall, these 
preliminary biological studies suggest that (cis-tach)Ru diphosphine complexes exhibit a 
dual-action cytotoxic effect, targeting cellular DNA by intercalation, as well as  by modes 
of action involving covalent binding with DNA. This robust, water-soluble molecular 
architecture could be further developed to produce next generation ruthenium 
chemotherapeutic agents. Further cell studies exploiting the tunability of phosphine 
ligands that result in targeted metallodrugs are discussed in Chapter 3.  
2.7 Future work 
To further understand the interplay between covalent and intercalative binding, it would 
be productive to test a (cis-tach)Ru complex containing a chelating phosphine but lacking 
a chlorido ligand, e.g., [Ru(CN)(cis-tach)(PP)]+ as this would show if a Ru–Cl bond, as well 
as a chelating phosphine, are essential for biological activity. The strongly bound cyano 
ligand would not aquate in the way the chlorido ligand does, so any activity arising from 
these complexes would result from non-covalent binding interactions. Further analyses 
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to differentiate between the activity arising from intercalative versus covalent binding 
could include Scatchard analysis, as a way of determining the number of binding sites 
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3.1 Introduction 
The ability to chemically functionalise a phosphine ligand is desirable for catalysis and 
medicinal applications including imaging, sensing, and therapy.114,193,194 In this work we 
discuss methods to conjugate small organic fluorophores to phosphine ligands. We aim 
to use the metal complexes derived from these fluorescent phosphines as potential 
therapeutic or imaging agents. The fluorescent phosphine complex conjugates described 
herein will be assessed in in vitro studies and be compared to the (cis-tach)Ru complexes 
described in Chapter 2.  
3.1.1 Methods to functionalise phosphine ligands 
The strategies to chemically conjugate an organic fluorophore to a diphosphine ligand 
discussed in this chapter are: 
• Phosphine fluorophore conjugation before metal coordination: 
 
• Phosphine fluorophore conjugation after metal coordination: 
 
• Direct phosphine fluorophore conjugation (without a backbone tether): 
 
A survey of the relevant literature for these methods is presented. 
3.1.1.1 Pre-coordination conjugation 
Many examples of phosphine ligand conjugates have been reported (see Figure 3.1 for 
examples). The tethers used to incorporate an organic fluorophore include ether, ester, or 
amide linkages. A pyrenyl ether conjugated monophosphine (A) was prepared and the 
luminescent properties of the corresponding Ru halide complexes were reported by Wolf 
et al.195 A mixed donor P,S-ligand (B) was reported by Mirkin et al., which featured an 
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amide tethered pyrenyl group and the resultant Rh complexes employed as fluorescent 
tweezers for anion sensing.196  
Jacquemin et al.116 have synthesised ligands (C) by a Pd-catalysed coupling of a coumarin-
containing aryl iodide with secondary aryl phosphines. The fluorescent triarylphosphine 
ligands (C) were complexed to Ru, Os and Au and the photophysical and anti-proliferative 
properties investigated in biological studies. Coumarin derivatives (D) have also been 
successfully conjugated to amino acid derived diphosphines reported by Smith et al.197 The 
crystal structures of the derived MCl2 complexes (M = Pd, Pt) showed intramolecular 
hydrogen bonding between the coumarin N–H and the N lone pair in the ligand backbone. 
To date, the luminescence properties of these complexes have not been reported.  
 
Figure 3.1. Chemical structures of previously reported phosphine ligand conjugates. 
Shaw and co-workers reported ligands (E) derived from amide coupling between 
bis((diphenylphosphino)methyl)glycine and amino acid esters.198 The Rh complexes of E 
were shown to be active in CO2 hydrogenation which was aided by the pendent amine of 
the ligand facilitating an outer coordination sphere mechanism. 
A versatile method of generating functionalised diphosphine conjugates such as F is via 
Ph2PCH2OH which Reetz
199 and Smith197,200 have shown can be condensed with a range 
of primary amines containing a variety of functional groups. 
3.1.1.2 Post-coordination conjugation 
Conjugating phosphines after coordination is a desirable methodology as it would allow 
diversification from a single metal complex precursor to create a library of functional 
complex conjugates. Despite this advantage, post-coordination conjugation techniques 
have been reported less frequently in the literature than pre-coordination conjugation. 
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Shaw et al. demonstrated that HATU-mediated amide coupling of carboxylic acid 
functionalized diphosphines was successful on a pre-formed Rh complex (Scheme 3.1) 
proceeding in 42% yield.201 In this example, a photoactive azobenzene moiety is coupled 
to the carboxylic acid groups of the coordinated ligands to give G. The light-induced 
cis/trans isomerization of the azobenzene motif led to structural changes in complex G 
which were studied by 1H NMR spectroscopy. The Rh complex G was tested in CO2 
hydrogenation catalysis and results were compared for the reaction when it performed in 
the light and in the dark. The effect of photocontrolled azobenzene switching was not 
found to significantly alter the rate of CO2 hydrogenation evidenced by the similar turn 
over frequencies for cis/trans-G (TOF = 16 ± 2 h–1 (cis-G) and 11 ± 2 h–1 (trans-G)).  
 
Scheme 3.1. Synthesis of a Rh diphosphine complex with diazobenzene linker, Shaw et 
al.201 
In another example of post-coordination conjugation, Dyson et al. reported cytotoxic 
(arene)Ru (RAPTA) derivatives (H) with a 4-(diphenylphosphino)phenol ligand (Scheme 
3.2).171 Small drug molecules such as aspirin, ibuprofen, ethacrinic acid and indomethacin 
were coupled to [(η6-p-cymene)Ru(PPh2(4-C6H4OH)Cl2] in a series of on-metal 
esterification reactions. 
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Scheme 3.2. Cytotoxic RAPTA complex conjugates (H), reported by Dyson et al.171 
In Scheme 3.2, the acid chloride derived from each small molecule drug is formed in situ 
before reaction with [(η6-p-cymene)Ru(PPh2(4-C6H4OH)Cl2] in the presence of base to 
give the new class of RAPTA drug conjugates. These Ru metallodrug conjugates were 
found to be more cytotoxic than either the Ru precursor or the small molecule drugs 
alone. Although the authors never observed ester cleavage of the complex conjugates, 
they suggest that once inside the cell, esterase enzymes could cleave this bond to separate 
the small drug fragment from the complex.  
3.1.1.3 Direct phosphine conjugation (without a tether) 
A series of diphosphine ligands derived from Mannich condensation with different 
amines have been reported. In these examples diphosphine conjugates (I) with different 
backbone functionalities (e.g., alkyl, alcohol, carboxylic acid) are readily formed from in 
situ generation of Ph2PCH2OH (from equimolar amounts of (CH2O)n and Ph2PH) 
followed by condensation with the relevant amine (Scheme 3.3).200 
 
Scheme 3.3. Formation of PCNCP ligands (I) from condensation with functionalised 
amines.  
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Another method of directly conjugating a monophosphine with a fluorescein-type 
chromophore was reported by Gabbaï et al. (Scheme 3.4).119 Reaction of o-(Ph2P)-C6H4Li 
with 3,6-di(t-butyldimethylsiloxy)xanthone followed by work up with acetic acid give the 
fluorescein ligand (J). The photophysical and coordination properties were explored 
(discussed later in Section 4.1.1, Chapter 4), and J was found to be an efficient sensor for 
Au(I) and Au(III) ions in aqueous solution.  
 
Scheme 3.4. Synthesis of ortho-diphenylphosphino fluorescein ligand (J), Gabbaï et al.119  
 
The remainder of this chapter will focus on chemically conjugating organic fluorophores 
to diphosphine ligands for their application as cytotoxic (cis-tach)Ru complexes. This 
methodology is not limited to fluorophores and could be extended to the coupling of any 
small molecule, such as drugs, carbohydrates, or peptides. 
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3.1.2 Research aims 
To gain an understanding of the ways to chemically conjugate phosphine ligands with 
small organic molecules, we aimed to carry out the following: 
• Explore different coupling methods of phosphine ligands bearing a reactive 
functional group. By exploiting previously reported methods for Ru and Rh 
chemistry, we hoped that coupling could be performed both pre-metal 
coordination and post-metal coordination (Scheme 3.5). 
 
Scheme 3.5. Proposed methods for pre-coordination and post-coordination conjugation. 
• Evaluate the most efficient method of synthesising fluorescent phosphine 
complex conjugates.  
• Study the photophysical properties of (cis-tach)Ru phosphine complex conjugates 
by UV-visible and fluorescence spectroscopy.  
• Assess the fluorescent (cis-tach)Ru complex conjugates as cytotoxic agents and 
gain insight into their mechanisms of action.  
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3.2 Synthesis of ligand conjugates 
3.2.1 Pre-coordination conjugation via amide bond formation 
We started with the carboxylic acid functionalised diphosphine 
bis((diphenylphosphino)methyl)glycine (L3.1). First, because of the amide coupling 
literature precedent on this type of ligand from Shaw et al., and second, because a 3-atom 
backbone gave the most cytotoxic (cis-tach)Ru complexes (see Section 1.2.3, Chapter 2). 
Ligand L3.1 was prepared by in situ formation of diphenylphosphinomethanol followed by 
condensation with glycine (Scheme 3.6).198  
 
Scheme 3.6. Literature synthesis of bis((diphenylphosphino)methyl)glycine L3.1.
198 
Two different classes of fluorescent amines were initially selected, one a pyrene derivative, 
and the other a 4-methylcoumarin derivative.  
First, 1-pyrenemethylamine (generated by deprotonation of the commercially available 1-
pyrenemethylamine hydrochloride salt with excess triethylamine) was coupled to L3.1 
using DIPEA and HATU (Scheme 3.7). After addition of DIPEA to deprotonate the 
carboxylic acid the desired product L3.2 detected, albeit as part of a mixture of products 
shown by the in situ 31P{1H} NMR spectrum (Figure 3.2). 
 
Scheme 3.7. Synthesis of L3.2 via HATU mediated amide coupling.  
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Figure 3.2. Stacked 31P{1H} NMR spectra for the synthesis of L3.2. a) In situ to show 
mixture of products, b) after aqueous workup, c) purified L3.2, d) Pt complex 3.2.  
The in situ 31P{1H} NMR spectrum of the mixture obtained from the reaction in Scheme 
3.7 contained several singlet resonances in the region around δP = –27.0 ppm, typical of 
PCNCP ligands (see Figure 3.2).200 There is a small difference in the 31P chemical shift for 
the desired ligand (δP = –26.4 ppm) compared to the starting material L3.1 (δP = –27.9 
ppm); however, this only becomes apparent after isolation of L3.2 from the crude reaction 
mixture. The hexafluorophosphate anion (present from HATU) can clearly be seen in the 
in situ 31P{1H} NMR (δP = –144.2 ppm, hept, 
1JPF = 710 Hz). This byproduct was removed 
by aqueous work up and the pure diphosphine ligand L3.2 was obtained following column 
chromatography and isolated in a 15% yield. The main loss in yield was attributed to the 
product partially coeluting with unreacted starting material, and despite efforts, this could 
not be improved.  
Coordination to Pt was achieved by addition of the ligand to [PtCl2(cod)] in a 1:1 molar 
ratio (Scheme 3.8). The Pt complex 3.2 has the expected platinum satellites in the 31P{1H} 
NMR spectrum with a characteristic 1JPPt coupling constant of 3416 Hz, typical of the 
ligand coordinating in a cis fashion (Figure 3.2). The formation of complex 3.2 was 
confirmed by HR-ESI-MS for [3.2–Cl]•+ (m/z 914.1784) with the expected platinum and 
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Scheme 3.8. Formation of PtCl2 complex 3.2.  
The pyrene ligand conjugate L3.2 reacted with [RuCl(cis-tach)(DMSO)2]Cl (2.1) in EtOH 
under reflux for 48 h to give complex 3.3 (Scheme 3.9). Despite the extended reaction 
time and elevated temperature, cleavage of the amide bond was not observed and the 
desired complex 3.3 was isolated in 81% yield. In the 31P{1H} NMR spectrum, the 6-
membered chelate gave a singlet resonance (δP = 41.6 ppm), at a chemical shift similar to 
that of the (cis-tach)Ru complex of dppp (2.7) (δP = 44.0 ppm). The formation of [3.3]
•+ 
was confirmed by HR-ESI-MS (m/z 950.2465) with the expected ruthenium and chlorine 
isotope pattern.  
 
Scheme 3.9. Formation of (cis-tach)Ru complex 3.3.  
The amide coupling reaction was attempted with 7-amino-4-methylcoumarinIII (Scheme 
3.10) to form the same ligand reported by Smith et al. (compound D in Figure 3.1).197 The 
in situ 31P{1H} NMR spectrum did not show a signal in the expected region. The reaction 
mixture contained multiple species according to the 31P{1H} NMR spectrum, with one 
signal tentatively assigned to the product (δP = –19.2 ppm); however, attempted isolation 
by column chromatography was not successful. 
 
III Prepared from 3-aminophenol306 
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Scheme 3.10. Attempted synthesis of coumarin ligand conjugate L3.3.  
We next aimed to synthesise fluorescent ligand conjugates by the direct Mannich 
condensation methods previously reported by Smith et al.200 
3.2.2 Direct conjugation 
The Mannich condensation of formaldehyde and diphenylphosphine with primary amines 
has previously been used as a route to new diphosphines.197,200 In this work, ligand 
conjugates containing an N-bound pyrenyl or coumarin moiety were targeted. The 
reactions of both 1-aminopyrene and 7-amino-4-methylcoumarin with 
diphenylphosphinomethanol (Scheme 3.11) appeared to proceed to the monosubstituted 
and disubstituted phosphines as indicated by the increase in the 31P{1H} NMR resonance 
at δP = –27.1 ppm in both cases. Unfortunately, the reactions could not be pushed to 
completion (only 60% of the mixtures contained the desired diphosphine ligand according 
to 31P{1H} NMR spectroscopy) and purification of the coumarin derivative by column 
chromatography gave material that was only 80% pure by 31P{1H} NMR spectroscopy 
with the only inseparable impurity being the monophosphine ligand corresponding to one 
condensation.  
The phenol substituted ligand (L3.4) was successfully prepared as previously reported, and 
it was suggested that the difficulty in achieving the correct stoichiometry for the 
preparation of L3.5 and L3.6 was due to their poor solubility in alcohol or chlorinated 
solvents. The formation of the coumarin derived ligand was confirmed by HR-ESI-MS 
(m/z 572.1921 for [L3.5+H]
•+). For the reaction with 1-aminopyrene, after 24 h, the 31P{1H} 
NMR spectrum showed 57% of the reaction mixture was the desired product L3.6; 
however, the isolated material was highly insoluble and attempts to purify it further were 
unsuccessful.  
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Scheme 3.11. Attempted synthesis of PCNCP ligands L3.5 and L3.6 derived from 
Ph2PCH2OH, and the synthesis of phenol conjugated ligand L3.4.  
Due to the limited solubility of L3.5 and L3.6, these ligands did not react with [RuCl(cis-
tach)(DMSO)2]Cl (2.1) and methods to conjugate the organic fluorophore via a linker 
were pursued. It is noted that L3.4 bearing a 4-hydroxyphenyl group would be a useful 
handle for post-coordination functionalisation in a manner similar to the method reported 
by Dyson employing (4-hydroxyphenyl)diphenylphosphine (see Scheme 3.2).171 
3.3 Synthesis of Ru complex conjugates 
3.3.1 Post-coordination conjugation via amide bond formation 
Following the successful coordination of the pyrene-conjugated diphosphine L3.2 to form 
Ru complex 3.3, effort shifted to synthesise a carboxylic acid functionalised (cis-tach)Ru 
complex (to be used as a coupling precursor). Considering that a flexible, aliphatic 
backbone resulted in a more cytotoxic (cis-tach)Ru complex (see dppp and dppb 
complexes 2.7-2.8 in Chapter 2), bis((diphenylphosphino)methyl)glycine (L3.1) was 
reacted with [RuCl(cis-tach)(DMSO)2]Cl (2.1), and the resulting functional complex 3.1 
was isolated in 96% yield (Scheme 3.12). Pleasingly, the carboxylic acid functionality did 
not interfere with coordination and the 1H, 13C{1H} and 31P{1H} NMR data are consistent 
with the structure of 3.1 shown in Scheme 3.12.  
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Scheme 3.12. Formation of carboxylic acid-functionalised (cis-tach)Ru complex 3.1. 
In the 31P{1H} NMR spectrum, the 6-membered chelate 3.1 gives a singlet resonance (δP 
= 40.4 ppm), in accord with the 6-membered (cis-tach)Ru metallacycle 2.7. In the 13C{1H} 
NMR spectrum for 3.1, the singlet for the carbonyl carbon (δC = 173.3 ppm in CD3OD) 
is very slightly shielded (~0.5 ppm) compared to the free ligand L3.1 (δC = 173.8 ppm in 
CD3OD). The HR-ESI-MS data are consistent with the expected [3.1]
•+ showing the 
expected ruthenium and chlorine isotope pattern and the IR signal (ν(CO) = 1722 cm–1) 
(solid state) for 3.1 is typical of an alkyl carboxylic acid.  
We set out to functionalise the carboxylic acid group of 3.1 with an organic fluorophore. 
Initial attempts, employing dicyclohexylcarbodiimide (DCC) as the amide coupling agent 
with either benzylamine (as a model for 1-pyrenylmethylamine) or 7-amino-4-methyl-
coumarin in dichloromethane did form the expected products (detected by HR-ESI MS 
and IR spectroscopy). However, the isolated materials were impure by 1H and 31P{1H} 
NMR spectroscopy (Scheme 3.13). By addition of 1-hydroxybenzotriazole (HOBt), which 
is commonly employed as an activating agent in DCC coupling reactions, analysis of the 
post reaction mixture revealed several resonances assigned to phosphine oxides, and thus 
highlighted the incompatibility of HOBt with phosphine complexes. In previous post-
coordination conjugation work, Shaw et al. reported amide coupling chemistry between 
carboxylic acid functionalised Rh phosphine complexes and amines using HATU as the 
coupling agent.198,201 
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Scheme 3.13. Attempted formation of 3.4 and 3.5 via DCC promoted amide coupling. 
By switching the amide coupling agent from DCC to HATU and attempting the same 
conditions that had worked for pre-coordination conjugation, the pyrenyl and coumarin 
functionalised complex conjugates were formed (as detected by HR-ESI-MS (m/z = 
894.2071 for 3.5 and m/z = 950.2465 for 3.3), however, the isolated complexes were also 
impure by 1H NMR spectroscopy, potentially due to unwanted side products from the 
amide coupling agent (Scheme 3.14 and Scheme 3.15).  
 
Scheme 3.14. Attempted formation of 3.3 via HATU promoted amide coupling.  
Chapter 3. Fluorescent phosphine complex conjugates 
73 
 
Scheme 3.15. Attempted formation of 3.5 via HATU promoted amide coupling. 
As is often employed for cationic Ru complexes, purification of 3.5 by column 
chromatography was attempted (silica gel eluting CH2Cl2/MeOH 0–20%).
202,203 The 
unreacted 7-amino-4-methylcoumarin was easily recovered and the orange band, 
consisting of the Ru-containing fractions was analysed. The 31P{1H} NMR spectrum 
showed multiple (slightly broadened) signals in the expected region (ca. δP = 40 ppm) 
suggesting that there may be multiple isomers in solution, thus rendering the phosphorus 
nuclei inequivalent. This contrasts with the pyrene complex conjugate 3.3, which, as 
expected, shows one sharp singlet in the 31P{1H} NMR spectrum (Figure 3.3). 
 
Figure 3.3. 31P{1H} NMR spectrum of coumarin complex conjugate 3.5 (a) and pyrene 
complex conjugate 3.3 (b). Inset: Expansion to show peak broadening for the coumarin 
containing complex.  
a) 
b) 
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We hypothesised that for 3.5, the peak broadening in the 31P{1H} NMR spectrum could 
be due to an equilibrium between the cis- and trans-configured amide isomers. The 
coumarin moiety could form intramolecular hydrogen bonds with the cis-tach NH2 
protons, potentially stabilising the cis-configured isomer (shown in cis-3.5, Figure 3.4). 
This particular diphosphine was previously observed to form an intramolecular hydrogen 
bond between the coumarin N–H and the backbone nitrogen in the solid-state structure 
of [PdCl(CH3)(L3.3)] reported by Smith et al. (Figure 3.4).
197 Furthermore, Yam et al. have 
investigated the cis-trans isomerisation of Pd(II) complexes bearing acetanilide conjugated 
phosphine ligands.204 The dominant trans isomer is observed in solution by 31P NMR 
spectroscopy, but a shift in the equilibrium from trans to cis was induced by the addition 





Figure 3.4. a) Possible cis-/trans- amide isomers of 3.5. cis-3.5 could form intramolecular 
hydrogen bonds between the coumarin oxygen and the cis-tach protons (highlighted in 
blue). b) Molecular structure of [PdCl(CH3)(L3.3)] from Smith et al. where PPh2 carbons 
(except ipso carbons) have been omitted for clarity. Intramolecular hydrogen bond N2–
H2…N1 (2.27 Å), shown in red.197  
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We aimed to understand this dynamic behaviour by VT-NMR experiments and 
(preliminary) DFT calculations (see below). The 31P{1H} NMR spectrum of 3.5 (in EtOH) 
was recorded at intervals from 20 °C to –80 °C (Figure 3.5). At 20 °C, two distinct broad 
singlets are observed (δP = 40.4 and 39.8 ppm) which begin to merge at –60 °C. Another 
set of resonances (δP = 36.1 and 35.5 ppm), potentially due to another amide isomer, are 
observed at 0 °C but merge to one signal between –50 °C and –60 °C. This is in 
accordance with both amide isomers existing in equilibrium at room temperature (giving 
rise to two sets of signals), and upon cooling, the more thermodynamically stable isomer 
is observed. 
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We also investigated the solution behaviour of 3.5 by NMR spectroscopy at elevated 
temperature. The 31P{1H} NMR spectrum of 3.5 (in EtOH) was recorded at intervals 
from 25 °C to 65 °C (Figure 3.6). At 25 °C, two sets of signals can be seen (one sharp set 
at δP = 36.1 and 35.8 ppm and one broad set at δP = 35.2 and 31.5 ppm). On heating the 
sample, the sharp signal at δP = 36.1 remains sharp and does not change chemical shift. 
The other signals broaden as temperature is increased and at 65 °C, the two downfield 
resonances have started to coalesce. From the high temperature 31P{1H} NMR spectra, it 
would appear that at least two conformations of the expected coumarin complex 
conjugate 3.5 exist in solution up to 65 °C. 
 
Figure 3.6. High temperature 31P{1H} NMR spectra of 3.5 in EtOH. 
DFT was used to analyse the effect of having a tethered group capable of hydrogen 
bonding to cis-tach as in complex 3.5 (Figure 3.4) versus complexes 3.4 and 3.3 bearing 
benzyl and pyrenyl groups, respectively. All calculations used DFT as implemented in 
Schrödinger’s Jaguar 8 package and the PBE0 functional. A standard 6-31G* basis set was 
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calculated Gibbs free energies for the two cis- and trans-isomers of each complex are 
presented in Table 3.1. The difference in Gibbs energy between each conformer (ΔG / 
kcal mol–1) indicates the slight preference for the cis-isomer (with both being energetically 
reasonable conformers at ambient temperature. In the case of the coumarin containing 
complex 3.5, this energy preference is greatest with the cis-isomer being 5.0 kcal mol–1 
lower in energy than the trans-isomer. In comparison, the cis-/trans-isomers of the benzyl 
and pyrenyl derivatives are closer in energy (1.8 kcal mol–1 and 3.0 kcal mol–1, respectively) 
consistent with the hypothesis that the coumarin group plays a role in stabilising the cis-
isomer by hydrogen bonding. 
Table 3.1. Calculated Gibbs free energies for geometric amide isomers of 3.3-3.5.a 
Substituent Complex Total Gibbs E / a.u.a ΔG / kcal mol–1 
pyrene 
cis-3.3 -3557.126252 0.0000 
trans-3.3 -3557.131013 2.9876 
benzyl 
cis-3.4 -3174.155634 0.0000 
trans-3.4 -3174.158424 1.7508 
coumarin 
cis-3.5 -3438.639985 0.0000 
trans-3.5 -3438.631952 5.0408 
aPBE0/6-31G*/LACV3P* level of theory.  
The calculated amide isomer structures did not show the expected hydrogen bonding for 
3.5. Further analysis is necessary to understand the dynamic solution behaviour of 
phosphine ligand conjugates with the potential to form hydrogen bonds to cis-tach.  
3.3.2 Post-coordination conjugation via ester bond formation 
There are many examples of organometallic Ru-phosphine complexes that show anti-
proliferative properties in vitro and in vivo.205–209 In the widely studied RAPTA complexes, 
although the replacement of a 1,3,5-triaza-7-phosphaadamantane (PTA) ligand with a 
triarylphosphine ligand lowers the aqueous solubility of the resulting complex, the added 
hydrophobicity can increase cellular uptake and thus, improve cytotoxicity.38,210 Therefore, 
functionalisation of a coordinated phosphine ligand may provide a potential method to 
chemically conjugate an organometallic complex with a small molecule to add further 
functionality. The work described below builds on the previously reported Ru complex 
bearing a (4-hydroxyphenyl)diphenylphosphine ligand (Scheme 3.16).  
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The [(η6-p-cymene)RuCl2{PPh2(4-C6H4OH)}] (3.7) was initially reported for the synthesis 
of metal containing dendrons (wedge shaped dendrimers).211 It was later exploited by 
Dyson et al. for the synthesis of cytotoxic compounds; they reported the synthesis of a 
small library of small organic drugs that were conjugated to 3.7 by an esterification 
reaction (promoted by an amine base or a activating agent (1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDCI) with DMAP)).171 The functionalised 
complexes were isolated and purified by column chromatography on silica gel. This 
method of post-coordination conjugation obviated the need to synthesise the free, air-
sensitive ligand conjugates. We viewed this methodology as a potential way to conjugate 
a small organic fluorophore to the Ru metallodrug. Therefore, the precursor complex 3.7 
was prepared following previously reported methods171,211 and reacted with a freshly 
prepared solution of 1-pyrenylcarbonyl chloride 3.6 (Scheme 3.16). 
 
Scheme 3.16. Synthesis of 3.7 and novel fluorescent RAPTA pyrene conjugate 3.8.171 
The RAPTA pyrene complex conjugate 3.8 was purified by column chromatography 
(silica gel, eluent CH2Cl2/MeOH 0–10%). The disappearance of the phenolic proton of 
3.7 (δH = 9.96 ppm) was monitored by 
1H NMR spectroscopy, as well as the appearance 
of a band in the IR spectrum (ν(C=O) = 1727 cm–1) that confirmed the formation of the 
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ester linkage. The HR-ESI-MS also confirmed the atomic composition of 3.8 displaying 
the expected ruthenium and chlorine isotope pattern.  
By analysing the ester carbonyl IR stretching frequency and 13C{1H} NMR signal (δC = 
166.0 ppm for 3.8), we observe the influence of a more electron-withdrawing pyrenyl 
group compared with the more electron-donating alkyl derivatives reported by Dyson et 
al. (see H in Scheme 3.2; δC = 168.9–174.8 ppm and ν(C=O) = 1746–1778 cm
–1).  
Although RAPTA complex conjugate 3.8 was not evaluated in vitro, its photophysical 
properties due to the pyrene fluorophore could be useful for studying cellular uptake by 
fluorescence microscopy and comparing the activity to the wide variety of previously 
reported RAPTA complexes. 
3.4 Fluorophore conjugation method evaluation 
The coupling of organic fluorophores to diphosphine ligand L3.1 or to the functional (cis-
tach)Ru complex 3.1 by amide bond formation are not clean reactions. In both cases of 
pre-coordination and post-coordination conjugation, many unwanted side-products 
(including phosphine oxides) are produced. The attempts at performing post-
coordination conjugation with common amide coupling agents DCC and HATU gave 
impure material which unfortunately was not successfully purified. However, it appears 
the functional (cis-tach)Ru complex 3.1 bearing a carboxylic acid group can act as a pivotal 
precursor to further functionalized Ru complex conjugates. Overall, the most efficient 
route to the pyrene complex conjugate 3.3 is shown in Scheme 3.9 (pre-coordination 
conjugation), where the conjugated ligand L3.2 is isolated and then coordinated in a 
subsequent step to [RuCl(cis-tach)(DMSO)2] (2.1). 
For organometallic RAPTA complexes, post-coordination conjugation of 3.7 with 1-
pyrenylcarbonyl chloride to give 3.8 followed by purification by column chromatography 
is a reliable route to high purity fluorescent RAPTA derivatives.  
3.5 Photophysical properties of phosphine conjugates 
The emission spectra for pyrene and pyrene conjugated diphosphine ligand L3.2 were 
recorded in CH2Cl2; the UV-visible absorption and emission spectra for the pyrene 
complex conjugate 3.3 were recorded in water and are shown in Figure 3.7. For pyrene 
and L3.2, the emission spectra exhibit maxima at λem = 464 nm and λem = 392 nm, 
respectively. The key difference is the blue-shift in the emission maximum of ca. 72 nm 
Chapter 3. Fluorescent phosphine complex conjugates 
80 
for L3.2 compared to pyrene which is presumably due to the prevention of excimer 
emission from the pyrenyl moiety in the amide conjugated phosphine ligand L3.2. For the 
(cis-tach)Ru complex conjugate in aqueous solution, the characteristic absorbance bands 
due to pyrene are the lowest energy absorption bands (λMax = 343 nm and 327 nm) due to 






Figure 3.7. a) Emission spectra for pyrene and pyrene ligand conjugate L3.2 recorded in 
CH2Cl2. b) UV-Visible absorption and emission spectra for complex 3.3 recorded in H2O 
(λEx = 343 nm).  
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In aqueous solution, the emission spectrum of 3.3 is comparable to that of L3.2 with one 
additional shoulder peak (λEm = 375 nm), but crucially the emission intensity for 3.3 is not 
significantly quenched upon metal coordination or by dissolution in water. Presumably, 
the pyrene fluorophore is sufficiently remote from the Ru centre that any MLCT 
quenching is supressed. As a result of its emission properties and high aqueous solubility, 
we aimed to use 3.3 as a dual chemotherapeutic/imaging agent for in vitro studies (see 
Section 3.6). 
The UV-visible absorption and emission spectra of 7-amino-4-methylcoumarin and the 
coumarin diphosphine ligand conjugate L3.5 were recorded in MeCN solution. Figure 3.8 
shows the normalised spectra where interestingly the bathochromic shift for the emission 
maxima between the aminocoumarin and the ligand conjugate (Δλem = 20 nm) is slightly 
greater than that for the absorbance maxima (Δλem = 16 nm). The intense absorption band 
for 7-amino-4-methylcoumarin (λabs = 341 nm) due to a π–π* transition is characteristic 
to other functionalised coumarin derivatives.116,214 
 
Figure 3.8. Normalised UV-visible absorption and emission spectra for 7-amino-4-
methylcoumarin and the corresponding ligand conjugate L3.5 recorded in MeCN, (λEx = 
350 nm). 
The bathochromic shift (red-shift) in the emission maximum could be due to an increased 
inductive effect from the alkyl substituents on the nitrogen as commonly seen with other, 
commercially available coumarin fluorophores (Figure 3.9).215 
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Figure 3.9. Summary of the photophysical properties of L3.5 and related aminocoumarins. 
aPhotophysical data taken from references 215,216. 
The emission spectrum of pyrene complex conjugate 3.8 was recorded in MeCN (Figure 
3.10) and displays one intense emission band (λem = 413 nm) which is red-shifted 
compared to the emission maximum of L3.2 (λem = 392 nm). It must be noted, however, 
that due to poor aqueous solubility, the emission spectrum of 3.8 has not been recorded 
in water. Solvatochromic effects may provide differences in the emission properties of 
pyrene conjugated Ru complexes, and this should be considered when designing aqueous 
soluble metallodrug conjugates.217,218 
 
Figure 3.10. Emission spectrum of 3.8 recorded in MeCN, (λEx = 350 nm). 
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3.6 Cytotoxicity 
The results in this section are from preliminary cell studies carried out at the University 
of York and form the basis of a collaborative study. The compounds tested were prepared 
by the author and the cell assays and microscopy were carried out by Dr. Karen Hogg and 
Dr. Joanne Marrison (University of York). With the luminescent (cis-tach)Ru complex 
conjugate 3.3 in hand, the aim was to study its biological activity and compare this with 
the previously tested cytotoxic (cis-tach)Ru complexes (Chapter 2). The compounds 
discussed in the following studies (Figure 3.11) are (cis-tach)Ru complexes 2.17-2.19, Ru 
pyrene complex conjugate 3.3, and cisplatin.  
 
Figure 3.11. Chemical structures of the (cis-tach)Ru complexes assessed in the following 
biological studies.  
3.6.1 Confocal microscopy 
With pyrene and coumarin (cis-tach)Ru complex conjugates prepared, we tested them as 
dual cytotoxic/imaging agents in a series of confocal microscopy experiments. 
Unfortunately, despite many attempts, the nature of these organic fluorophores 
(excitation wavelengths below 400 nm, see Figure 3.7 and Figure 3.8) made them 
unsuitable for the Zeiss LSM 780 multiphoton confocal microscope. The instrument 
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requires a fluorophore with an excitation wavelength above 405 nm and so no confocal 
microscopy was possible. 
3.6.2 Flow cytometry viability study 
The viability of A549 and 293T cells was assessed by a DRAQ7 assay which was used to 
detect apoptotic or membrane-compromised cells.191,194 DRAQ7 selectively stains 
damaged/dead cells and does not enter live cells; thus, by analysing the cell populations 
by flow cytometry, the relative uptake of the test compounds can be monitored over time. 
The cells were analysed after 24 h, 48 h and 7 days following treatment with the different 
(cis-tach)Ru complexes. Figure 3.12 and Figure 3.13 show representative examples of the 
contour plots obtained showing the live cells (bottom half of each plot) and dead cells 
(top left quadrant) where the analysis has been gated on single cells to avoid counting cell 
debris.  
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A549 24 h 48 h 7 d 
Control 
   
Cisplatin 
   
RuTer 
2.17 
   
RuPyr 
3.3 
   
Figure 3.12. Representative contour plots generated from DRAQ7 flow cytometry assay. 
Plots show A549 cells treated with cisplatin and (cis-tach)Ru complexes (12.5 µM).  
A plot summarising the 24 h and 48 h data from the DRAQ7 assay for A549 cells (Figure 
3.14) shows that only compound 2.17 (Figure 3.12) had a significant cytotoxic effect after 
24 h. All other compounds showed very little cytotoxicity, as determined by this assay. 
The data for the 7-day analysis (which based on the contour plots shows almost all the 
cells to be dead) has not been included in this summary plot, due to the low number of 
cells detected. Ideally for this type of analysis >10,000 cells would be counted and after 7 
days, typically only 1,000–2,000 would be detected.  
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Figure 3.13. Representative contour plots generated from DRAQ7 flow cytometry assay. 
Plots show 293T cells treated with cisplatin and (cis-tach)Ru complexes (12.5 µM). 
A plot summarising the 24 h and 48 h data from the DRAQ7 assay for 293T cells (Figure 
3.14) shows that, although compound 2.17 was again the most cytotoxic, all the (cis-
tach)Ru complexes had a significant cytotoxic effect after 24 h, in all cases exceeding the 
activity level of cisplatin. 






Figure 3.14. Summary plots showing data summary from DRAQ7™ assay contour plots 
for, a) A549 cells and b) 293T cells, treated with cisplatin, 2.17, 2.18, 2.19, and 3.3 (6.25 
and 12.5 µM). 
Samples were taken from the 293T cells after 24 h of treatment and visualised by confocal 
microscopy. The different cell morphologies can be seen in the images with reference to 
the corresponding contour plot that shows the amount of cell death (Figure 3.15). 
Ruptured cell membranes (indicative of cells undergoing apoptosis) can clearly be seen in 
cells treated with compounds 2.17, 2.19, and 3.3, in line with a high percentage of dead 
cells detected (25–95%). The images of the cells treated with cisplatin and 2.18 show some 
blebbing of the cell membrane but overall, the cells are more intact, and this correlates 
with a lower percentage of dead cells detected (10–15% for cisplatin and 15–25% for 
2.18).  
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Control Cisplatin 2.18 (RuQuin) 
   
   
2.17 (RuTer) 2.19 (RuExQuin) 3.3 (RuPyr) 
   
   
Figure 3.15. DRAQ7™ contour plots and corresponding confocal microscopy images 
of 293T cells after 24 h of treatment with cisplatin and (cis-tach)Ru complexes (12.5 µM). 
3.7 Conclusions 
It has been shown that using amide coupling chemistry, small organic fluorophores can 
be conjugated to phosphine ligands both pre- and post-metal coordination. The known 
diphosphine bis((diphenylphosphino)methyl)glycine L3.1 is a versatile amide coupling 
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partner with a variety of aryl and alkyl amines. Amide coupling protocols employing 
HATU have successfully formed the desired ligand conjugates; however, yields are low 
due to side product and phosphine oxide formation, and loss of material upon purification. 
The useful Ru synthon 3.1 has been subjected to post-coordination conjugation 
conditions; however, although the complex conjugates 3.3-3.5 have been detected in the 
reaction mixtures, this coupling route is low-yielding and produces impure material. This 
leads us to conclude that, at this time, independent synthesis of fluorescent ligand 
conjugates (followed by coordination) is the preferred route.  
We have found that phosphorus-based Mannich condensations to form ligands with 
organic fluorophores directly incorporated into the backbone is possible. However, due 
to low solubility, it is difficult to purify these materials. As high aqueous solubility has 
remained a priority for this project, these ligands were not investigated further.  
The photophysical properties of all novel compounds have been investigated by UV-
visible and fluorescence spectroscopy. In all cases, they display the expected features 
attributed to pyrenyl or coumarin chromophores, and the coordination of the fluorescent 
ligands does not quench emission intensity. However, the emission properties of both 
pyrene and coumarin are not suitable for confocal fluorescence microscopy in our hands, 
due to instrument requirements of having a minimum excitation wavelength laser of 405 
nm. 
The cytotoxicity of 3.3 was investigated by flow cytometry and confocal microscopy and 
compared to 2.17-2.19. Changing the structure of the chelating phosphine from an all-
carbon backbone to a PCNCP backbone does not have a detrimental effect on the 
cytotoxicity of the resulting complex. Moreover, this nitrogen atom provides a useful 
point of derivatization for metal diphosphine drug conjugates. 
3.8 Future work 
Our primary focus has been to use a (cis-tach)Ru complex with a suitable fluorophore for 
confocal fluorescence microscopy and further biological assays. Based on the examples 
containing fluorophores with red-shifted emission properties (see work from the Smith, 
Gabbaï and Higham groups), fluorescein dyes should be investigated. Many fluorescein 
precursors are commercially available, such as 5- or 6-aminofluorescein (Figure 3.16) and 
these could be applied in the Ru conjugation chemistry discussed in this Chapter.  
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Figure 3.16. Commercially available aminofluorescein dyes. a Taken from reference 216. 
Following productive discussions with Dr. Martin Smith (University of Loughborough), 
we had aimed to use some of the fluorescein and rhodamine tagged diphosphine ligands 
prepared in the Smith group (Figure 3.17). These preformed ligands should coordinate to 
[RuCl(cis-tach)(DMSO)2]Cl in the same way as L3.2 and their photophysical properties are 
in the region of the visible spectrum that is required for microscopy and flow cytometry 
studies. Unfortunately, due to delays associated with COVID-19, we were not able to 
carry out further biological imaging studies using these ligands.  
 
Figure 3.17. Selected fluorescein and rhodamine conjugated diphosphines, prepared by 
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4.1 Introduction 
The use of organic fluorophores as a spectroscopic probe has become widespread in 
organic and organometallic chemistry. Organic dyes with specific luminescence properties 
that are amenable to microscopy are desirable for applications in imaging and 
catalysis.219,220 In this chapter, the synthesis of a range of pyrene-substituted phosphine 
ligands and a study of their coordination and photophysical properties is reported. The 
highly conjugated nature of polyaromatic substituents has previously been shown to 
confer exceptional air-stability when compared to simple phenylphosphines.221–223 
Through a combined experimental and theoretical approach, we have systematically 
studied the photophysical and air stability properties of pyrenylphosphines, and their 
associated (arene)Ru(II) coordination chemistry. 
4.1.1 Fluorescent probes  
Polyaromatic hydrocarbons (PAHs) have been widely studied due to their applications as 
organic fluorophores, stimuli sensors, and biological imaging agents. The D2h symmetric 
molecule, pyrene is of particular interest due to its characteristic photophysical properties, 
excimer formation, high quantum yield and long-lived excited states. Although pyrene has 
16 π electrons and does not follow Hückel’s (4n + 2) rule for aromaticity, it is planar and 
classified as aromatic.224 This property makes pyrene a useful molecule to study π–π 
stacking interactions, intercalation chemistry, and luminescence. The chemistry of pyrene 
has been extensively reviewed.196  
The luminescence properties of pyrene are concentration dependent; at low 
concentrations, the molecule exhibits fluorescence at 375 nm and at high concentration, 
an excimer state produces intense emission at 470 nm. This excimer state, combined with 
high fluorescence quantum yield, microenvironment sensitivity and the diverse tunability 
of the pyrene core, has led to it being a widely used chemical probe.  
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In 1987 Akasaka et al. reported the synthesis of diphenyl-1-pyrenylphosphine (DPPP) and 
its application in hydroperoxide sensing in lipids (Scheme 4.1).225 The free phosphine is 
non-emissive but upon oxidation, the DPPP oxide exhibits intense blue fluorescence (λEx 
= 352 nm, λEm = 380 nm).  
 
Scheme 4.1. Oxidation of DPPP by hydroperoxides, investigated by Akasaka et al.225 
This difference in emission intensity of the P(III) and P(V) species has been attributed to 
photoelectron transfer (PeT) quenching from the phosphorus lone pair to the pyrene 
chromophore. As a result, DPPP was later applied to monitoring lipid peroxidation in cell 
membranes by Noguchi et al.120 More recently, a DPPP derivative conjugated with an 
alkyltriphenylphosphonium iodide moiety developed by Shioji et al. showed that the probe 
selectively accumulated in the mitochondria of HepG2 cells (Scheme 4.2).226  
 
Scheme 4.2. Synthesis of a pyrene conjugated fluorescent probe designed to target the 
mitochondria.  
The first rationally designed P(III)/P(V) molecular probes for sensing hydroperoxides via 
a PeT quenching mechanism were based on a substituted benzoxadiazole (Scheme 
4.3a).106 The phosphines are weakly fluorescent (ΦF = 0.014–0.050 in MeCN) but upon 
oxidation with hydroperoxides, the corresponding phosphine oxides are highly emissive, 
as shown by significantly increased fluorescence quantum yields (ΦF = 0.36–0.44 in 
MeCN). A novel phosphine, conjugated with a 7-hydroxycoumarin fluorophore also 
showed an immediate increase in emission intensity after treatment with H2O2 in aqueous 
conditions (Scheme 4.3b).105 
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Scheme 4.3. Fluorophore conjugated phosphine PeT probes.105,106 
The photochemistry of fluorescent phosphine conjugates was investigated by Gabbaï et 
al.119,227 The authors exploited the phosphorus-to-fluorophore PeT quenching mechanism 
with a fluorescein conjugated phosphine (Scheme 4.4) by studying the emission properties 
of the phosphine and phosphine oxide. The emission switch-on effect was also achieved 
by metal coordination of the phosphine, which also prevents the PeT quenching 
mechanism. This concept was used to demonstrate the selective sensing of Au(III) ions 
in water. The quantum yields for the phosphine, phosphine oxide, and phosphine Au–Cl 
complex are ΦF = 0.12, 0.54 and 0.29, respectively (Scheme 4.4).
IV 
 
IVQuantum yields relative to fluorescein in 0.1 M NaOH (ΦF = 0.91). 
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Scheme 4.4. Fluorescein conjugated phosphine and synthesis of phosphine oxide, and 
Au–Cl complex, Gabbaï et al.119 
Unlike the examples from Gabbaï (where the fluorescein chromophore is conjugated to 
the phosphine by an o-phenylene linker), Higham et al. observed that there was no 
emission switch-on effect with BODIPY conjugated phosphines (via a p-phenylene linker) 
and no appreciable change in fluorescence quantum yield upon coordination to coinage 
metals (Figure 4.1).228 This is likely due to the BODIPY chromophore being sufficiently 
remote from the phosphine lone pair that the PeT quenching mechanism is suppressed.  
 
Figure 4.1. Chemical structures of BODIPY conjugated phosphines, reported by 
Higham et al.228 
Higham developed the synthesis of BODIPY-conjugated primary phosphines (Figure 4.1). 
Theoretical calculations demonstrated that, by having highly conjugated groups, the 
HOMOs of these primary phosphines are delocalised from the phosphorus lone pairs 
which imparts stability to air oxidation. In addition, the primary phosphines formed the 
expected mono- and bis-phosphine carbonyl complexes of molybdenum and tungsten, 
[M(CO)5(H2PR)] and cis-[M(CO)4(H2PR)2] (M = Mo, W). The fluorescence properties of 
the complexes do not show any significant reduction in the quantum yield compared to 
the free primary phosphine. This is presumably due the distance between the heavy metal 
atom and the BODIPY chromophore.118,229 
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Huang et al. reported a series of triaryl phosphine oxides (PyrxPPh3–x, x = 1–3) (Figure 4.2) 
that exhibit temperature dependent fluorescence from –50 to 100 °C.230 These 
compounds were shown to be robust over a large temperature range and could be used 
without deoxygenation treatment, making them suitable candidates for molecular 
thermometers. 
 
Figure 4.2. Fluorescent triarylphosphine oxides, Huang et al.230 
This series of phosphine oxides led us to consider the parent primary, secondary and 
tertiary phosphines, which were not considered in the studies by Huang, and investigate 
their coordination chemistry. In 2017, during our study of pyrenylphosphines, Walensky 
et al. reported the synthesis and fluorescent properties of tris(pyrenyl)pnictogen 
compounds that displayed quantum yields from well below 1% to ca. 13% for (Pyr)3P and 
ca. 14% for the phosphine oxide (Pyr)3PO (Figure 4.3).
231 It is noted that only modest 
luminescent enhancement was observed for these bulky tris(pyrenyl)pnictogen 
compounds upon oxidation from Pn(III) to Pn(V).  
 
Figure 4.3. Tris(1-pyrenyl)pnictogen compounds prepared by Walensky et al.231 
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4.1.2 Coordination chemistry   
The coordination chemistry of primary and secondary phosphines has received little 
attention compared to the ubiquitous use of tertiary phosphines. The resulting complexes 
that retain at least one reactive P–H bond are interesting for post-coordination 
modification. Reid et al. synthesised Ru halide complexes of the form trans-[RuX2(PR3)4] 
(X = Br, Cl; PR3 = PhPH2, Ph2PH),
232,233 and several organometallic examples including 
Mo(V) phosphinecarboxamide carbonyl, and (arene)Ru(II) (see below) have also been 
prepared.234,235  
With the development of more air-stable primary phosphine ligands that contain 
ferrocenyl or mesityl substituents, the coordination chemistry of these ligands was 
explored.235–237 Hey-Hawkins et al. extended the early studies of Reid with a series of Ru 
half-sandwich complexes with primary and secondary ferrocenyl phosphines of type [(p-
cymene)RuCl2(PR3)] (PR3 = FcPH2, FcCH2PH2, (FcCH2)2PH) (Figure 4.4). The properties 
of the complexes were explored by NMR spectroscopy, IR spectroscopy and X-ray 
crystallography. 238,239 The effect of phosphine coordination on the 1JPH coupling constants 
was investigated, with the values increasing from ca. 200 Hz (free phosphines) to ca. 400 
Hz in the Ru complexes. This large increase in coupling constant is thought to involve a 
strengthening of the P–H bond (as confirmed by an increase of ~80 cm–1 in the ν(P–H) 
IR stretching frequency). Moreover, it has been reported that metal coordination can 
weaken the P–H bond and lead to the formation of bridged phosphanido and 
phosphinidene complexes (through dehydrohalogenation), which are often insoluble, 
polymeric materials.235,236 
 
Figure 4.4. Half-sandwich (p-cymene)Ru complexes reported by Hey-Hawkins et al.238,239 
All the ferrocenyl phosphine complexes display “three-legged piano stool” structures as 
expected, and the sum of the three L–M–L angles is around 250–260°, significantly lower 
than the idealised 270°. The Ru–P bond lengths (2.296(2)–2.312(2) Å) are shorter than 
typical Ru complexes of tertiary phosphines (2.34–2.37 Å) presumably due to the decrease 
in steric bulk at the phosphorus centre.  
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Interestingly, for the purpose of this work, Gamez et al. reported the synthesis and 
cytotoxicity of Ru(II) arene complexes with 1-pyrenylphosphine ligands (Scheme 4.5).240 
It was found that changing the arene capping ligand from p-cymene to methyl benzoate 
greatly increased the biological activity of the resulting complexes. In addition, the 
biological activity was sensitive to the phosphine substituents, with methyl groups proving 
more efficient than phenyl groups in most cases.25 Despite the authors reporting many 
biological studies including EB-DNA displacement assays, the luminescence properties 
of these complexes were not evaluated.  
In 2020, during our study of pyrenylphosphines, Gamez and co-workers reported the 
synthesis of pyrenylphosphines and phosphonites derived from (1-pyrenyl)PCl2 and 
studied the cytotoxicity of the corresponding (arene)Ru(II) complexes.241 
 
Scheme 4.5. Synthesis of pyrenylphosphine Ru complexes reported by Gamez et al.240 
Diphenyl-1-pyrenylphosphine (DPPP) is prone to undergo cyclometallation, which has 
been shown to increase the phosphorescence efficiency for the resulting metal complexes. 
Yip et al. observed phosphorescence quantum yields of up to 1.5 ×10–2 (ΦP = 1.5%) for 
the cyclometalated Pt complex shown in Scheme 4.6.242  
 
Scheme 4.6. Switching on the phosphorescence of pyrene by cycloplatination.242 
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Direct coordination of the pyrenyl ring to the Pt atom was required for increased 
phosphorescence, while the Pt–Cl complex showed very low emission intensity.  
4.1.3 Research aims 
To expand the chemistry of pyrenylphosphines, we aimed to carry out the following: 
• Synthesise the set of primary, secondary, and tertiary 1-pyrenyl phosphines shown 
in Scheme 4.7. Apart from the previously reported (Pyr)3P,
231 these phosphines 
and some of the required precursors would be novel. 
• Expand this family of phosphines to include the 2-pyrenylphosphine regioisomers 
shown in Scheme 4.8 in Section 4.2.  
 
Scheme 4.7. Summary of 1-pyrenylphosphine targets for this work.  
• Study the coordination behaviour of this new class of ligands, concentrating on 
Ru with a view to studying the resulting complexes as cytotoxic agents. 
• Rationalise the photophysical properties of pyrenylphosphines using a 
combination of UV-visible and fluorescence spectroscopy with DFT calculations.  
• Explore the air-stability of pyrenylphosphines experimentally and justify the 
results by calculating the SOMO energies of the phosphine radical cations. 
4.2 Synthesis of pyrenylphosphines 
Pyrenylphosphines are relatively bulky arylphosphines and are interesting for their 
luminescence properties. Walensky et al. reported the synthesis and fluorescence 
properties of tris(1-pyrenyl)pnictogen compounds including tris(1-pyrenyl)phosphine.231  
Scheme 4.8 outlines the conventional numbering for pyrene, describes the nomenclature 
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used in this chapter and details the synthetic procedures to access the regioisomeric 1- 
and 2-pyrenylphosphines. 
 
Scheme 4.8. Synthetic routes to some of the regioisomers of substituted pyrenes.  
The steric profile of 1-pyrenylphosphines is analogous to 1-naphthylphosphines, whereas 
2-pyrenylphosphines have a similar steric profile to analogous phenylphosphines. Herein, 
we report the synthesis of primary and secondary phosphines derived from 1-
bromopyrene. An Ir-catalysed C–H functionalisation reaction, initially reported by 
Marder et al. selectively activates the C–H bonds at the 2- and 7-positions of pyrene.243  
These useful aryl boronic esters can be converted to 2-bromopyrene by reaction with 
CuBr2 (Scheme 4.8). Following this transformation, 2-bromopyrene could be used as a 
precursor to phosphines in an analogous way to 1-bromopyrene to give novel pyrene 
conjugated ligands with different steric properties. 
In 2018, Mathey et al. reported a simple method for the preparation of 2- or 2,7-
functionalised pyrenes via a 1,2-phosphinyl migration from the corresponding 1- or 1,6-
substituted derivatives (Scheme 4.9).244 The reaction employed a AlCl3/NaCl melt and 
proved an effective way to generate 2-pyrenyl compounds with various phosphine, 
phosphine oxide and phosphonium substituents. The newly formed 2-functionalised 
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pyrenes could be used as building blocks for 2-pyrenyl substituted aryl or alkenyl 
compounds via Pd-catalysed C–P bond cleavage.  
 
Scheme 4.9. Regioselective synthesis of 2- or 2,7-functionalised pyrenes via phosphinyl 
migration (FG = functional group; alkenyl (CHCHCO2C(CH3)3) or aryl (4-MeOC6H4)), 
reported by Mathey et al.244 
To begin our study, 1-bromopyrene 4.2 was prepared from pyrene by oxidative 
bromination conditions employing HBr and H2O2 following the reported procedure 
(Scheme 4.10).245  
 
Scheme 4.10. Literature method for the synthesis of 4.2.245 
The following section describes the syntheses and characterisation of phosphines derived 
from 1-bromopyrene 4.2. To date, attempts to prepare phosphines from 2-bromopyrene 
have been unsuccessful (see Section 4.2.5).  
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4.2.1 Synthesis of 1-pyrenylphosphine 
Yip et al. reported the synthesis of diethyl(1-pyrenyl)phosphonate (4.3) by lithium-halogen 
exchange of 4.2 using tBuLi, followed by reaction with diethyl chlorophosphate.246 In this 
work, reduction of the phosphonate 4.3 with lithium aluminium hydride resulted in the 
novel 1-pyrenylphosphine L4.1 (Scheme 4.11).  
 
Scheme 4.11. Synthesis of diethyl 1-pyrenylphosphonate 4.3 and the synthesis of 1-
pyrenylphosphine L4.1.  
In the 31P{1H} NMR spectrum of L4.1, a sharp singlet resonance (δP = –132.2 ppm) is 
observed, characteristic of an aryl primary phosphine (cf. PhPH2, δP = –131 ppm). In the 
31P NMR spectrum, a triplet of doublets is seen with a characteristically large one bond 
P–H coupling (1JPH = 203 Hz, Figure 4.5). The triplet is further split by a second coupling 
presumably due to the proton at the 2 position of pyrene (3JPH = 7 Hz). In the 
1H NMR 
spectrum (Figure 4.5) the –PH2 protons appear as a doublet (δH = 4.45 ppm, 
1JHP = 204 
Hz) which integrates for 2H. The product was isolated as a pale-yellow solid which is 
resistant to air oxidation in an uncapped CDCl3 solution for over 24 h (see Section 4.5).  
  






Figure 4.5. a) 31P NMR spectrum of L4.1. b) 
1H NMR spectrum of L4.1, recorded in CDCl3. 
4.2.2 Synthesis of bis(1-pyrenyl)phosphine 
The bis(1-pyrenyl)phosphine L4.2 was synthesised by two independent routes. First, as 
with the synthesis of many secondary phosphine oxides (SPOs), reaction of 1-
pyrenylmagnesium bromide 4.4 with diethylphosphite gave secondary phosphine oxide 
4.5. An in situ 31P{1H} NMR resonance at δP = 20.3 ppm with a 
1JPH of 482 Hz was 
assigned to 4.5. However, analysis of the isolated material indicated that a major 
component was unreacted 1-bromopyrene, indicating that Grignard conditions would 
need to be improved. Reduction of the crude 4.5 was achieved with DIBAL-H to give 
the desired L4.2 although in a modest yield of 20% following isolation by filtration through 
silica (Scheme 4.12).  
By modifying this route with the addition of NaH to deprotonate the diethylphosphite 
prior to addition of a solution of 4.4, the yield of 4.5 was improved to 50%. The SPO 4.5 
was purified by trituration with a methyl tert-butyl ether (MTBE)/hexane mixture to 
remove unreacted diethylphosphite. The 31P NMR spectrum of 4.5 clearly shows a 
characteristically large one bond P–H coupling (1JPH = 482 Hz) and the resonance is 
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further split into a doublet of triplets with a (3JPH = 16 Hz, Figure 4.6) due to the two 
pyrenyl 2-H protons. In the 1H NMR spectrum the P–H resonance is at δH = 9.39 ppm 
(1JHP = 482 Hz, see Figure 4.6). 
 






Figure 4.6. a) 31P NMR spectrum of 4.5. b) 1H NMR spectrum of 4.5 with the P–H 
resonance highlighted to show the large coupling constant (1JHP = 482 Hz).  
Reduction of 4.5 with DIBAL-H to give bis(1-pyrenyl)phosphine L4.2 appeared to be 
quantitative by 31P{1H} NMR spectroscopy but isolated yields of the desired phosphine 
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were always low (~25%), probably due to losses during the removal of the aluminium 
salts by filtration. 
Thus, an alternative route, avoiding generation of the SPO, which could also be carried 
out as a one-pot procedure was developed which gave the secondary phosphine L4.2 in a 
76% yield (Scheme 4.13). Lithiation of 1-bromopyrene, followed by reaction with 
Me2NPCl2, gave the amino phosphine 4.6. This could be isolated or immediately 
converted to the chlorophosphine by treatment with an excess of HCl (2 M in Et2O). The 
chlorophosphine 4.7  was reduced with LiAlH4 to give L4.2.  
 
Scheme 4.13. Synthesis of bis(1-pyrenyl)phosphine L4.2 via chlorophosphine 4.7.  
The 31P NMR resonance for L4.2 at δP = –59.5 ppm (
1JPH = 223 Hz) is upfield of 
diphenylphosphine (cf. δP = –40.0 ppm). Each step of the reaction depicted in Scheme 
4.13 was followed by in situ 31P{1H} NMR spectroscopy (Figure 4.7). 




Figure 4.7. In situ 31P{1H} NMR reaction monitoring for the synthesis of L4.2. 
4.2.3 Synthesis of tris(1-pyrenyl)phosphine 
To access tris(1-pyrenyl)phosphine, reaction of 4.2 with PCl3 or P(OEt)3 was attempted 
(Scheme 4.14). The route employing P(OEt)3 was reported by Huang et al. however, the 
authors never isolated the tertiary phosphine, en route to the phosphine oxide. In addition, 
the authors did not report any 31P{1H} NMR data, characterising the products only by 1H, 
13C and MALDI mass spectrometry.  
The tris(1-pyrenyl)phosphine L4.3 was prepared following the procedure recently reported 
by Walensky et al. After full consumption of PCl3 (as determined by in situ 
31P{1H} NMR 
spectroscopy) a new species at δP = –30.6 ppm was observed which corresponded to the 
desired compound, in agreement with the literature value (Scheme 4.14).231 
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With pure samples of the primary, secondary, and tertiary pyrenyl phosphines L4.1-L4.3 in 
hand, their coordination behaviour was investigated.  
4.2.4 Synthesis and Ru coordination of bidentate pyrenylphosphine ligands 
This section details synthetic attempts to make diphosphine ligands bearing pyrenyl (Pyr) 
substituents. We predicted that the luminescence properties of these diphosphines could 
be exploited as biological imaging agents when used in combination with (cis-tach)Ru 
complexes. The unsymmetrical diphosphine precursor Ph2PCH2CH2PCl2 was prepared 
and was reacted with the Grignard reagent of 1-bromopyrene (Scheme 4.15). The in situ 
31P{1H} NMR spectrum showed full consumption of the –PCl2 resonance of the starting 
material with δP = 196.4 ppm (d, 
3JPP = 30 Hz) and after 1 h, the 
31P{1H} NMR spectrum 
showed the expected signals for L4.4 with a new doublet resonance corresponding to –
P(Pyr)2 (δP = –35.2 ppm, 
3JPP = 38 Hz). 
 
Scheme 4.15. Synthesis of unsymmetrical diphosphine ligand L4.4.  
The unsymmetrical ligand L4.4 was reacted with [RuCl(cis-tach)(DMSO)2]Cl (2.1) in a 
mixture of THF (to dissolve the ligand) and MeOH (to dissolve the Ru precursor) 
(Scheme 4.16). Although L4.4 was only partially soluble, analysis of the solid obtained 
displayed two new resonances in the 31P{1H} NMR spectrum (Figure 4.8) consistent with 
formation of the desired chelate complex [RuCl(L4.4)(cis-tach)]Cl 4.8 (δP = 72.0 ppm (d, 
3JPP = 23 Hz), 69.7 ppm (d, 
3JPP = 23 Hz)). 
 
Scheme 4.16. Formation of (cis-tach)Ru complex 4.8. 
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Figure 4.8. 31P{1H} NMR spectra for a) diphosphine L4.4, and b) [RuCl(L4.4)(cis-tach)]Cl 
4.8. 
The steric bulk and limited solubility of ligands bearing two pyrenyl substituents makes 
them challenging to work with. To mitigate this, we aimed to incorporate a spacer/linker 
between the phosphorus and pyrenyl moieties. As seen before, complexes with a pyrene 
group tethered from the metal centre, can exhibit interesting luminescence properties due 
to the pyrene excimer state.107 We aimed to install an alkyl tethered pyrenyl group to 
unsymmetrical diphosphine ligand precursors with ethylene and phenylene backbones. 
Using purely alkyl tethers to attach a pyrenyl fluorophore was paused at this stage and 
instead we turned our attention to the use of solubilising groups, such as esters or amides. 
The methods to functionalise diphosphine ligands with organic fluorophores using these 
linkers are presented in Chapter 3. 
4.2.5 Synthesis of 2-pyrenylphosphines 
Marder et al. reported the selective functionalisation of the C–H  bonds in the 2-position 
of pyrene.243 The reaction of pyrene with bis(pinacolato)diboron (B2pin2) catalysed by 
[Ir2(µ-OMe)2(cod)2]/dtbpy forms the desired monosubstituted product 4.11 (Scheme 
4.17). Unfortunately, competing disubstitution to form the 2,7-bis(boryl)pyrene 4.12 
cannot be fully suppressed and necessitates the use of column chromatography, which 
leads to a modest yield of 4.11. 
3JPP = 23 Hz 
a) 
b) 
3JPP = 38 Hz 
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Scheme 4.17. Synthesis of 4.11 and 4.12, reported by Marder et al.243 
In the recent report, Bonifazi et al. described the use of 4.11 as a precursor to O-annulated 
medium-ring polycyclic aromatic hydrocarbons.247 In a private communication with Dr. 
Davide Bonifazi (Cardiff University), we learned that they also observed disubstitution 
giving significant quantities of 4.12. Acting on their advice of keeping the reaction 
temperature <80 °C to disfavour the second borylation, and always using fresh, dry SiO2 
for column chromatography, we were able to improve the isolated yields of 4.11 from 
~10% to ~50% (comparable to Bonifazi et al.).  
The monosubstituted pyrenyl boronic ester 4.11 can be converted to 2-bromopyrene 4.13 
by reaction with 3 equiv. of CuBr2 (Scheme 4.18). On isolation of 4.13, the white solid 
rapidly darkened on exposure to ambient light. 
 
Scheme 4.18. Synthesis of 4.13, reported by Marder et al.243 
Despite the sensitivity of 4.13, the synthesis of primary and tertiary 2-pyrenylphosphines 
was attempted by the methods (i-iv) shown in Scheme 4.19. Unfortunately, none of the 
proposed methods given in Scheme 4.19 gave the desired products, as briefly detailed 
below. 
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Scheme 4.19. Conditions for the attempted syntheses of 2-pyrenylphosphines. i) nBuLi, 
–78 °C, THF, (EtO)2P(O)Cl, LiAlH4, TMSCl. ii) 
nBuLi, –78 °C, THF, (Et2N)2PCl. iii) 
Ph2PH, Pd(OAc)2 (5 mol%), DMF, 130 °C. iv) 
nBuLi, –78 °C, THF, PCl3.  
 
Attempted method i: The addition of (EtO)2P(O)Cl to 2-lithiopyrene produced a purple 
solution which gave approx. 8 broad resonances in the region δP = +30 to –15 ppm in 
the in situ 31P{1H} NMR spectrum.  
Attempted method ii: The addition of (Et2N)2PCl to 2-lithiopyrene produced a bright green 
solution which gave a broad resonance at δP = 83 ppm (ω½ ~ 120 Hz) in the in situ 
31P{1H} 
NMR spectrum. Interestingly, addition of two equivalents of HCl (in Et2O solution) 
caused the solution to rapidly darken and did provide another broad resonance in the 
expected –PCl2 region δP = 132 ppm (ω½ ~ 140 Hz), along with another unidentified 
broad resonance at δP = 127 ppm (ω½ ~ 130 Hz). After addition of LiAlH4 to this mixture, 
the in situ 31P{1H} NMR spectrum revealed two broad resonances, one of which at δP = 
–139 ppm (ω½ ~ 85 Hz) was tentatively assigned to the primary 2-pyrenylphosphine. The 
second signal at δP = 33 ppm (ω½ ~ 85 Hz) is in the expected region for the primary 
phosphine oxide. Attempted isolation of this material by filtration of the THF solution 
through a small silica plug returned a sticky black solid which contained no observable 31P 
NMR resonances.  
Attempted method iii: The attempted cross-coupling of 2-bromopyrene with Ph2PH 
catalysed by Pd(OAc)2 in DMF gave a dark brown solution. After 30 h at 130 °C, the only 
31P{1H} NMR resonance observed was due to Ph2PH, albeit significantly broadened, at 
δP = –39 ppm (ω½ ~ 90 Hz).  
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Attempted method iv: The attempted synthesis of tris(2-pyrenyl)phosphine by addition of 2-
lithiopyrene to PCl3 produced a green solution immediately which gave approx. 12 species 
in the in situ 31P{1H} NMR spectrum in the region δP = +65 to –10 ppm. 
Summary of attempted syntheses i-iv: In each of the syntheses described above, the reaction 
mixtures were intensely coloured (purple, green, brown, or black) and contained multiple 
species, in contrast to the relatively clean analogous reactions of 1-lithiopyrene. It is 
suggested that radicals may be formed that give rise to the deeply coloured mixtures, and 
that paramagnetic species are producing the peak broadening in the 31P NMR spectra. It 
is known that 2-pyrenyl radicals are formed from boron or nitrogen substituted pyrene 
cores, such as 2,7-bis(BMes2)pyrene.
248,249 As a result of the failure of each of these routes, 
the proposed investigation of the luminescence properties and coordination chemistry of 
2-pyrenylphosphines could not be completed. Further studies into the nature of these 
materials, their photophysical properties, and possible radical reactivity is warranted. 
4.3 Coordination chemistry 
4.3.1 Ruthenium coordination chemistry 
The primary, secondary, and tertiary pyrenylphosphines (L4.1-L4.3) were reacted in a 2:1 
molar ratio with [(p-cymene)RuCl2]2 to give mononuclear complexes of the form [(p-
cymene)Ru(PR3)Cl2]. The primary phosphine L4.1 was reacted with [(p-cymene)RuCl2]2 in 
CH2Cl2 at room temperature (Scheme 4.20), and within 1 h full conversion to the expected 
complex was observed by a downfield shift in the 31P{1H} NMR resonance from –132.2 
ppm to –26.9 ppm (ΔδP = 105.3 ppm). 
 
Scheme 4.20. Formation of Ru complex 4.14.  
Single crystals suitable for X-ray diffraction were grown by slow evaporation of a 
concentrated CH2Cl2 solution of 4.14 at room temperature (Figure 4.9). The Ru–P bond 
length of 2.298(2) Å is within the range for previously reported primary phosphine 
complexes of Ru (2.296(2)–2.312(2) Å). The sum of the L–M–L angles, ΣL–M–L (which 
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should be 270° for a symmetric octahedral complex where the arene occupies one face) 
is significantly smaller for 4.14 (ΣL–M–L = 254.5°), in good agreement with previously 
reported Ru ferrocenylphosphine derivatives (ΣL–M–L = 250.6° to 254.4°).
238,250 The bulky 
pyrene moiety is oriented away from  the cymene iso-propyl group and the C(11)–P(1)–
Ru(1) bond angle is 120.2(2)°. 
 
Figure 4.9. Single crystal X-ray crystallography structure of 4.14. Hydrogen atoms (except 
for the –PH2 group) have been omitted for clarity. Thermal ellipsoids at 50% probability 
level. Selected bond lengths (Å) and angles (°): Ru1–Cl1 2.4093(17), Ru1–Cl2 2.4082(15), 
Ru1–P1 2.298(2), P1–C11 1.808(7); Cl2–Ru1–Cl1 87.14(6), P1–Ru1–Cl1 84.86(7), P1–
Ru1–Cl2 82.54(7), C11–P1–Ru1 120.2(2). 
A diagram showing the crystal packing for 4.14 is shown in Figure 4.10. The pyrene 
groups are stacking with a slipped parallel arrangement commonly observed with other 
pyrene-containing molecules. For example, short pyrenyl-pyrenyl distances are present in 
the diruthenium complexes reported by Therrien et al. (3.49 Å)251 and 1-pyrenyl-
carbothioamides and carboxamides (3.32–3.36 Å).252  In the later examples pyrene 
stacking in the solid state increased the fluorescence quantum yield of these compounds.  
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Figure 4.10. Crystal packing diagram of 4.14 to show intermolecular pyrenyl-pyrenyl 
interactions with the centroid-centroid distances marked in red. 
Closer analysis of the crystal structure of 4.14 shows the slipped parallel stacking of the 
pyrenyl groups (Figure 4.11). The pyrenyl carbon atoms with the shortest distances: C12–
C24 (3.484 Å), C14–C18 (3.533 Å) and C16–C20 (3.526 Å) are highlighted in Figure 4.10 
and are within the normal range of pyrene stacked compounds. The average of these inter-
atomic distances (3.51 Å) is around 0.1 Å longer than the sum of the van der Waals’ radii 
for carbon (3.40 Å). As a result, this interaction could arise from weak van der Waals’ 





Figure 4.11. a) Schematic to show the slipped parallel stacking arrangement of pyrene. b) 
The crystal structure of 4.14 to show packing arrangement. (All atoms except pyrene 
omitted for clarity).  
We considered whether cyclometallation of the primary phosphine Ru complex 4.14 
would change the photophysical properties, in a manner similar to cycloplatinated pyrene 
complexes previously reported (see Scheme 4.6). It was hoped that the pyrenyl substituent 
would undergo a cyclometallation reaction to give a 5-membered metallacycle while 
leaving the P–H bonds intact. However, L4.1 did not cyclometallate under the conditions 
employed to give 4.15 (Scheme 4.21) and the yellow precipitate that was obtained 
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produced 7 singlets in the 31P{1H} NMR spectrum. Complete consumption of the starting 
material L4.1 was observed and the main resonance at δP = –58 ppm coupled with a broad 
1H NMR spectrum may indicate a phosphide-bridged species (see Scheme 4.21) resulting 
from deprotonation of the primary phosphine by NaOAc, or decomposition of the Ru 
complex.  
 
Scheme 4.21. Attempted cyclometallation of L4.1 to give Ru complex 4.15 and suggested 
structure of bridged species.  
In contrast to the chemistry displayed by L4.1, the DPPP ligand is readily cyclometalated 
in the presence of NaOAc to give Ru complex 4.16 (Scheme 4.22). Clean formation of 
the expected 5-membered metallacycle is evidenced by the characteristic 31P{1H} NMR 
resonance (δP = 67.1 ppm; cf. δP = 66.0 ppm for the analogous 
naphthyldiphenylphosphine derivative).253 
 
Scheme 4.22. Formation of 4.16 by cyclometallation of DPPP with NaOAc.  
The secondary pyrenylphosphine L4.2 was reacted with [(p-cymene)RuCl2]2 in CH2Cl2 at 
room temperature and within 2 h, full conversion to the expected complex was observed 
by a downfield shift in the 31P{1H} NMR resonance from δP = –58.0 ppm to δP = +5.2 
ppm (ΔδP = 63.2 ppm). 
Chapter 4. Photophysical properties of air-stable pyrenylphosphines 
116 
 
Scheme 4.23. Formation of Ru complex 4.17. 
The coordination chemical shifts for the Ru(II) complexes of L4.1 (ΔδP = +105.3 ppm) 
and L4.2 (ΔδP = +63.2 ppm) are in agreement with known Ru complexes of primary and 
secondary phosphines.238 As expected, from the data for other primary phosphine metal 
complexes, the 1JPH coupling constants significantly increased by ca. 200 Hz, in accordance 
with donation of the phosphine lone pair into the Ru 4d t2g orbitals, similar to primary 
phosphine complexes previously reported.254,255 This phenomenon is rationalised by 
Bent’s rules where, upon coordination, the P–H bond(s) have more s-orbital character 
consistent with a rehybridization towards sp2, resulting in a large increase in the coupling 
constant.256,257 
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On coordination of L4.1 to Ru, the 
3JPH coupling constant also increases from 7 Hz to 13 
Hz. To understand the origin of this additional coupling a 1H–31P{1H} HMBC correlation 
spectrum of [(p-cym)RuCl2(L4.1)] (4.14) was obtained (Figure 4.12). This showed the 
intense correlation peak corresponding to the large P–H coupling and an additional 
correlation peak to one of the pyrenyl protons (δH = 8.37 ppm, d, 





Figure 4.12. a) The 31P NMR spectrum of 4.14. b) Selected region of the 1H–31P{1H} 
HMBC NMR spectrum of 4.14 showing the most intense 1H–31P correlations.  
The observed FTIR data for the ν(P–H) stretching mode(s) also indicate a strengthening 
of the P–H bond because the stretching frequencies increase by ca. 70–90 cm–1 (see Table 
4.1) which is consistent with the behaviour of phenylphosphines,232 mesitylphosphines, 
and ferrocenylphosphines.239 A summary of the NMR and FTIR data for 
1JPH = 391 Hz 3JPH = 
13 Hz 
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pyrenylphosphines L4.1-L4.3 and the corresponding (p-cymene)Ru complexes is given in 
Table 4.1. 
Table 4.1. Selected FTIR and NMR data of pyrenylphosphines (L4.1-L4.3) and (p-
cymene)Ru complexes. 
Compound ν(P–H) (cm–1)a δ(31P, ppm)b 1JPH (Hz) 
3JPH (Hz) δ(
1H, ppm)b 
PyrPH2, L4.1 2274, 2298 –132.2 203 7 4.5 
Pyr2PH, L4.2 2294 –58.0
d 223 –c 6.2d 
Pyr2POH, 4.5 2296 20.4 482 –
c 9.4 
Pyr3P, L4.3 – –30.4 – – – 
RuPyrPH2, 4.14 2352, 2386 –26.9 391 13 6.2 
RuPyr2PH, 4.17 2369 5.2 405 –
c 8.0 
aFTIR obtained neat. bNMR spectrum obtained in CDCl3. 
cSignal too broad to resolve 
coupling. dNMR spectrum obtained in C6D6. 
The tertiary phosphine L4.3 was reacted with [(p-cymene)RuCl2]2 in CH2Cl2 at room 
temperature (Scheme 4.24). As previously observed with tris(1-naphthyl)phosphine, no 
coordination was detected, even after extended reaction time, presumably due to the bulk 
of this tertiary phosphine. Over the course of 3 h, a yellow solid precipitated, analysis of 
which showed it to be the free ligand. Since, over time, L4.3 also precipitates out of a 
chloroform solution, it was proposed that the tertiary phosphine forms a poorly soluble 
solvate with chlorinated solvents.  
 
Scheme 4.24. Attempted formation of Ru complex 4.18.  
4.3.2 Platinum coordination chemistry 
To form their PtCl2 complexes, both L4.3 and tris(1-naphthyl)phosphine (PNp3) were 
reacted in a 1:1 molar ratio with [PtCl2(cod)] (Scheme 4.25 and Scheme 4.26). No 
coordination was observed in either reaction with only free ligand present in solution 
which, after 3 h, began to precipitate. 
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Scheme 4.25. Attempted formation of Pt complex [PtCl2(L4.3)2] (4.19). 
 
Scheme 4.26. Attempted formation of Pt complex [PtCl2(PNp3)2] (4.20). 
Mingos et al. reported that by employing the more reactive Pt precursor 
[Pt(NCMe)4](BF4)2, all complexes derived from bulky arylphosphines were formed as the 
trans isomer, trans-[Pt(NCMe)2(PR3)2](BF4)2. When the reaction was attempted with the 
PNp3 ligand (Scheme 4.27), a mixture of partially soluble products including one 
tentatively assigned to trans-[Pt(NCMe)2(PNp3)2](BF4)2 based on the 
1JPPt coupling 
constant was obtained.258 
 
Scheme 4.27. Reported formation of trans-[Pt(NCMe)2(PNp3)2](BF4)2, Mingos et al.
258 
4.3.3 Gold coordination chemistry 
The tertiary phosphine L4.3 was reacted in a 1:1 molar ratio with [(tht)AuCl] in CH2Cl2 at 
room temperature and monitored by in situ 31P{1H} NMR spectroscopy (Scheme 4.28). 
After 7 h, a white precipitate had formed and the 31P{1H} NMR spectrum of the solution 
contained several broad signals (δP = 8.1, 17.0, 20.0 ppm). In the report from Mingos et 
al.,258 the reaction between tris(1-naphthyl)phosphine and [(tht)AuCl] gave a 31P{1H} 
NMR resonance at δP = 7.0 ppm but the isolation of the desired [(Np3P)AuCl] was 
unsuccessful.  
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Scheme 4.28. Attempted formation of Au complex [(L4.3)AuCl] (4.21). 
As a comparison, the previously prepared diphenyl(1-pyrenyl)phosphine (DPPP) ligand 
was reacted in a 1:1 molar ratio with [(tht)AuCl] in CH2Cl2 at room temperature (Scheme 
4.29). Quantitative conversion to complex 4.22 occurred over 7 h and it was characterised 




Scheme 4.29. Formation of [(DPPP)AuCl] (4.22). 
These results are in agreement with the study of Mingos et al. on the Au coordination 
chemistry of naphthyl and anthracenyl phosphines.258 Reduction in the steric bulk by 
replacing two pyrenyl groups with two phenyl groups, appears to have enabled formation 
of the Au complex 4.22. As the linear Au–Cl complex [(L4.3)AuCl] would not form, it 
appears that the bulk of the three 1-pyrenyl substituents of L4.3 inhibits metal coordination.  
It would be worthwhile to study the non-coordinating properties of L4.3 further, for 
example in combination with bulky boranes for use in Frustrated Lewis Pair (FLP) 
chemistry. The inherent luminescent behaviour could be a useful spectroscopic reporter 
for the reactions of L4.3 derived FLPs with small molecules. 
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4.4 Photophysical properties of pyrenylphosphines and Ru complexes 
The UV-visible absorption spectra in CH2Cl2 were recorded for L4.1, L4.2, 4.5 and the 
corresponding (p-cymene)Ru complexes 4.14 and 4.17 (Table 4.2). The spectra all display 
vibronically structured absorption features attributed to π→π* transitions within the 
pyrene moiety (Figure 4.13 and Figure 4.14). In addition to these transitions, a lower 
energy absorption is observed at ca. 354 nm for L4.2 and 4.5 (ε = 25,600 and 19,000 M
–1 
cm–1 respectively). The calculated electronic transitions are indicated by the black bars 
overlaid on the UV-visible absorption spectra (for details, see 4.4.1). 
Table 4.2. Absorption and emission data for L4.1, L4.2, 4.5 and (p-cymene)Ru complexes 
4.14 and 4.17. 
 
Compound λabs [nm] (ε [10
3 M–1 cm–1])a λem [nm] Φf
b 
PyrPH2, L4.1 337 (12), 322 (7), 274 (13), 242 (25) 384 0.09 
Pyr2PH, L4.2 337 (31), 322 (18), 274 (35), 242 (63) 383 0.14 
Pyr2POH, 4.5 337 (53), 321 (33), 274 (61), 242 (110) 386 0.18 
Ru PyrPH2, 4.14 337 (16), 322 (9), 274 (20), 242 (41) 387 0.04 
Ru Pyr2PH, 4.17 337 (16), 322 (12), 273 (22), 241 (37) 388 0.03 
aMeasured in deaerated CH2Cl2. 
bΦf = fluorescence quantum yield, reference: Quinine 
sulfate (Φf = 0.58, λex = 350 nm, in 0.1 M H2SO4). 
The UV-visible absorption spectra for the (p-cymene)Ru complexes are dominated by the 
same ligand centred π→π* transitions as the free ligands albeit with a slight loss of fine 
vibronic structure. No additional lower energy absorption bands were observed for the 
Ru complexes 4.14 and 4.17 (Figure 4.13 and Figure 4.14). 
 






Figure 4.13. Experimental solution state (CH2Cl2) UV-visible absorption spectra for a) 
L4.1, and b) [(p-cym)RuCl2(L4.1)] (4.14). The oscillator strength axes correspond to the 
calculated electronic transitions (black bars) at the CAM-B3LYP/6-31G(d)/LANL2DZ 
level of theory. 
  








Figure 4.14. Experimental solution state (CH2Cl2) UV-visible absorption spectra for a) 
L4.2, b) [(p-cym)RuCl2(L4.2)] (4.17), and c) Pyr2POH 4.5. The oscillator strength axes 
correspond to the calculated electronic transitions (black bars) at the CAM-B3LYP/6-
31G(d)/LANL2DZ level of theory. 
The emission spectra were recorded for all compounds in deaerated CH2Cl2 solution (1.2 
×10–5 M) and in each case an emission profile consistent with pyrene monomer emission 
is observed (λem = 383–388 nm). The emission spectra are broad and unstructured in 
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contrast to some other pyrenylphosphines reported.195,260 Analysis of the emissive 
properties of L4.2, 4.5 and [(p-cym)RuCl2(L4.2)] (4.17) reveal that oxidation of the 
phosphine increases the measured emission intensity, whereas phosphine coordination to 
Ru dramatically decreases emission intensity (Figure 4.15). The emission ‘switch-on’ effect 
by oxidation has been previously studied and is attributed to the preclusion of P lone pair-
to-fluorophore PeT quenching. It was hypothesised that coordination to Ru could also 
induce emission switch-on; however, quenching mechanisms due to the presence of a 
heavy Ru atom are known.261,262 
 
Figure 4.15. Experimental solution state (CH2Cl2) emission spectra of L4.2, 4.5 and [(p-
cym)RuCl2(L4.2)] (4.17) all exhibit λmax at ca. 385 nm. The quantum yields for the free 
phosphine, phosphine oxide and Ru complex are Φf = 14%, 18% and 3%, respectively. 
Fluorescence quantum yields (Φf) were measured in deaerated CH2Cl2 using quinine 
sulfate (0.1 M in H2SO4) as standard (see Experimental for details). As expected, the 
fluorescence quantum yield for L4.1 and L4.2 is significantly reduced compared to pyrene 
(Φf = 0.58, λex = 333 nm, in cyclohexane), presumably due to PeT quenching from the 
phosphine lone pair.263 An approximately 2-fold increase in quantum yield was observed 
going from L4.1 to L4.2, as expected due to two pyrenyl substituents per molecule in the 
latter case. In CH2Cl2, there is an increase in emission intensity upon oxidation of L4.2 to 
4.5 (Φf = 14% and 18% respectively). Although this effect may not be considered a 
dramatic fluorescence switch-on, it is in accord with the modest luminescence 
enhancements reported by Walensky for (Pyr)3P (Φf = 13%) going to phosphine oxide 
(Pyr)3PO (Φf = 14%).
231 
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We have observed significant fluorescence quenching of the pyrene chromophore in [(p-
cym)RuCl2(L4.1)] (4.14) and [(p-cym)RuCl2(L4.2)] (4.17) with Φf = 4% and 3% respectively, 
possibly due to non-radiative decay processes associated with the heavy-atom effect (Ru). 
The electronic basis of the observed absorption and fluorescence properties for L4.1-L4.2, 
4.5, 4.14, and 4.17 have been investigated by DFT calculations. 
4.4.1 TD-DFT calculations 
Time-dependent density functional theory (TD-DFT) calculations were performed in 
Gaussian 09 (D.01).264 Initial geometry optimizations were performed on all ligands and 
complexes using the B3LYP functional,265–268 Pople basis set 6-31G(d) on all atoms, apart 
from Ru, where an additional LANL2DZ basis set and effective core potential was 
used.269 A converged ground state was found for each molecule and a frequency 
calculation returned no imaginary frequencies indicating the structure to be a minimum 
on the potential energy surface. Where a crystal structure was available as for [(p-
cym)RuCl2(L4.1)] (4.14), the computed geometry agreed with the structure determined by 
X-ray crystallography.  
TD-DFT was used to calculate the UV-visible absorption properties using the CAM-
B3LYP functional and the previously mentioned basis set.270 Solvation corrections were 
included using the polarisable continuum model with CH2Cl2 (ε = 9.1) as solvent.
271 The 
LANL2DZ basis set has been used before to accurately model the excited states of Fe 
and Ru complexes, and in our studies, it produced reasonable agreement with 
experiment.218,272 We calculated the first 20 vertical singlet excited states for each ligand 
L4.1, L4.2, 4.5 and Ru complex and the excited state of interest (selected by the presence 
of a high oscillator strength ( f ), which is a measure of the probability of that excitation 
to occur) was investigated. In all cases, the lowest energy electronic transitions involved 
HOMO→LUMO transitions centred around 345 nm (3.6 eV, f = 0.828 for 4.14). The 
TD-DFT derived vertical singlet excitations agree quite well with the recorded UV-visible 
absorption spectra with the most significant excitations corresponding to S0→S1 and 
S0→S2 transitions within the pyrene substituents.  
To understand the absence of any low energy absorption bands with MLCT character, 
we analysed the frontier molecular orbitals involved. For [(p-cym)RuCl2(L4.1)] (4.14), the 
TD-DFT derived contour surface diagrams of the HOMO-1 to LUMO+1 are shown in 
Figure 4.16. 
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LUMO+1  –0.02 eV 
 
LUMO  –0.04 eV 
 
HOMO-1  –0.28 eV 
 
HOMO  –0.25 eV 
Figure 4.16. CAM-B3LYP/6-31G(d)/LANL2DZ-derived surface diagrams of the MOs 
of [(p-cym)RuCl2(L4.1)] (4.14), (isovalue = 0.02). The dominant transition is a 
HOMO→LUMO transition centred on pyrene. 
From our calculations, for 4.14, the lowest energy transition that contains contributions 
from a MLCT band (HOMO-1→LUMO) is predicted to be at 449 nm (2.76 eV) and has 
a very low oscillator strength (f = 0.003) and therefore has a very low probability of 
occurring. 
4.5 Air stability of pyrenylphosphines 
Significant progress towards predicting the air-stability of primary phosphines has been 
made by Higham and co-workers.221,223,273,274 Their work, summarised in the following 
section, provides a qualitative trend between phosphine orbital distribution and 
experimentally assessed air-stability. A combined experimental and theoretical analysis of 
~30 phosphines has allowed for the design and prediction of new air-stable 
derivatives.115,229 
First, the authors established that the calculated HOMO orbital energies increased with 
increasing conjugation (e.g., HOMO E, phenylphosphine = –6.87 eV; 1-
naphthylphosphine = –5.80 eV). Moreover, for phosphines containing substituents with 
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more extended π-systems, the HOMO comprised no significant phosphorus character, 
which indicated enhanced stability to air oxidation.  
Second, when the phosphine radical cations were modelled, in each case, the singly 
occupied molecular orbital (SOMO) was found to incorporate the phosphorus atom. The 
use of sterically bulky, heteroatom-containing, or highly conjugated substituents can raise 
the computed SOMO energy of the phosphine radical cation. In 2011, Higham et al. 
reported that if the computed SOMO energy is higher than –10 eV then, for the set of 
phosphines analysed, they were generally resistant to air-oxidation. Phosphines with a 
SOMO energy below –10 eV were found to be air-sensitive and experimental oxidation 
monitoring by 31P NMR spectroscopy of the neat samples as well as in solution confirmed 
these findings for a relatively small selection of 7 phosphines.274 It is noted that the 
calculated “threshold” energy of –10 eV is significant, but would need to be expanded to 
a much larger set of phosphine structures to test the model and further understand the 
mechanism of phosphine oxidation by O2.  
4.5.1 Radical cation SOMO calculations 
The radical cation SOMO energies may be used as a predictor of air-stability for a variety 
of phosphine ligands. The SOMO energies for the phenylphosphines follow the trend: 
PhPH2 < Ph2PH < Ph3P which explains the experimental observation that the primary 
phosphine oxidises rapidly in air, the tertiary phosphine is air-stable, and the secondary 
phosphine displays moderate air-sensitivity. Building on the results of Higham et al., by 
comparison, the 1-pyrenylphosphines have much higher SOMO energies, rendering even 
the primary phosphine L4.1 air-stable (see Figure 4.17). For completeness, the SOMO 
energies for primary, secondary, and tertiary 1-naphthylphosphines have been calculated, 
and unsurprisingly, these display intermediate behaviour compared to the phenyl and 1-
pyrenyl derivatives. It is noted that the radical cation SOMO energies correlate with the 
degree of conjugation of the aryl phosphine substituent: pyrenyl > naphthyl > phenyl, 
and this can be used as a useful design principle for air-stable phosphines.  
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Figure 4.17. Plot of the radical cation SOMO energies of 1-pyrenylphosphines L4.1-L4.3 
(■), 1-naphthylphosphines (■), and phenylphosphines (■). Red line indicates –10 eV 
stability threshold.  
We sought to understand the inherent air-stability of L4.1-L4.2 through analysis of the 
frontier molecular orbitals. As previously seen with phosphines containing conjugated 
substituents, if the HOMO is delocalised from the phosphorus lone pair, enhanced air-
stability may be observed.223,275 For the primary pyrenylphosphine L4.1, the HOMO is 
delocalised away from the phosphorus atom over the π-system of the pyrene substituent 
(Figure 4.18). For the secondary phosphine L4.2, the HOMO is partially located at the 
phosphorus lone pair but also highly delocalised over the pyrene substituents and thus, 
the SOMO energies for these two compounds are particularly high (–9.58 eV for L4.1 and 
–8.30 eV for L4.2). This indicates that they should display enhanced air-stability (cf. SOMO 































Figure 4.18. B3LYP/6-31G(d)-derived surface diagrams of the HOMOs of L4.1-L4.2, 
(isovalue = 0.02). 
By comparing the calculated SOMO energies of L4.1-L4.3 with air-stable phosphines 
known in the literature, we expect 1-pyrenylphosphines to display significant resistance 
to air oxidation.115,221 
4.5.2 Experimental air stability 
The relative air-stability of pyrenylphosphines were assessed by 31P NMR spectroscopy 
and compared to other phosphines. Experiments were carried out by dissolving 20 mg of 
each compound in aerated CDCl3 in a vial open to air. The solutions were kept uncapped 
and static, and a proton-coupled 31P NMR spectrum was obtained (3 s relaxation delay, 
NOE effects removed) immediately to record any initial oxidation, and then at intervals 
over 120 h. The sample solutions were stored in uncapped NMR tubes for the duration 
of the experiment. The following points summarise the key findings:  
• The primary pyrenylphosphine L4.1 (SOMO energy = –9.58 eV) oxidised around 
20% over the duration of the experiment, and the secondary and tertiary 
pyrenylphosphines L4.2-L4.3 showed no sign of oxidation.  
• The following phosphines were found to be persistent (i.e., showed <1% 
oxidation) in solution after 120 h, (SOMO energies given in brackets): P(C6F5)3 (–
10.50 eV), P(o-tolyl)3 (–9.52 eV), PhPMe2 (–10.42 eV), 2-dicyclohexylphosphino-
2',4',6'-tri-isopropylbiphenyl (XPhos) (–9.21 eV), and (2,4,6-tri-tert-
butylphenyl)phosphine (Mes*PH2) (–10.28 eV).  
• It is surprising that P(C6F5)3 and PhPMe2 were not oxidised during the experiment 
as their SOMO energies are below the –10 eV threshold while, as expected, P(o-
tolyl)3 was stable to air oxidation.  
Chapter 4. Photophysical properties of air-stable pyrenylphosphines 
130 
In addition to L4.1 and L4.2 showing minimal air-oxidation in solution over 120 h, the 
primary and secondary pyrenylphosphine complexes 4.14 and 4.17 are completely stable 
in solution over a period >3 months as determined by no change in their 31P{1H} and 1H 
NMR spectra. With a greater understanding of the luminescence and stability properties 
of pyrenylphosphines L4.1-L4.3, further investigation into what makes a phosphine ligand 
stable is warranted.  
4.6 Conclusions 
It has been shown that 1-bromopyrene is a suitable precursor for the synthesis of primary, 
secondary, and tertiary 1-pyrenylphosphines L4.1-L4.3. The secondary phosphine L4.2 can 
either be synthesised in a three-step (one-pot) procedure via aminophosphine 4.6 and 
chlorophosphine 4.7, or by formation of the pyrenyl Grignard reagent 4.4 and reaction 
with diethylphosphite to give the SPO 4.5 followed by reduction. As the number of 
pyrenyl substituents on the phosphine increases, the solubility in common organic 
solvents decreases. As a result, this renders the synthesis of bidentate pyrenylphosphines 
difficult, with only L4.4 being reported and shown to coordinate to Ru(II). As previously 
observed with tris(1-naphthyl)phosphine, the solution phase chemistry of L4.3 is limited 
as it forms a highly insoluble solvate with chlorinated solvents, and we struggled to study 
its chemistry further in non-chlorinated solvents, such as hexane, benzene, and DMSO.  
The primary and secondary pyrenyl phosphines L4.1-L4.2 cleanly form mononuclear Ru 
complexes when reacted with [(p-cymene)RuCl2]2. The coordination behaviour has been 
explored spectroscopically and for 4.14 by single crystal X-ray diffraction. Intermolecular 
− interactions are observed in the solid state, and the structural parameters agree with 
similar interactions observed in other pyrene-containing molecules. These complexes are 
ideal candidates for further P–H bond modification, and reactions to the corresponding 
phosphinidine complexes could shed more light on the ligand coordination properties.  
The photophysical properties of pyrenylphosphines and their Ru complexes have been 
explored spectroscopically and by supporting TD-DFT calculations. In CH2Cl2, there is a 
modest increase in emission intensity upon oxidation of L4.2 to 4.5 (Φf = 14% and 18% 
respectively). However, an intense fluorescence quenching effect is observed when 
coordinating L4.1-L4.2 to Ru, which is attributed to non-radiative decay processes of the 
excited state due to the proximity of the metal centre to the pyrene chromophore.  
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Due to the extended π-systems of the pyrenylphosphines they display superior air-stability 
compared to phenylphosphines. This has been investigated by experimental and 
theoretical studies which show the SOMO energies of pyrenylphosphine radical cations  
to be high in energy in line with other air-stable primary and secondary phosphines.  
4.7 Future work 
The synthesis of a bidentate pyrenylphosphine ligand with –PPh(Pyr) substituents could 
afford the desired photophysical properties without the solubility and coordination 
difficulties associated with –P(Pyr)2 groups. The synthesis was attempted from 
PhClPCH2CH2PClPh and several resonances were observed in the in situ 
31P{1H} NMR 
spectrum, of which about 55% of the mixture was two singlet resonances (δP = –24.3 and 
–24.5 ppm) which were tentatively assigned to the rac- and meso- forms of the ligand. 
Recrystallisation of the crude material did not improve the purity. Further development 
of methods to synthesise bidentate pyrenylphosphines with alkyl or solubilising linkers 
would be worthwhile.  
An exploration of the photophysical properties of these ligands and complexes by using 
higher level DFT calculations to optimise the excited state geometries may lead to a better 
understanding of the significant metal coordination quenching effect which could direct 
ligand design to phosphines with fluorescence sensing applications, for example as a 
sensitive method for catalyst detection.  
In an ongoing collaboration with Dr. Natalie Fey (University of Bristol) and Dr. Lee 
Higham (Newcastle University), the aim is to explore air-stability descriptors for a large 
set of phosphines from the Ligand Knowledge Base (LKB). The hope is that this would 
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5.1 Introduction 
There have been numerous reports describing pincer complexes as versatile catalysts for 
many types of organic transformations such as transfer hydrogenation, Heck and Suzuki–
Miyaura cross-coupling, hydroamination, allylic alkylation, and many more.124 Since the 
pioneering work on cyclometalated phosphine pincer complexes by Shaw et al. and amine 
pincer complexes by van Koten et al. in the 1970s, chemists have exploited the tunability 
of pincer complexes to develop many thousands of variants.276,277 This is due to the many 
points of derivatisation available, such as the donor atoms and substituents, backbone 
structure, metal centre, and ancillary ligands. The area of transition metal pincer 
complexes has been extensively reviewed.124,145,278 A Web of Science search for “pincer 
complex” (articles and reviews, conducted February 2021) shows the rapid increase in 
reports that started in the late 1990s (Figure 5.1). In contrast, a Web of Science search for 
“non-symmetric pincer” returns only 22 reports, and this field has not experienced 
anything like the exponential growth over the last two decades. Of the 5,000+ reports on 
pincer complexes, fewer than five (~0.1% of the total) concern phosphine complexes 
with non-symmetric metallacycles. Considering the few early reports on non-symmetric 
pincer complexes show promising results for highly active catalysts, this underexplored 
area of organometallic chemistry has considerable scope for development. In this chapter, 
a series of symmetric and non-symmetric PCP-pincer complexes and an evaluation of 
their activity in catalytic allylic alkylation is reported.  
 
Figure 5.1. Web of Science, total publications by year for “pincer complex” and “non-
symmetric pincer” (articles and reviews), search conducted February 2021. 
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Most pincer complexes are derived from C2v symmetric ligands which give rise to 
complexes with two fused 5-membered metallacycles (i.e., 5,5-metallacycles). Very few 
examples with non-symmetric metallacycles are known due to lengthy ligand syntheses. 
Although several non-symmetric examples containing two different donor atoms are 
known, the least developed class of pincer complexes are those that contain two 
metallacycles of different size (see 5,6-metallacycles, Figure 5.2). The inclusion of non-
symmetric metallacycles allows modulation of the ligand bite angle and more flexible 
derivatives have been shown to have superior catalytic properties compared to more rigid 
5,5-metallacyclic systems.144 
5.1.1 Non-symmetric pincer ligands 
Figure 5.2 shows the different sized PCP-pincer complexes with examples of symmetric 
(5,5-, 6,6- and 7,7-metallacyclic) and non-symmetric (4,5-, and 5,6-metallacyclic) systems. 
For additional examples, including larger metallacycles, see the recent reviews of Morales-
Morales et al.126,127 It is worth noting that the only known examples of 5,6-metallacycles 
are either bis-phosphite or mixed phosphine-phosphite Pd complexes, reported by 
Eberhard et al.144,279 There are no literature examples of 4,5- or 4,6-metallacyclic PCP-
pincer complexes or all-carbon based 5,6-metallacycles as depicted in Figure 5.2. 
 
Figure 5.2. The different sized metallacycles discussed in this Chapter. L = ancillary 
ligand. 
In the 2018 review from Crabtree et al.,124 the authors noted that there were very few 
examples of pincer ligands with non-symmetric metallacycles, only highlighting the 5,6-
Pd(II) bis-phosphite complex studied by Eberhard and co-workers 15 years previously.144 
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5.1.2 Applications of pincer complexes in medicine and catalysis 
Due to the enhanced thermal stability that pincer complexes display compared to many 
other organometallic complexes, they have been widely used in biological and catalytic 
contexts. The following examples demonstrate the enhanced reactivity that may be gained 
when using larger, non-symmetric metallacycles. 
Zhang et al. reported P-chiral ligands that would result in the formation of 6,6-
metallacycles. The ligands were applied in Pd-catalysed asymmetric allylic alkylation of 
1,3-diphenyl-2-propenyl acetate with dimethyl malonate (Scheme 5.1).280 Under the 
conditions used, high yields (90–99%) and moderate enantioselectivities (50–75% ee) 
were achieved. The authors reported the observation of a singlet resonance in the 31P 
NMR spectrum (δP = 18.7 ppm) of the reaction mixture for the reaction between [(η
3-
C3H5)PdCl2]2 and the PNP-pincer ligand, implying two chemically equivalent phosphine 
environments. No further coordination chemistry of these ligands has been reported. The 
ligands were also applied in Ru-catalysed asymmetric hydrosilylation which resulted in 
high yields (85–98%) and modest enantioselectivities (47–66%). The authors did not 
report any coordination studies on the Ru pincer complexes.281 
 
Scheme 5.1. P-chiral ligands reported by Zhang et al. for asymmetric allylic alkylation 
catalysis.280  
Both symmetric and non-symmetric metallacycles have been used as cytotoxic agents 
against many cancer cell lines. Novel, bimetallic Au(III) 5,5-metallacycles that contain a 
Pd(II) diphosphine moiety have been investigated for activity against some cisplatin-
resistant human cancer cell lines.282 The high activity of the complexes was attributed to 
the inhibition of thioredoxin reductase and glutathione reductase, which in turn caused 
cell death by apoptosis. In addition, a series of Pd(II) pincer complexes based on amino 
acid functionalised picolinylamide ligands has been reported to be highly cytotoxic to 
several human cancer cell lines.283 Of these palladacycles that contain NNN- and NNS-
donors, some of the most active variants are 5,6-metallacycles (Figure 5.3).  
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Figure 5.3. Representative examples of cytotoxic Au and Pd pincer complexes.282,283 
Milstein et al. studied the difference in reactivity between a ‘normal’ 5,5-metallacyclic Pt(II) 
complex and the ‘long-arm’ variant (5,6-metallacyclic Pt(II) complex, Scheme 5.2).284,285 
The hemilability of the 6-membered amine chelate was implicated in the quantitative 
formation of a trimeric Pt cluster when the PCN-Pt(II) pincer complex was reduced with 
H2 (5 atm.) at 65 °C, (Scheme 5.2). Under the same conditions, the ‘normal’ 5,5-
metallacycle was found to be completely inert, demonstrating the influence of the amine 
arm length on hemilability.  
 
Scheme 5.2. Example of studies investigating metallacycle ring size of PCN-Pt(II) 
complexes reported by Milstein et al.285 
The groups of van Leeuwen and Kamer published a series of studies detailing the effect 
of diphosphine bite angle in Pd-catalysed allylic alkylation.286–290 For the alkylation of 2-
hexenylacetate with sodium diethyl(methyl)malonate, the authors employed catalysts 
derived from [Pd(DBA)2] and diphosphine. As the ligand bite angle increased, a slight 
decrease in catalytic activity was observed, coupled with a stronger preference for the 
linear alkylation product 2-(2-hexen-1-yl)-2-methylmalonate (Scheme 5.3).286 For the 
largest bite angle Pd diphosphine complex employing Xantphos (bite angle = 110°), 
exclusive formation of the linear product was observed, which was attributed to a steric 
effect of the diphosphine embracing the allyl fragment, thus inhibiting formation of the 
branched regioisomer. Despite the increased selectivity towards the linear products with 
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catalysts derived from the widest bite angle ligands Xantphos (110°) and Sixantphos 
(106.5°), the reaction rate for these catalysts was diminished. The best linear selectivity 
while maintaining high catalyst activity was achieved with the moderately wide bite angle 
ligand DPEPhos (102.7°). 
 
Scheme 5.3. Allylic alkylation of 2-hexenylacetate with sodium diethyl methylmalonate 
catalysed by Pd(II) pincer complexes, reported by van Leeuwen et al.286 
In a later study, Kamer et al. reported a series of DPEPhos ligands modified with chiral 
carboxylic acid or ether auxiliaries.291 The asymmetric induction of these new ligands was 
assessed in Pd-catalysed asymmetric allylic alkylation, where moderate enantioselectivities 
(up to 70% ee) were achieved when using cyclohexyl-2-enyl acetate as the substrate with 
dimethyl malonate as the nucleophile. 
A structure-activity relationship for symmetric 5,5- and non-symmetric 5,6-metallacyclic 
Pd(II) pincer complexes was reported by Eberhard et al. (Scheme 5.4).144,279 This was the 
first report of a Pd(II) pincer complex being used as a catalyst for this alkylation reaction. 
The pincer complexes were applied as catalysts for the alkylation of cinnamyl acetate with 
sodium dimethyl malonate and the regioselectivity was found to be sensitive to the ligand 
structure. The more flexible 5,6-metallacycles were found to be far more active catalysts 
than the 5,5-metallacycles while maintaining high linear to branched product ratios (up to 
95 : 5 linear selectivity). The authors reported that the synthesis of the analogous Pd(II) 
complexes with two 6-membered metallacycles was not successful. It was predicted that 
6,6-metallacycles would show even higher catalytic activity in allylic alkylation.  
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Scheme 5.4. Allylic alkylation of cinnamyl acetate with sodium dimethyl malonate 
catalysed by Pd(II) pincer complexes, reported by Eberhard et al.144,280 
 
5.1.3 Research aims 
In order to investigate the effect of metallacycle ring size on the Pd coordination 
chemistry and catalytic activity of organometallic pincer complexes, we aimed to: 
• Synthesise pincer complexes with both symmetric and non-symmetric 
metallacycles (Figure 5.4).  
 
Figure 5.4. Chemical structures of the aminophosphine 5,5-, 5,6-, and 6,6-metallacycles 
discussed in this chapter. 
• Analyse the structural features of the more rarely studied derivatives and compare 
these to known 5,5-metallacycles. 
• Target an all-carbon backbone pincer ligand that would result in 5,6-metallacycles.  
• Develop structure-activity relationships for aminophosphine organopalladium 
pincer complexes as catalysts in the allylation of dimethylmalonate, and to 
compare our novel derivatives to the current state-of-the-art catalysts.  
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5.2 Synthesis of ligands and precursors 
5.2.1 Aminophosphine ligands 
5.2.1.1 From 1,3-diaminobenzene 
The symmetric aminophosphine ligand L5.1, previously prepared by Liu and co-workers 
for use in Ir-catalysed transfer hydrogenation, was prepared from deprotonation of 1,3-
diaminobenzene with nBuLi followed by reaction with tBu2PCl at elevated temperature 
(Scheme 5.5).131 After the reported reaction time of 16 h, the in situ 31P{1H} NMR 
spectrum showed that only 63% of the mixture corresponded to the desired product. Full 
consumption of the starting material to give L5.1 was achieved after 48 h under reflux. 
After precipitation of the LiCl with pentane, L5.1 was isolated in 78% yield with the 
31P{1H} 
NMR chemical shift matching the literature value (δP = 58.2 ppm). 
 
Scheme 5.5. Synthesis of symmetric aminophosphine ligand L5.1.
131 
5.2.1.2 From 3-aminobenzylamine 
The analogous reaction was performed with 3-aminobenzylamine (Scheme 5.6). After full 
consumption of tBu2PCl, the in situ 
31P{1H} NMR spectrum showed the clean formation 
of the new ligand L5.2 in 72% yield, comparable to the symmetric variant L5.1.  
 
Scheme 5.6. Synthesis of non-symmetric aminophosphine ligand L5.2. 
The ligand was characterised by two singlet resonances for L5.2 (δP = 81.6 and 59.3 ppm). 
The resonance for the C6H4–NH–P
tBu2 phosphine agrees with L5.1, and the resonance for 
the CH2–NH–P
tBu2 phosphine is ~21 ppm further downfield. As expected, the two 
phosphorus nuclei do not observably couple to each other as they are seven bonds apart. 
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In the 1H NMR spectrum, two overlapping doublets corresponding to the two sets of 
PtBu2 protons are seen (δH = 1.13 and 1.10 ppm). In addition, each of the four aryl-C–H 
protons, as well as the benzylic hydrogens can be distinguished.  
In the 13C{1H} NMR spectrum for L5.2, the magnitudes of the JCP coupling constants are 
of note. There are two doublet resonances corresponding to the two sets of -C(CH3)3 
substituents (δC = 28.2 ppm (d, 
2JCP = 15 Hz)) and δC = 28.5 ppm (d, 
2JCP = 15 Hz)). Next, 
the -PC(CH3)3 carbons give two doublet resonances (δC = 34.3 ppm (d, 
1JCP = 19 Hz)) 
and δC = 34.4 ppm (d, 
1JCP = 19 Hz)) with only slightly larger coupling than the 
2JCP 
coupling constants. The -CH2 carbon gives a doublet resonance (δC = 55.2 ppm (d, 
2JCP = 
30 Hz)) with a larger coupling constant than the other 2JCP and 
1JCP couplings. 
5.2.1.3 From m-xylylenediamine 
The ligand precursor to 6,6-metallacyclic complexes was prepared from the reaction with 
m-xylylenediamine (Scheme 5.7). Deprotonation of both amine groups with nBuLi gave a 
purple suspension. After full consumption of tBu2PCl, the in situ 
31P{1H} NMR spectrum 
showed the clean formation L5.3 containing one singlet resonance (δP = 81.6 ppm), almost 
identical to the resonance for the CH2–NH–P
tBu2 phosphine of L5.2. In the 
1H NMR 
spectrum, the symmetry of the molecule results in just three aryl-C–H signals and one 
benzylic hydrogens environment. 
 
Scheme 5.7. Synthesis of symmetric aminophosphine ligand L5.3. 
5.2.1.4 Less bulky phosphine substituents 
The reactions highlighted above can be extended to other chlorophosphines, with iPr2PCl 
and Ph2PCl also forming the desired aminophosphine pincer ligands following 
deprotonation with either nBuLi or 4-dimethylaminopyridine (DMAP) (Scheme 5.8). With 
this series of nine 5,5-, 5,6-, and 6,6-ligands L5.1-L5.9 in hand, we could investigate the 
influence of metallacycle size and phosphorus substituent on the coordination behaviour 
and catalytic activity.  
For the synthesis of all-carbon backbone pincer ligands that would result in 5,6- and 6,6-
metallacycles (compounds 5.4-5.7 and L5.10) see Section 5.6.2. 
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Scheme 5.8. Synthesis of aminophosphine ligands L5.1-L5.9, shown with 
31P{1H} NMR 
chemical shifts.  
5.3 Pd coordination chemistry 
We started our study with the Pd coordination of the PtBu2 substituted aminophosphine 
ligands L5.1-L5.3. The symmetrical pincer L5.1 was reacted in a 1:1 molar ratio with 
[PdCl2(cod)] in toluene under reflux for 18 h (Scheme 5.9). Analysis of the in situ 
31P{1H} 
NMR spectrum showed a singlet resonance (δP = 119.5 ppm) assigned to the pincer 
complex 5.8. The formation of the 5,5-metallacycle is associated with a large coordination 
chemical shift (ΔδP = 61.3 ppm). As with the free ligands, the symmetry of the molecule 
means there are only two aryl-C–H resonances in the 1H NMR spectrum. Formation of 
the desired Pd–Cl complex was confirmed by comparison to the previously reported 
NMR and HR-MS data. 
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Scheme 5.9. Formation of 5,5-Pd–Cl complex 5.8. 
The coordination of the 5,6-PtBu2 ligand L5.2 is surprisingly facile compared to L5.1. 
Immediately upon addition of a dichloromethane solution of L5.2 to [PdCl2(NCPh)2], the 
in situ 31P{1H} NMR spectrum showed the expected AB pattern consisting of two doublet 
resonances with large coupling constants (2JPP = 406 Hz) assigned to 5.9 (Scheme 5.10). 
The coordination of the inequivalent phosphorus nuclei (which do not show coupling to 
each other in the free ligand) now give a large coupling constant, characteristic of the 
phosphines arranged in a trans geometry. The 2JPP coupling constant falls within the 
normal range for related Pd complexes.144,279 The different chelate ring sizes have a 
significant influence on the coordination chemical shift which, for the 6-membered 
metallacycle is small (ΔδP = 8.2 ppm), and for the 5-membered metallacycle is large (ΔδP 
= 63.0 ppm), in agreement with the ΔδP for complex 5.8.  
 
Scheme 5.10. Formation of 5,6-Pd–Cl complex 5.9. 
Crystals of 5.9 suitable for X-ray diffraction were grown by evaporation of a concentrated 
solution of 5.9 in dichloromethane at room temperature (Figure 5.5). The molecular 
structure showed bond lengths that fall within the typical range for similar complexes, 
with Pd1–P2 (in the 6-membered ring) slightly longer than Pd1–P1 (2.3436(4) vs. 2.3096(4) 
Å). The complex adopts a distorted square planar geometry with the 6-membered 
metallacycle in a boat conformation and the 5-membered metallacycle in an envelope 
conformation. From the front-on view of the structure, a significant deviation from 
planarity can be seen from the P1–Pd1–P2 bond angle (161.693(14)°) which holds the 
PtBu2 groups significantly above and below the aryl-Pd–Cl plane.  




Figure 5.5. Single crystal X-ray crystallography structure of 5.9 (side view and front-on 
view). Hydrogen atoms have been omitted for clarity. Thermal ellipsoids at 50% 
probability level. Selected bond lengths (Å) and angles (°): Pd1–Cl1 2.4171(3), Pd1–P1 
2.3096(4), Pd1–P2 2.3436(4), Pd1–C1 2.0392(14); Cl1–Pd1–P1 94.460(12), Cl1–Pd1–P2 
94.674(12), P1–Pd1–P2 161.693(14), C1–Pd1–Cl1 172.96(4), C1–Pd1–P1 81.70(4), C1–
Pd1–P2 90.67(4). 
Clearly, there is a difference in kinetics of the C–H bond activation of L5.1 and L5.2 by Pd 
with 5,5-metallacycle formation requiring elevated temperature and extended reaction 
time while the 5,6-metallacycle formation occurs rapidly at room temperature. Therefore, 
we anticipated the formation of a symmetric 6,6-metallacycle to be rapid. We began by 
taking a solution of L5.3 and [PdCl2(cod)] in toluene and heating (Scheme 5.11), at which 
point a yellow solution with some insoluble material was observed.  
 
Scheme 5.11. Reactions for the attempted formation of 6,6-Pd–Cl complex 5.10. 
The in situ 31P{1H} NMR spectrum of the toluene solution showed a singlet resonance in 
the expected region (δP = 88 ppm), as well as an additional resonance attributed to the 
unreacted ligand. However, ESI-MS did not detect the desired complex in the mixture. 
Next, we tried to synthesise 5.10 by reaction of L5.3 with [PdCl2(NCPh)2] as the Pd 
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precursor. When either dichloromethane or toluene were used, the same two broad signals 
(δP = 78 and 79 ppm) were observed in the in situ 
31P{1H} NMR spectra. Analysis of the 
reaction mixture from L5.3 and [PdCl2(NCPh)2] in dichloromethane by HR-ESI-MS, the 
molecular ion corresponding to [M–H]•+ for the 6,6-metallacycle (5.10) (m/z 563.1713) 
with the expected palladium and chlorine isotope pattern was detected. However, the 
31P{1H} NMR spectrum of the isolated complex (following precipitation from hexane) 
showed a sharp singlet resonance (δP = 79.6 ppm) which when compared to the ligand 
gives an upfield coordination chemical shift of ~2 ppm and was tentatively assigned to 
the expected complex.  
This unexpected coordination chemical shift and limited solubility of the isolated complex 
led us to assign the product to a diphos-bridged polymeric material. When repeating the 
reaction between L5.3 and [PdCl2(cod)] in toluene under reflux (Scheme 5.11), after 4 h, 
the in situ 31P{1H} NMR spectrum showed a singlet resonance in the expected region (δP 
= 89 ppm). This time, after removal of the volatiles, extraction of the resulting solid into 
hexane provided the expected complex 5.10 with a characteristic downfield coordination 
chemical shift, consistent with forming a 6-membered metallacycle (ΔδP = 8.3 ppm). HR-
ESI-MS also confirmed formation of the desired complex with the molecular ion 
corresponding to [M–H]•+ for 5.10 observed (m/z 563.1713) with the expected palladium 
and chlorine isotope pattern. In conclusion, due to the formation of a coordination 
polymer, the symmetric 6,6-Pd–Cl complex was more difficult to synthesise than the non-
symmetric 5,6-Pd–Cl complex, contrary to our predictions.  
Analysis of the 1H NMR spectra was also indicative of the formation of the desired pincer 
complexes (Figure 5.6). In each case, formation of the pincer complex caused a downfield 
shift of the P(C(CH3)3)2 resonances of ~0.5 ppm accompanied by a change in the splitting. 
In the case of the free ligands, the signals are doublets due to coupling to one 31P nucleus. 
Upon coordination, the P(C(CH3)3)2 resonances are apparent triplets for 5.8 and 5.10, as 
the protons are split by two P nuclei, and are overlapping doublets in the case of 5.9. The 
aromatic region of the 1H NMR spectra are also informative, with the spectra for the 5,5-
metallacycle showing three aryl C–H resonances for the free ligand L5.1 and two for the 
complex 5.8. For the non-symmetric 5,6-metallacycle, the free ligand L5.2 clearly has four 
distinct aryl C–H resonances and the complex 5.9 has three. For the symmetric 6,6-
metallacycle, the free ligand L5.3 contains three aryl C–H resonances and only two for the 
complex 5.10 (Figure 5.6). In the 1H NMR spectrum for 5.10 there are two resonances 
for the P(C(CH3)3)2 each of which integrates for 18H (δH = 0.98 ppm (t, 
3JHP = 7 Hz) and 
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1.60 ppm (t, 3JHP = 7 Hz)), indicating their chemical inequivalence, despite the complex 
being symmetric.  
  
Figure 5.6. Selected regions of the 1H NMR spectra for a) L5.1, b) 5.8, c) L5.2, d) 5.9, e) 
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Colourless crystals of 5.10 suitable for X-ray diffraction were grown by slow evaporation 
of its concentrated hexane solution at room temperature (Figure 5.7). 
  
Figure 5.7. Single crystal X-ray crystallography structure of 5.10 (side view and front-on 
view). Hydrogen atoms have been omitted for clarity. Thermal ellipsoids at 50% 
probability level. Selected bond lengths (Å) and angles (°): Pd1–Cl1 2.3812(5), Pd1–P1 
2.3631(5), Pd1–P2 2.3382(5), Pd1–C1 2.0580(18); P1–Pd1–Cl1 89.437(17), P2–Pd1–Cl1 
92.083(18), P2–Pd1–P1 175.400(18), C1–Pd1–Cl1 174.86(5), C1–Pd1–P1 89.96(5), C1–
Pd1–P2 88.91(5). 
Due to the two methylene groups in the ligand backbone, the PtBu2 substituents are held 
high above and below the aryl-Pd–Cl plane. The crystal structure of 5.10 (Figure 5.7) 
shows the conformation of the ring is half chair with pseudo axial and equatorial tBu 
groups and the NMR inequivalence implies that conformational fluxionality is slow on 
the NMR timescale. This could be the reason for inequivalent P(C(CH3)3)2 protons in the 
solution 1H NMR spectrum. Due to the additional methylene unit in the ligand backbone, 
the bite angle (P1–Pd1–P2) for 5.10 is relaxed to 175.4° which is ~14° larger than for the 
non-symmetric 5,6-metallacycle 5.9. This bite angle is greater than the one reported for 
5,6-PiPr2 Pd–Cl complex reported by Eberhard (P–Pd–P = 168.3°), which, in turn, is ~8° 
larger than the analogous 5,5-PiPr2 Pd–Cl complex (P–Pd–P = 160.4°, see Scheme 5.4).
144 
The Pd–P bond lengths in 5.10 (2.3631(5) and 2.3382(5) Å) are comparable to the Pd1–
P2 bond length for the 6-membered metallacycle of complex 5.9 (2.3436(4) Å, see Table 
5.1). In 5.9, the Pd–P bond length of the 5- membered metallacycle is significantly shorter 
(2.3096(4) Å), presumably to accommodate the extra ring strain. 
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Table 5.1. Selected bond lengths (Å) and bond angles (°) in 5,6-metallacycle (5.9) and 
6,6-metallacycle (5.10).  
Bond 5,6-Pd–Cl (5.9) (Å) 6,6-Pd–Cl (5.10) (Å) 
Pd1–Cl1 2.4171(3) 2.3812(5) 
Pd1–P1 2.3096(4) 2.3631(5) 
Pd1–P2 2.3436(4) 2.3382(5) 
Pd1–C1 2.0392(14) 2.0580(18) 
Angle 5,6-Pd–Cl (5.9) (°) 6,6-Pd–Cl (5.10) (°) 
P1–Pd1–Cl1 94.460(12) 89.437(17) 
P2–Pd1–Cl1 94.674(12) 92.083(18) 
P1–Pd1–P2 161.693(14) 175.400(18) 
C1–Pd1–Cl1 172.96(4) 174.86(5) 
 
We encountered difficulties when attempting to form non-symmetric 5,6- and symmetric 
6,6-Pd–Cl metallacycles using ligands with less bulky phosphorus substituents than PtBu2 
(e.g., PiPr2 and PPh2). In the attempted synthesis of complexes derived from P
iPr2 ligands 
L5.5-L5.6 and PPh2 ligands L5.8-L5.9, mixtures containing very insoluble precipitates were 
obtained (Scheme 5.12).292 
 
Scheme 5.12. a) Reactions for the attempted formation of 5,6-Pd–Cl complexes 5.12 and 
5.15. b) Reactions for the attempted formation of 6,6-Pd–Cl complexes 5.13 and 5.16. 
The in situ 31P{1H} NMR spectra of the mixtures from the attempted synthesis of 5.12 
and 5.15 did display the expected AB pattern along with unknown impurities. In both 
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cases, the isolated material was highly insoluble. Analysis by HR-ESI-MS confirmed the 
formation of non-symmetric 5,6-metallacycles (m/z = 459.1321 for PiPr2 (5.12) and m/z 
= 595.0683 for PPh2 (5.15)). The difficulties associated with the formation of monomeric 
Pd–Cl complexes has been documented in the literature.144,293 For a related 5,5-
bis(phosphite) PCP-pincer ligand, Pringle et al. reported that coordination to 
[PdCl2(NCPh)2] was very slow under thermal conditions. Over the course of 6 days under 
reflux in 1,2-dichloroethane, the observed polymeric material very slowly dissolved to 
form the desired complex in 77% yield (Scheme 5.13). The slow reaction rate was 
enhanced by performing the reaction under microwave conditions at 150 °C in 1,2-
dichloroethane (92% yield after 1 h).  
In another example, Eberhard et al. noted that when attempting to form the 6,6-Pd 
bis(phosphite) PCP-pincer complex with PiPr2 substituents, only polymeric species were 
recovered, and a successful synthesis was not reported (Scheme 5.13).144 
 
Scheme 5.13. a) Pringle et al. previously reported the synthesis of a 5,5-Pd bis(phosphite) 
PCP-pincer complex via insoluble polymeric species.293 b) Eberhard et al. attempted 
synthesis of 6,6-Pd bis(phosphite) PCP-pincer complex where only polymeric species 
were recovered.144  
To investigate this interesting behaviour further, Pd(II) trifluoroacetate, [Pd(TFA)2] was 
used and found to be a suitable precursor to soluble, monomeric Pd–TFA complexes 
with any metallacycle size, and phosphine substituent. Moreover, these complexes form 
rapidly under mild conditions (25 C, 20 min), rather than the harsh conditions required 
to form some Pd–Cl complexes (110 C, 6 h) (Scheme 5.14). 
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Scheme 5.14. Formation of 5,6-Pd–TFA complexes 5.18, 5.21, and 5.24. 
For the 5,6-metallacycles, the 31P{1H} NMR spectra exhibit the expected AB patterns 
(Figure 5.8). For the non-symmetric PiPr2 complex 5.21, 
2JPP = 388 Hz, for the non-
symmetric PPh2 complex 5.24, 
2JPP = 447 Hz and for the non-symmetric P
tBu2 complex 
5.18, (2JPP = 367 Hz). For 5.18, the 
2JPP is considerably smaller than in the analogous Pd–
Cl complex 5.10 (2JPP = 406 Hz). This trend in coupling constants for 5,6-Pd–TFA 
complexes (2JPP: P
tBu2 < P
iPr2 < PPh2) reflects the trans influence of the phosphine donor 
substituents (i.e., two good σ-donating P ligands will mutually weaken their bonds to the 
metal leading to a smaller 2JPP coupling). 
Figure 5.8. 31P{1H} NMR spectra for a) 5,6-PtBu2 (L5.2), b) 5.18, c) 5,6-P
iPr2 (L5.5), d) 5.21, 
e) 5,6-PPh2 (L5.8), f) 5.24. 
The numbering schemes for Pd aminophosphine complexes with chloride or 
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moisture, and elevated temperatures (up to 100 °C), making them suitable catalysts for 
reactions that employ forcing conditions. We did not observe hydrolysis of the P–N 
bonds for any of these complexes by 31P{1H} NMR spectroscopy, even in solvents that 
were not rigorously dried. 
 
Figure 5.9. Summary of Pd aminophosphine complexes.  
For the formation of the 5,6-PtBu2 complex, as well as the main set of  resonances assigned 
to the Pd–TFA complex 5.18 (2JPP = 367 Hz), a second pair of  doublets corresponding 
to the Pd–Cl complex 5.9 (~2% of  the mixture by 31P{1H} NMR spectroscopy) was 
observed (2JPP = 406 Hz, Figure 5.10). We assumed that this chloride impurity could come 
from the palladium(II) trifluoroacetate (97%) commercial starting material as the reagent 
is prepared by reaction of PdCl2 with aqueous hydrochloric acid, then sodium hydroxide 
solution, followed by treatment with excess trifluoroacetic acid. For the case of the PiPr2 
and PPh2 complexes, although the same batch of [Pd(TFA)2] was used, the Pd–Cl 
impurity was not detected. 
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Figure 5.10. 31P{1H} NMR spectrum for the isolated material 5,6-PtBu2 Pd–TFA 
complex 5.18, with Pd–Cl 5.9 impurity. 
The formation of soluble 6,6-metallacyclic Pd–TFA complexes was also possible using 
the corresponding 6,6-ligand L5.3 and [Pd(TFA)2] at room temperature (Scheme 5.15). For 
the PtBu2 substituted ligand this corresponded to a small downfield coordination chemical 
shift (ΔδP = 11 ppm), thus clarifying the previously ambiguous result of the formation of 
Pd–Cl  complex 5.10 (see Scheme 5.11). Initially a ΔδP of ~2 ppm upfield was observed, 
but after extraction of 5.10 into hexane, we found a more expected coordination shift 
(ΔδP = 8 ppm).  
 
Scheme 5.15. Formation of 6,6-Pd–TFA complex 5.19. 
The weakly bound nature of the trifluoroacetate ligand was evident in the ESI-MS 
experiments. For the non-symmetric 5,6-PtBu2 Pd–TFA complex 5.18, a minor peak 
corresponding to the [M–H]•+ ion was present (m/z = 627.1703), but the most abundant 
ion detected was due to loss of trifluoroacetate, [M–TFA]•+ (m/z = 515.1991) upon 
ionisation. It is proposed that a weakly bound ligand in this position could lead to a more 
active catalyst, where an incoming substrate may bind to the Pd centre following ligand 
dissociation in this position.  
A summary of the NMR spectroscopy data for L5.1-L5.9 and associated Pd complexes is 
given in Table 5.2.  
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Ligand/Complex δP / ppm
a ΔδP
b 2JPP / Hz 
L5.1 5,5-P
tBu2 58.2
c – – 
5.8 [(L5.1)PdCl] 119.5
c 61.3 – 
5.17 [(L5.1)Pd(TFA)] 119.9
c 61.7 – 
L5.2 5,6-P
tBu2 81.6, 59.3 – – 
5.9 [(L5.2)PdCl] 122.2, 89.7 62.9, 8.1 406 
5.18 [(L5.2)Pd(TFA)] 125.9, 92.7
c 66.6, 11.1 367 
L5.3 6,6-P
tBu2 81.6 – – 
5.10 [(L5.3)PdCl] 89.9
c 8.3 – 
5.19 [(L5.3)Pd(TFA)] 92.7
c 11.1 – 
L5.4 5,5-P
iPr2 46.0
c – – 
5.11 [(L5.4)PdCl] 114.3
c,e 68.3 – 
L5.5 5,6-P
iPr2 67.9, 49.1
c – – 
5.21 [(L5.5)Pd(TFA)] 118.5, 89.4 69.4, 21.5 388 
L5.6 6,6-P
iPr2 68.0
c – – 
5.22 [(L5.6)Pd(TFA)] 84.9 16.9 – 
L5.7 5,5-PPh2 24.8
c – – 
5.14 [(L5.7)PdCl] 76.9
d,e 52.1 – 
L5.8 5,6-PPh2 41.7, 25.0 – – 
5.24 [(L5.8)Pd(TFA)] 88.5, 63.2 63.5, 21.5 447 
L5.9 6,6-PPh2 42.7
c – – 
5.25 [(L5.9)Pd(TFA)] 59.7 17.0 – 
aChemical shifts recorded in CDCl3 and given in ppm. 
bCoordination chemical 
shifts (ΔδP) are relative to the free ligands (ΔδP = δP(complex) – δP(ligand)). 
cNMR 
spectrum recorded in CD2Cl2. 
dNMR spectrum recorded in DMSO-d6. 
eFrom 
reference 133. 
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5.4 Catalytic allylation of dimethylmalonate 
5.4.1 Catalysis under standard conditions 
With the set of symmetric and non-symmetric aminophosphine pincer ligands L5.1-L5.9 in 
hand, we investigated their performance as ligands for catalysts for the allylation of 
dimethylmalonate. Using the conditions reported by Eberhard,144 we employed two 
equivalents of sodium dimethylmalonate with respect to the limiting substrate cinnamyl 
acetate to push the reaction to high conversion (Scheme 5.16 and Table 5.3). 
 
Scheme 5.16. Regioselectivity in the allylation of sodium dimethylmalonate.  
Table 5.3. Catalytic allylation of dimethylmalonate under standard conditions.a 
Entry Ligand 











































>99 87 >99 89 
aReaction conditions: 0.5 mmol of cinnamyl acetate, 1.0 mmol of sodium 
dimethylmalonate, 2.5 × 10–2 mmol of [Pd], 2.5 × 10–2 mmol of ligand, in THF (total 
volume = 10 mL), 60 °C, 6 h. bConversion and selectivity determined by GC-MS 
using dodecane as internal standard. 
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It should be noted that for the low conversion runs (<20%), the observed linear selectivity 
is very high (>99%). When the reaction was run without ligand, using either [Pd(TFA)2], 
[PdCl2(cod)], or [PdCl2(NCPh)2], the conversions were: <1%, 12%, and <1% respectively, 
indicating both a strong reliance on the pincer ligand for catalytic activity, as well as a 
modest amount of background activity for [PdCl2(cod)]. Some trends can be discerned 
from the data presented in Table 5.3: 
• The catalysts derived from 5,5- and 5,6-PtBu2 substituted aminophosphine ligands 
(L5.1-L5.2) (Table 5.3, Entries 1 and 4) showed significantly lower activity (11–48% 
conversion) after 6 h than the ligands with smaller PiPr2 and PPh2 substituents. 
• The 6,6-metallacyclic catalysts showed superior activity to the other metallacycle 
sizes, with all derivatives giving >99% conversion (Table 5.3, Entries 7-9). 
• In general, PPh2 substituents show the highest linear selectivity (87–94%), 
followed by PtBu2 substituents (80–91%), followed by P
iPr2 substituents (66–
69%). However, the 6,6-PiPr2 (L5.6) derived Pd–Cl catalyst afforded >99% 
conversion and 94% linear selectivity (Table 5.3, Entry 8), far higher than the 
average of the other PiPr2 derivatives. 
This intriguing result with L5.6 led us to investigate this highly active and selective catalyst 
further. We studied the catalytic activity of L5.6 with [Pd(TFA)2] and [PdCl2(NCPh)2] 
monitoring the reaction after 2 h and varying the catalyst loading from 1.25–5 mol% and 
temperatures from 25–60 °C (Table 5.4). These results demonstrated the enhanced 
activity gained from using [Pd(TFA)2] as Pd source, where at 60 °C, full conversion was 
achieved at 1.25 mol% whilst retaining good linear selectivity, compared with only 48% 
conversion when using the [PdCl2(NCPh)2] precursor (Table 5.4, Entry 3). Using 
[Pd(TFA)2] and reducing the temperature to 40 °C did not decrease the conversion (>99% 
conversion over 2 h). Surprisingly, a slight reduction in linear selectivity (60%) was 
observed at the lower temperature (Table 5.4, Entries 4-6). Excellent linear selectivity 
(>99%) was restored by reducing the reaction temperature to 25 °C where, after 2 h, the 
reaction conversion was <10%. By extending the reaction time to 20 h, the 5 and 2.5 mol% 
runs had gone to ~50% conversion (Table 5.4, Entries 7-8). 
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Table 5.4. Catalytic allylation of dimethylmalonate using 6,6-PiPr2 ligand L5.6 at various 














1 5 60 >99 78 >99 67 
2 2.5 60 95 87 >99 63 
3 1.25 60 48 92 >99 78 
4 5 40 – – >99 60 
5 2.5 40 – – >99 60 
6 1.25 40 – – >99 61 
7 5 25 – – 49c >99 
8 2.5 25 – – 48c 96 
9 1.25 25 – – 12c >99 
aReaction conditions: 0.5 mmol of cinnamyl acetate, 1.0 mmol of sodium dimethylmalonate, 
2.5 × 10–2 – 6.25 × 10–3 mmol of [Pd], 2.5 × 10–2 – 6.25 × 10–3 mmol of L5.6, in THF (total 
volume = 10 mL), 2 h. bConversion and selectivity determined by GC-MS using dodecane 
as internal standard. cReaction time 20 h. 
5.4.2 Structure-activity relationships  
The strong influence of metallacycle size and phosphine substituent on the linear 
selectivity of the alkylation product is not straightforward. Overall, some interesting 
trends were observed: (i) for the PtBu2 and PPh2 substituted ligands, the linear selectivity 
decreased as the metallacycle size is increased (5,5- > 5,6- > 6,6-); (ii) for PiPr2 substituted 
ligands, the linear selectivity was low with linear-to-branched ratio of 2:1 for 5,5- and 5,6-
metallacycles; the linear-to-branched ratio was dramatically greater at 15:1 for the 6,6-
metallacycle; (iii) as the ligand bite angle increases (162° for 5,6-metallacycle 5.9 to 175° 
for 6,6-metallacycle 5.10), we observe an increase in catalytic activity. 
Through a short optimisation of temperature and catalyst loading, as well as variation of 
the Pd–X ancillary ligand from chloride to trifluoroacetate, we achieved significantly 
increased catalytic activity with good conversion and excellent linear selectivity (linear-to-
branched ratio of >20:1) at ambient temperature. 
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5.4.3 Identifying unexpected alkylation product 
The GC chromatogram (Figure 5.11) shows the outcome of the reaction (full 
consumption of cinnamyl acetate) run using the catalyst derived from [Pd(TFA)2] and 6,6-
PiPr2 ligand L5.6 (Table 5.4, Entry 3). When the reaction proceeds to high conversion, 
another product (t = 11.3 min) is produced in significant quantities. 
 
Figure 5.11. Representative GC chromatogram for the allylation of dimethylmalonate.  
This unknown compound (X) was isolated from the post-reaction mixture by column 
chromatography and analysed by 1H and 13C NMR spectroscopy, HR-EI-MS and IR 
spectroscopy. The accurate mass for X (m/z = 304.1456) was found to be an exact match 
for C21H20O2, seemingly a dimerisation product of cinnamyl acetate.  
The Pd-catalysed dimerisation of cinnamyl acetate was reported by Garg et al. as a useful 
procedure for the synthesis of the fluorescent probe molecule, diphenylhexatriene 
(Scheme 5.17).294 The reaction conditions they used gave the Z-triene in quantitative yield. 
Furthermore, these conditions were suitable to convert the branched isomer of cinnamyl 
acetate, as well as cinnamyl pivalate and cinnamyl chloride to diphenylhexatriene in high 
yield (70-95%). Cinnamyl carbonate was the only substrate tested which gave a low yield 
of diphenylhexatriene (27%).  
 
Scheme 5.17. Pd catalysed synthesis of diphenylhexatriene, Garg et al.294 
Under our catalytic conditions, it is surprising that a cinnamyl acetate dimerisation 
product would form in a significant quantity since two equivalents of sodium 
dimethylmalonate were used. Moreover, the additions of the two substrates to the catalyst 
were carried out in quick succession before heating the reaction mixture to temperature. 
X 
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The IR spectra (carbonyl region) for cinnamyl acetate, dimethyl malonate, the 
linear/branched allylation product, and X are shown in Figure 5.12. It is not conclusive 
that the unknown product X (ν(C=O) = 1731 and 1747 cm–1) contains an acetate or 
malonate group, as the stretching frequency is comparable to both cinnamyl acetate 
(ν(C=O) = 1734 cm–1) and dimethyl malonate (ν(C=O) = 1736 and 1754 cm–1) carbonyl 
stretching frequencies. 
Cinnamyl acetate Unknown product (X) 
  
Dimethyl malonate Linear/branched product 
  
Figure 5.12. IR spectra (carbonyl region) of cinnamyl acetate, unknown product (X), 
dimethyl malonate, and the linear/branched allylation product.  
The 1H NMR spectra for cinnamyl acetate, the unknown X, and an analytical sample of 
methyl (E)-4-phenylbut-3-enoate are shown in Figure 5.13. It is apparent that X does not 
contain an acetate group, due to the lack of signals for the methyl protons at δH = 2.10 
ppm and the methylene protons at δH = 4.73 ppm. The 
1H NMR spectrum of purified X 
appears to correspond to a symmetrical compound with 24 protons, which could be 
formed from di-allylation of dimethylmalonate. The signal for the methylene protons at 
δH = 2.85 ppm is further upfield than the methylene protons for (E)-4-phenylbut-3-
enoate (δH = 3.26 ppm), consistent with being alpha to a quaternary carbon, rather than 
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Figure 5.13. 1H NMR spectra in CDCl3 for a) cinnamyl acetate, and b) purified product 
X, and c) methyl (E)-4-phenylbut-3-enoate.  
Initially, we were confused that the NMR spectroscopy and mass spectrometry data were 
not consistent for the proposed structure of this product. The observed accurate mass is 
consistent with loss of one CO2Me group to give the [M–CO2Me]
•+ ion (m/z = 304.1456). 
All NMR spectroscopy data are in accord with the di-allylation product shown in Figure 
5.13. It is still surprising that di-allylation occurs when the molar ratio of sodium 
dimethylmalonate to cinnamyl acetate is 2:1.  
5.5 Conclusions 
We have shown that aminophosphine ligands form palladacycles with 5,5-, 5,6-, or 6,6-
membered rings (Figure 5.14), whose chemistry is sensitive to the phosphine substituents 
and whether the fourth ligand is Cl or CF3CO2 (TFA). The bulky P
tBu2 ligands form very 
stable, soluble, monomeric Pd–Cl complexes in any of the three metallacycle sizes. When 
smaller PiPr2 of PPh2 substituents are present, insoluble Pd-coordination polymers are 
produced. On switching the anionic ligand from chloride to trifluoroacetate, not only are 
the desired monomeric pincer complexes formed, but the C–H activation reaction is 
much more rapid and occurs under mild conditions. This provides access to highly active 
Pd(II) catalysts with a weakly bound TFA ligand and these have been applied in the 
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Figure 5.14. Aminophosphine Pd(II) pincer complexes discussed in this work.  
Promising preliminary results indicate that the activity of these catalysts generally increases 
with increasing metallacycle size: 5,5- < 5,6- < 6,6-, which mirrors earlier studies of 
Eberhard et al. using pincer complexes derived from phosphinite donors. In addition, the 
linear selectivity for the allylation product is highest for PPh2 substituted complexes; the 
most highly active and selective pincer catalyst discovered was with L5.6 containing P
iPr2 
donors. Overall, we have discovered readily synthesised aminophosphine 
organopalladium pincer complexes that catalyse the allylation of dimethylmalonate with 
high activity and excellent linear selectivity under mild conditions.  
5.6 Future work 
There are three main strands that we propose should be pursued in future work building 
on the Pd-pincer complexes described above.  
5.6.1 High-throughput screening 
First, a high-throughput screening approach using the Chemspeed parallel synthesis 
platform should be applied to obtain a clearer picture of the factors that influence catalyst 
activity and selectivity. The parameters that would be varied would be the phosphine 
ligand structure (L5.1-L5.9), Pd source, catalyst loading, temperature, and solvent. This 
study may lead to a deeper understanding of the catalysis and then to logical developments 
for improving the design of new catalysts for the allylation reaction and indeed to other 
catalytic processes.  
5.6.2 Attempted preparation of all-carbon-backbone pincer ligands 
Secondly, all carbon-backbone non-symmetric pincer ligands could also be targeted that 
would compliment the range of aminophosphine and phosphite pincer ligands that have 
proved fruitful ligand classes for catalysis. This will require more work to develop 
phosphine syntheses from the non-symmetric ligand precursors that are required. To date, 
although many examples of all-carbon-backbone ligands that form symmetric 
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metallacycles exist, there are no reports of phosphine pincer complexes with non-
symmetric metallacycles. This is most likely due to the high number of steps required to 
synthesise these ligands (see examples from Milstein285 incorporating both NMe2 and 
PtBu2 donor groups (Scheme 5.2) and examples from Eberhard
279 incorporating mixed 
phosphine-phosphinite donors (Scheme 5.4)).  
Jensen et al. have shown that a 6,6-metallacyclic Pd–Cl complex with a bis(phosphinite) 
ligand is an effective catalyst for the Heck reaction (see Figure 5.2).137 We were interested 
in phosphines that would give symmetric 6,6-metallacycles; therefore, the symmetric diol 
5.5 was prepared by LiAlH4 reduction of 1,3-C6H4(CH2CO2H)2 5.4.
295 Next, tosylation 
using conditions reported by Sigman et al. with TsCl, NEt3, and DMAP gave the novel 
bis-tosylate 5.6 (Scheme 5.18). Analogous chemistry could be carried out with the non-
symmetric diol (see Scheme 5.18) reported by Mann et al.,296 which is prepared in four 
steps from commercially available m-toluoyl chloride.  
 
Scheme 5.18. Preparation of novel bis-tosylate ligand precursor 5.6.  
The OTs groups of 5.6 were displaced with two equivalents of tBu2PLi(BH3) to give the 
novel borane protected ligand 5.7 (Scheme 5.19). Removal of the borane groups required 
forcing conditions (DABCO, 10 equiv.), as simply stirring with the weaker base 
diethylamine was ineffective. The mechanism of phosphine borane deprotection has been 
studied by Lloyd-Jones and co-workers and they report that similarly harsh conditions are 
necessary to remove the borane groups from trialkyl phosphines.297 Monitoring the 
deprotection by in situ 31P{1H} NMR spectroscopy over 18 h showed the disappearance 
of the broad signal at δP = 44.5 ppm (corresponding to phosphine-borane 5.7) and a new 
sharp singlet at δP = 29.5 ppm (corresponding to the free phosphine L5.10).  
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Scheme 5.19. Synthesis of 6,6-PtBu2 ligand L5.10.  
Due to the difficulties with phosphine-borane deprotection, only a small-scale preparation 
of L5.10 has been possible. The presence of excess DABCO prohibited successful Pd 
coordination of L5.10. When a solution of L5.10 was added to [PdCl2(NCPh)2], the solution 
instantly deposited a black precipitate, possibly due to DABCO reducing the Pd(II) to 
Pd(0). Due to the difficulties in forming non-symmetric all-carbon-backbone ligands from 
phosphine-borane precursors, these have not been tested in catalysis alongside 
aminophosphine ligands L5.1-L5.9. 
5.6.3 Mechanism of allylic alkylation 
Finally, the mechanism of allylic alkylation catalysed by Pd(II)-pincer complexes is not yet 
understood. This section is a discussion of the mechanism for allylic alkylation catalysed 
by PCP-Pd(II) pincer complexes and provides a commentary on related literature 
examples where Pd(0)/Pd(II) and Pd(II)/Pd(IV) redox cycles are proposed. In the study 
performed by Eberhard et al. utilising bis(phosphite)-Pd(II) pincer complexes, the 
alkylation of deuterated allylic acetate substrate resulted in products with a 1:1 ratio of 
C(sp3)-deuteration and C(sp2)-deuteration, implying the reaction proceeds through a 
symmetrical (η3-allyl)Pd intermediate (Scheme 5.20).144 In their study, it was not 
determined whether the X– ligand (chloride, acetate, or triflate) remained bound to Pd 
during the catalytic cycle, and neither a Pd(0)/Pd(II) nor a Pd(II)/Pd(IV) cycle was 
proposed. 
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Scheme 5.20. Alkylation of deuterated allylic acetate, Eberhard et al.144 
In 2004, Szabó and co-workers provided evidence for bis(phosphite)-Pd(II) pincer 
complex catalysed allylation of aldehydes and imines via (η1-allyl)Pd intermediates.298 In 
2009, the Szabó group reported that Pd(II) pincer complexes could catalyse the coupling 
of alkenes with diaryliodonium salts via proposed aryl-Pd(IV) intermediates.146 In the 
same year they reported allylic C–H acetoxylation via proposed (η3-allyl)Pd(IV) 
intermediates.147 On the basis of the observations from Szabó and from Eberhard, we 
propose that aminophosphine Pd(II) pincer complexes could catalyse allylic alkylation via 
(η1-allyl)Pd(II) intermediates or via (η3-allyl)Pd(IV) intermediates. 
For the latter case, the properties of the PCP-pincer ligands (tridentate, rigid, monoanionic 
chelating ligand), may allow stabilisation of Pd(IV) intermediates. This led us to propose 
the following mechanism for allylic alkylation (Scheme 5.21): (i) oxidative addition of 
cinnamyl acetate to give an (η1-allyl)Pd(IV) intermediate; (ii) η3-allyl formation by 
deprotonation (loss of AcOH) to give a cationic (η3-allyl)Pd(IV) intermediate; (iii) 
nucleophilic attack on the η3-allyl predominantly at the less hindered terminus; (iv) 
product dissociation to complete the catalytic cycle.  
Chapter 5. Non-symmetric PCP metallacycles for alkylation catalysis 
164 
 
Scheme 5.21. Proposed catalytic cycle for allylic alkylation via (η3-allyl)Pd(IV) 
intermediate. 
Although the oxidative addition of cinnamyl acetate has not been observed with Pd(II) 
complexes, the formation of a Pd(IV) complex following oxidative addition with an allyl 
bromide was reported by Malinakova et al. (Scheme 5.22).299 This work demonstrates that 
Pd(IV) oxidative addition complexes can be accessed without the use of strongly oxidising 
iodine(III) reagents. 
 
Scheme 5.22. Formation of (η1-allyl)Pd(IV) complex via oxidative addition of Pd(II) 
complex with allyl bromide, Malinakova et al.299 
Through further studies, it may be possible to observe whether Pd(IV) aminophosphine 
pincer complexes are viable intermediates under the catalytic conditions. This could then 
be extended to other allyl electrophiles and strongly oxidising iodonium salts to see if 
similar results to those of Szabó et al. are obtained.146,147 Experimental mechanistic studies 
should be supported by a computational study of the mechanism, in particular the 
oxidative addition step to see if (η1-allyl)Pd(II) or (η3-allyl)Pd(IV) intermediates are 
realistic.  
By carrying out the project extensions outlined above, it is hoped that a deeper 
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6.1 General 
Unless otherwise stated, all manipulations were carried out under an inert atmosphere (N2) 
using standard Schlenk line techniques or in a glovebox (Ar). All glassware was oven-
dried (200 °C) and cooled under vacuum prior to use. Unless otherwise stated, chemicals 
and reagents were purchased from commercial suppliers and used without further 
purification. Anhydrous solvents (Et2O, THF, MeCN, hexane, toluene, CH2Cl2) were 
used unless otherwise stated. These were obtained from an Anhydrous Engineering 
alumina column drying system based on the Grubbs design and deoxygenated prior to 
use by successive freeze-pump-thaw cycles or by sparging with nitrogen and stored over 
4 Å molecular sieves. CDCl3, CD2Cl2, THF-d8, and C6D6 were distilled from CaH2 and 
stored over 4 Å molecular sieves. Anhydrous pentane and EtOH were purchased from 
Sigma, stored over 4 Å molecular sieves and deoxygenated by sparging with nitrogen. 
Anhydrous MeOH and CD3OD were purchased, stored over 3 Å molecular sieves and 
deoxygenated by sparging with nitrogen. DMSO-d6 was purchased from Sigma and used 
without further purification.  
All NMR spectra were acquired at ambient temperature on Jeol ECS300, Jeol ECS400, 
Varian 400, Varian VNMRS 500, Bruker 400 or Bruker Avance III HD CryoCarbon 500 
MHz spectrometer equipped with a 13C-observe (DCH) cryogenic probe. Chemical shifts 
(δ) are quoted in parts per million (ppm) and 1H and 13C{1H} NMR spectra are referenced 
relative to the deuterated solvent. 31P{1H} NMR spectra are referenced relative to 85% 
H3PO4 as an external standard. Mass spectrometry was carried out by the Mass 
Spectrometry Service, University of Bristol on either a VG Analytical Autospec (EI) or 
VG Analytical Quattro (ESI) spectrometer. UV-vis studies were performed on an Agilent 
Cary 300 spectrophotometer. Photophysical data were obtained on a Perkin Elmer LS-45 
fluorescence spectrometer. X-ray crystallography was performed by the University of 
Bristol Crystallography Service using a Bruker AXS Microstar or a Bruker Kappa Apex II 
diffractometer. Elemental analyses were performed by the University of York 
Microanalytical service. 
The following starting materials and reagents were purchased from commercial suppliers 
and purified prior to use. Amines (NEt3, EtN
iPr2, NBu3, pyridine) and ClSiMe3 were each 
distilled from CaH2 under vacuum and stored over activated 4 Å molecular sieves. 
Chlorophosphines (Ph2PCl, 
tBu2PCl, 
iPr2PCl, PhPCl2, PCl3) and phosphines (Ph2PH, 
tBu2PH) were distilled under vacuum. 
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The following compounds were prepared from literature procedures and spectroscopic 
data agreed with that reported:  
cis-[RuCl2(DMSO-S)3(DMSO-O)],








4-methylcoumarin,306 1-bromopyrene (4.2),307 diethyl 1-pyrenylphosphonate (4.3),246 
diphenyl(1-pyrenyl)phosphine (DPPP),240 Mes*PH2,




All other commercial reagents were used without further purification. 
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6.2 Experimental procedures and characterising data for Chapter 2 – 
Ru metallodrugs with DNA intercalating diphosphine ligands 
6.2.1 NMR Assignments for Ru complexes 
For Ru complexes 2.10 and 2.17-2.19, the following NMR assignment labels are used: 
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6.2.2 Synthesis of ligands and complexes 
6.2.2.1 Synthesis of [RuCl(DMSO-S)2(cis-tach)]Cl, 2.1 
Following the reported procedure,82 cis,cis-1,3,5-
triaminocyclohexane (330 mg, 2.55 mmol) was added to a 
solution of cis-[RuCl2(DMSO)4] (1.24 g, 2.55 mmol) in DMSO 
(100 mL). The mixture was heated to 130 °C for 1 h yielding 
a yellow solution before being cooled and the complex 
precipitated by addition of EtOAc (1000 mL). The mixture 
was then cooled to –20 °C for 18 h to form more precipitate. 
The precipitate was filtered off, washed with EtOAc (200 mL) and dried in vacuo to give 
2.1 as a pale yellow solid. Yield: 795 mg (74%). 1H NMR (400 MHz, D2O) (δ, ppm): 4.50 
(d, 2JHH = 12.2 Hz, 2H, NH2, N
2), 4.21 (d, 2JHH = 12.2 Hz, 2H, NH2, N
2), 3.86 (s, 2H, NH2, 
N1), 3.50 (s, 2H, CH, Cy2), 3.33 (s, 12H, (CH3)SO), 3.23 (s, 1H, CH, Cy
1), 2.19–1.94 (m, 
4H, CH2, Cy
3 + Cy4), 1.81 (d, 2JHH = 15.2 Hz, 2H, CH2, Cy
3). 13C{1H} NMR (101 MHz, 
D2O) (δ, ppm): 44.5 (s, (CH3)2SO), 43.9 (s, CH, Cy
1), 42.8 (s, CH, Cy2), 33.0 (s, CH2, Cy
4), 
32.1 (s, CH2, Cy
3). HRMS (ESI): m/z calculated for C10H27ClN3O2RuS2 [M]
•+ = 422.0269, 
found = 422.0263. 
6.2.2.2 Synthesis of 3',4'-bis(diphenylphosphino)-2,2':5',2''-terthiophene, L2.11 
A solution of 3',4'-dibromo-2,2':5',2''-terthiophene 2.11 (914 
mg, 2.25 mmol) in Et2O (30 mL) was cooled to –78 °C and 
a solution of nBuLi (1.6 M in hexane) (1.55 mL, 2.48 mmol) 
was added dropwise. A yellow precipitate was observed, and 
the solution was stirred at –78 °C for 2 h before Ph2PCl (0.41 mL, 2.25 mmol) was added 
dropwise over 10 min. The mixture was then slowly warmed to room temperature and 
stirred for 18 h. The resulting mixture was filtered to remove the LiCl precipitate and then 
the solvent removed in vacuo to give the monophosphine intermediate as a yellow powder. 
The procedure was repeated to give the diphosphine. The residue was purified by a short 
(2 × 1 cm) silica column (50% Et2O/CH2Cl2) to obtain the product as a yellow solid. 
Yield: 0.275 g (20%). Crystals suitable for X-ray diffraction were grown by slow 
evaporation of a saturated CH2Cl2 solution of the product at room temperature. 
1H NMR 
(400 MHz, CDCl3) (δ, ppm): 7.25 – 7.19 (m, 8H, PPh2), 7.12 – 7.09 (m, 12H, PPh2), 7.07 
(dd, 3JHH = 5.1 Hz, 
4JHH = 1.3 Hz, 2H, CH), 6.63 (dd, 
3JHH = 5.1 Hz, 
4JHH = 3.6 Hz, 2H, 
CH), 6.60 (dd, 3JHH = 3.6, 
4JHH = 1.2 Hz, 2H, CH). 
13C{1H} NMR (101 MHz, CDCl3) (δ, 
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ppm): 144.0, 139.3, 135.5, 134.1, 132.5, 129.4, 127.9, 127.7, 127.2, 126.9. 31P{1H} NMR 
(162 MHz, CDCl3) (δ, ppm): –17.3 (s, 2P). HRMS (MALDI): m/z calculated for 
C36H26P2S3 [M+H]
•+ = 617.0745, found = 617.0752. 
6.2.2.3 Synthesis of 2,3-dichlorodibenzo[f,h]quinoxaline, 2.16 
1,4-dihydrodibenzo[f,h]quinoxaline-2,3-dione 2.14 (600 mg, 2.30 
mmol), PCl3 (4.0 mL, 46.0 mmol) and DMF (9 mL) were heated 
to 100 °C for 16 h. The dark red solution was cooled to room 
temperature and the product precipitated by the addition of 
degassed water. The yellow solid was then filtered off, washed 
with EtOH, and dried in vacuo. Yield: 0.75 g (84%). 1H NMR (400 MHz, CDCl3) (δ, ppm): 
9.07 (d, 3JHH = 7.5 Hz, 2H, CH), 8.63 (d, 
3JHH = 8.2 Hz, 2H, CH), 7.83 (t, 
3JHH = 7.2 Hz, 
2H, CH), 7.75 (t, 3JHH = 7.5 Hz, 2H, CH). 
13C{1H} NMR (100 MHz, CDCl3) (δ, ppm): 
139.6, 137.3, 131.9, 130.4, 128.2, 126.0, 126.0, 123.0. HRMS (APCI): m/z calculated for 
C16H8N2Cl2 [M]
•+ = 299.0137, found = 299.0130. APCI mass spectrum exhibited the expected 
chlorine isotope pattern.  
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6.2.2.4 Synthesis of 2,3-bis(diphenylphosphino)dibenzo[f,h]quinoxaline, L2.13 
A solution of Ph2PH (0.35 mL, 2.0 mmol) in THF (10 mL) 
was cooled to –78 °C and a solution of nBuLi (1.6 M in hexane, 
1.38 mL, 2.20 mmol) was added dropwise. The orange 
solution was stirred at this temperature for 2 h before a 
solution of 2,3-dichlorodibenzo[f,h]quinoxaline 2.16 (270 mg, 
0.90 mmol) in THF (5 mL) was added dropwise and stirred for a further 12 h with 
warming to room temperature. The solution was then quenched at –78 °C by the addition 
of sat. aq. NH4Cl (5 mL) and warmed to room temperature. The aqueous layer was 
extracted with THF (3 × 10 mL) and filtered through silica. The volatiles were removed 
in vacuo, the residue dissolved in EtOAc and filtered off to remove soluble impurities. The 
remaining solid was recrystallised from EtOAc to give a yellow solid. Yield: 0.12 g (22%). 
1H NMR (400 MHz, CDCl3) (δ, ppm): 8.67 (dd, 
3JHH = 8.0 Hz, 
4JHH = 1.4 Hz, 2H, CH), 
8.57 – 8.53 (m, 2H, CH), 7.72 (ddd, 3JHH = 8.4 Hz, 
3JHH = 7.0 Hz, 
4JHH = 1.5 Hz, 2H, CH), 
7.56 (ddd, 3JHH = 8.1 Hz, 
3JHH = 7.0 Hz, 
4JHH = 1.2 Hz, 2H, CH), 7.44 – 7.36 (m, 8H, PPh2), 
7.34 – 7.25 (m, 12H, PPh2). 
13C{1H} NMR (100 MHz, CDCl3) (δ, ppm): 162.3 – 162.0 
(m), 140.2, 136.1, 134.8, 131.7, 130.1, 129.7, 128.9, 128.3, 127.8, 125.8, 122.7. 31P{1H} 
NMR (162 MHz, CDCl3) (δ, ppm): –10.24 (s, 2P). HRMS (ESI): m/z calculated for 
C40H29N2P2 [M+H]
•+ = 599.1800, found = 599.1809. 
6.2.2.5 Synthesis of [RuCl(dppbz)(cis-tach)]Cl complex, 2.10 
A solution of 2.1 (50 mg, 0.11 mmol) and 1,2-
bis(diphenylphosphine)benzene (80 mg, 0.18 mmol, 1.8 eq) in 
MeOH (15 mL) was heated under reflux for 48 h. The solution 
was cooled, unreacted phosphine was removed by filtration and 
the solution was concentrated (approx. 5 mL). Et2O (90 mL) was 
added to precipitate the product which was filtered off and dried 
to give a pale yellow solid. Yield: 62 mg (77%). 1H NMR (500 MHz, CD3OD) (δ, ppm): 
8.07 (ddd, 3JHP = 9.8 Hz, 
3JHH = 5.4 Hz, 
4JHH = 1.9 Hz, 4H, PPh2, Ar
2a), 7.55 – 7.49 (m, 6H; 
2H, PPh2, Ar
4a, 4H, PC6H4P, Br
2 + Br3), 7.45 (t, 3JHH = 7.7 Hz, 4H, PPh2, Ar
3a), 7.41 – 7.37 
(m, 4H, PPh2, Ar
3b), 7.37 – 7.32 (m, 2H, PPh2, Ar
4b), 7.15 (ddd, 3JHP = 9.5 Hz, 
3JHH = 5.9 
Hz, 4JHH = 1.6 Hz, 4H, PPh2, Ar
2b), 4.92 (d, 2JHH = 12.1 Hz, 2H, NH2, N
2), 3.86 (d, 2JHH = 
12.0 Hz, 2H, NH2, N
2), 3.56 (s, 2H, CH, Cy2), 2.72 (s, 1H, CH, Cy1), 2.29 (d, 2JHH = 15.1 
Hz, 1H, CH2, Cy
4), 2.14 (d, 2JHH = 15.3 Hz, 1H, CH2, Cy
4), 1.86 (d, 2JHH = 15.0 Hz, 2H, 
CH2, Cy
3), 1.74 (d, 2JHH = 15.9 Hz, 2H, CH2, Cy
3), 1.39 (s, 2H, NH2, N
1). 13C{1H} NMR 
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(126 MHz, CD3OD) (δ, ppm): 145.6 (vt, |
1JPC + 
2JP’C| = 82 Hz, PC6H4P, Br
1), 136.8 (t, 
|2JPC + 
4JP’C| = 10 Hz, PPh2, Ar
2a), 133.6 (m PPh2, Ar
1a + Ar1b), 133.5 (t, |2JPC + 
3JP’C| = 
16 Hz, PC6H4P, Br
2), 133.0 (t, |3JPC + 
4JP’C| = 9 Hz, PPh2, Ar
2b), 131.8 (s, PC6H4P, Br
3), 
131.7 (s, PPh2, Ar
4a), 131.1 (s, PPh2, Ar
4b), 130.5 (t, |3JPC + 
5JP’C| = 9 Hz, PPh2, Ar
3b), 129.5 
(t, |3JPC + 
5JP’C| = 9 Hz, PPh2, Ar
3a), 44.8 (s, CH, Cy2), 44.4 (s, CH, Cy1), 35.6 (s, CH2, Cy
4), 
34.3 (s, CH2, Cy
3). 31P{1H} NMR (162 MHz, CD3OD) (δ, ppm): 73.0 (s, 2P). Elemental 
analysis for [RuCl(dppbz)(cis-tach)]Cl.CH2Cl2 (C37H41Cl4N3P2Ru): calcd. C, 53.38; H, 4.96; 
N, 5.05%. Found: C, 53.61; H, 4.84; N, 5.14%. HRMS (ESI): m/z calculated for 
C36H39ClN3P2RuS3 [M]
•+ = 712.1352, found = 712.1357. ESI mass spectrum exhibited the 
expected ruthenium/chlorine isotope pattern for 2.10. 
6.2.2.6 Synthesis of [RuCl(L2.11)(cis-tach)]Cl complex, 2.17 
A solution of 2.1 (27 mg, 0.060 mmol) and L2.11 (67 mg, 
0.11 mmol, 1.8 eq) in MeOH (15 mL) was heated under 
reflux for 18 h. The solution was cooled, unreacted 
phosphine was removed by filtration and the solvent was 
removed in vacuo. The residue was dissolved in CH2Cl2 (1 
mL), and Et2O (15 mL) was added to precipitate the 
product which was filtered off and dried to give a pale 
yellow solid. Yield: 36 mg (65%). 1H NMR (500 MHz, CD2Cl2) (δ, ppm): 7.81 – 7.76 (m, 
4H, PPh2, Ar
2a), 7.67 – 7.59 (m, 4H, PPh2, Ar
2b), 7.54 (t, 3JHH = 7.7 Hz, 4H, PPh2, Ar
3a), 
7.42 (t, 3JHH = 7.4 Hz, 4H, PPh2, Ar
4a), 7.18 (t, 3JHH = 7.4 Hz, 2H, PPh2, Ar
4b), 7.08 (dd, 3JHP 
= 15.5 Hz, 3JHH = 6.9 Hz, 4H, PPh2, Ar
3b), 7.04 (dd, 3JHH = 5.1 Hz, 
4JHH = 1.2 Hz, 2H, CH, 
Br6), 6.51 (dd, 3JHH = 5.1 Hz, 
4JHH = 3.6 Hz, 2H, CH, Br
5), 6.39 (dd, 3JHH = 3.6 Hz, 
4JHH = 
1.2 Hz, 2H, CH, Br4), 4.21 (d, 2JHH = 12.0 Hz, 2H, NH2, N
2), 3.58 (s, 2H, CH, Cy2), 3.21 
(d, 2JHH = 12.0 Hz, 2H, NH2, N
2), 2.80 (s, 1H, CH, Cy1), 2.07 – 1.89 (m, 4H; 2H, CH2, 
Cy3, 2H, CH2, Cy
4), 1.81 (d, 2JHH = 15.8 Hz, 2H, CH2, Cy
3), 1.46 (s, 2H, NH2, N
1). 13C{1H} 
NMR (126 MHz, CD2Cl2) (δ, ppm): 143.9 (vt, |
1JPC + 
2JP’C| = 84 Hz, PC12S3P, Br
1), 134.7 
(t, |2JPC + 
4JP’C| = 10 Hz, PPh2, Ar
2a), 132.5 (t, |2JPC + 
4JP’C| = 10 Hz, PPh2, Ar
2b), 132.3 (s, 
PC12S3P, Br
2), 130.7 (s, PPh2, Ar
4a + Ar4b), 130.3 (s, PPh2, Ar
3a), 130.2 – 130.0 (m, PC12S3P, 
Br4 + Br3, Ar1a + Ar1b), 128.3 (s, PC12S3P, Br
6), 128.1 (t, |3JPC + 
5JP’C| = 10 Hz, PPh2, Ar
3b), 
127.7 (s, PC12S3P, Br
5), 43.7 (s, CH, Cy1), 43.6 (s, CH, Cy2), 35.4 (s, CH2, Cy
4), 34.2 (s, CH2, 
Cy3). 31P{1H} NMR (162 MHz, CD2Cl2) (δ, ppm): 56.2 (s, 2P). Elemental analysis for 
[RuCl(L2.11)(cis-tach)]Cl.CH2Cl2 (C43H43Cl4N3P2RuS3): calcd. C, 51.50; H, 4.32; N, 4.19%. 
Found: C, 51.52; H, 4.40; N, 4.20%. HRMS (ESI): m/z calculated for C42H41ClN3P2RuS3 
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[M]•+ = 882.0671, found = 882.0685. ESI mass spectrum exhibited the expected 
ruthenium/chlorine isotope pattern for 2.17. 
6.2.2.7 Synthesis of [RuCl(L2.12)(cis-tach)]Cl complex, 2.18 
A solution of 1 (27 mg, 0.060 mmol) and L2 (54 mg, 0.11 
mmol, 1.8 eq) in MeOH (15 mL) was heated under reflux for 
48 h. The solution was cooled, unreacted phosphine was 
removed by filtration and the solvent was removed in vacuo. 
The residue was dissolved in CH2Cl2 (1 mL), and Et2O (15 mL) 
was added to precipitate the product which was filtered off and 
dried to give a red solid. Yield: 21 mg (44%). Crystals suitable 
for X-ray diffraction were grown by slow evaporation of a saturated MeOH solution of 
[2.18]PF6 at room temperature. 
1H NMR (500 MHz, CD3OD) (δ, ppm): 8.19 (ddd, 
3JHP 
= 7.9 Hz, 3JHH = 7.1 Hz, 
4JHH = 3.3 Hz, 4H, PPh2, Ar
2a), 8.08 (dd, 3JHH = 6.5 Hz, 
4JHH = 
3.5 Hz, 2H, CH, Br3), 7.93 (dd, 3JHH = 6.5 Hz, 
4JHH = 3.5 Hz, 2H, CH, Br
4), 7.52 (t, 3JHH = 
7.2 Hz, 4H, PPh2, Ar
4a), 7.45 (t, 3JHH = 7.0 Hz, 4H, PPh2, Ar
3a), 7.38 – 7.34 (m, 6H, PPh2, 
Ar3b + Ar4b), 7.14 (ddd, 3JHP = 7.9 Hz, 
3JHH = 7.2 Hz, 
4JHH = 3.3 Hz, 4H, PPh2, Ar
2b), 5.10 
(d, 2JHH = 12.0 Hz, 2H, NH2, N
2), 4.15 (d, 2JHH = 11.9 Hz, 2H, NH2, N
2), 3.62 (s, 2H, CH, 
Cy2), 2.78 (s, 1H, CH, Cy1), 2.40 (d, 2JHH = 15.0 Hz, 1H, CH2, Cy
4), 2.18 (d, 2JHH = 15.0 
Hz, 1H, CH2, Cy
4), 1.90 (d, 2JHH = 15.6 Hz, 2H, CH2, Cy
3), 1.76 (d, 2JHH = 15.3 Hz, 2H, 
CH2, Cy
3), 1.58 (s, 2H, NH2, N
1). 13C{1H} NMR (126 MHz, CD3OD) (δ, ppm): 159.9 (vt, 
|1JPC + 
2JP’C| = 111 Hz, PC8N2P, Br
1), 138.1 (t, |2JPC + 
4JP’C| = 10 Hz, PPh2, Ar
2a), 133.7 
(s, PC8N2P, Br
4), 132.9 (t, |2JPC + 
4JP’C| = 10 Hz, PPh2, Ar
2b), 131.9 (s, PPh2, Ar
4a + Ar4b), 
131.2 (s, PC8N2P, Br
2), 131.1 (s, PC8N2P, Br
3), 130.6 (t, |3JPC + 
5JP’C| = 9 Hz, PPh2, Ar
3a), 
128.9 (t, |3JPC + 
5JP’C| = 9 Hz, PPh2, Ar
3b), 44.8 (s, CH, Cy2), 44.4 (s, CH, Cy1), 35.5 (s, 
CH2, Cy
4), 34.3 (s, CH2, Cy
3). 31P{1H} NMR (162 MHz, CD3OD) (δ, ppm): 63.9 (s, 2P). 
Elemental analysis for [RuCl(L2.12)(cis-tach)]Cl.CH2Cl2 (C39H41Cl4N3P2Ru): calcd. C, 
52.95; H, 4.67; N, 7.92%. Found: C, 52.69; H, 4.69; N, 7.71%. HRMS (ESI): m/z 
calculated for C38H39ClN5P2Ru [M]
•+ = 764.1414, found = 764.1411. ESI mass spectrum 
exhibited the expected ruthenium/chlorine isotope pattern for 2.18. 
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6.2.2.8 Synthesis of [RuCl(L2.13)(cis-tach)]Cl complex, 2.19 
A solution of 2.1 (32 mg, 0.070 mmol) and L2.13 (54 
mg, 0.091 mmol, 1.3 eq) in EtOH (20 mL) was heated 
under reflux for 48 h. The solution was cooled, 
unreacted phosphine was removed by filtration and the 
solvent was removed in vacuo. The residue was dissolved 
in CH2Cl2 (1 mL), and Et2O (15 mL) was added to 
precipitate the product which was filtered off and dried 
to give a red solid. Yield: 25 mg (40%). 1H NMR (500 
MHz, CD3OD) (δ, ppm): 8.49 – 8.42 (m, 6H; 4H, PPh2, Ar
2a, 2H, CH, Br6), 7.78 (d, 3JHH 
= 7.8 Hz, 2H, CH, Br5), 7.68 (t, 3JHH = 7.1 Hz, 2H, PPh2, Ar
3b), 7.63 (t, 3JHH = 7.4 Hz, 4H, 
PPh2, Ar
4a + Ar4b), 7.34 – 7.26 (m, 6H; 4H, PPh2, Ar
3a, 2H, PPh2, Ar
3b), 7.21 – 7.12 (m, 8H; 
4H, PPh2, Ar
2b, 2H, CH, Br7, 2H, CH, Br8), 5.33 (d, 2JHH = 11.8 Hz, 2H, NH2, N
2), 4.27 
(d, 2JHH = 11.8 Hz, 2H, NH2, N
2), 3.69 (s, 2H, CH, Cy2), 2.72 (s, 1H, CH, Cy1), 2.48 (d, 
2JHH = 15.0 Hz, 1H, CH2, Cy
4), 2.24 (d, 2JHH = 15.0 Hz, 1H, CH2, Cy
4), 1.91 (d, 2JHH = 15.5 
Hz, 2H, CH2, Cy
3), 1.74 (d, 2JHH = 15.4 Hz, 2H, CH2, Cy
3), 1.45 (s, 2H, NH2, N
1). 13C{1H} 
NMR (126 MHz, CD3OD) (δ, ppm): 158.8 (vt, |
1JPC + 
2JP’C| = 112 Hz, PC4N2P, Br
1), 
141.3 (s, PC16N2P, Br
3), 138.7 (|2JPC + 
4JP’C| = 10 Hz, PPh2, Ar
2a), 133.1 (m PPh2, Ar
1a + 
Ar1b), 132.9 (t, |2JPC + 
4JP’C| = 10 Hz, PPh2, Ar
2b), 132.1 (s, PC16N2P, Br
8), 132.0 (s, PPh2, 
Ar4a + Ar4b), 131.1 (s, PC16N2P, Br
2), 130.5 (t, |3JPC + 
5JP’C| = 9 Hz, PPh2, Ar
3a), 129.6 (s, 
PC16N2P, Br
4), 128.9 (t, |3JPC + 
5JP’C| = 9 Hz, PPh2, Ar
3b), 128.5 (s, PC16N2P, Br
7), 126.5 (s, 
PC16N2P, Br
6), 123.4 (s, PC16N2P, Br
5), 44.8 (s, CH, Cy2), 44.4 (s, CH, Cy1), 35.7 (s, CH2, 
Cy4), 34.3 (s, CH2, Cy
3). 31P{1H} NMR (162 MHz, CD3OD) (δ, ppm): 63.3 (s, 2P). 
Elemental analysis for [RuCl(L2.13)(cis-tach)]Cl.1.5CH2Cl2 (C47.5H46Cl5N5P2Ru): calcd. C, 
55.54; H, 4.51; N, 6.82%. Found: C, 55.54; H, 4.78; N, 7.17%. HRMS (ESI): m/z 
calculated for C46H43ClN5P2Ru [M]
•+ = 864.1726, found = 864.1710. ESI mass spectrum 
exhibited the expected ruthenium/chlorine isotope pattern for 2.19. 
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6.2.2.9 Synthesis of [RuCl(dppa)(cis-tach)]Cl complex, 2.20 
A solution of 2.1 (27 mg, 0.060 mmol) and (Ph2P)2NH (42 mg, 
0.11 mmol, 1.8 eq) in MeOH (15 mL) was heated under reflux 
for 18 h. The solution was cooled, unreacted phosphine was 
removed by filtration and the solvent was removed in vacuo. The 
residue was dissolved in CH2Cl2 (1 mL), and Et2O (15 mL) was 
added to precipitate the product which was filtered off and dried 
to give a yellow solid. Yield: 31 mg (76%). Crystals suitable for X-ray diffraction were 
grown by slow evaporation of a saturated MeOH solution of the product at room 
temperature. 1H NMR (500 MHz, CD3OD) (δ, ppm): 7.85 – 7.73 (m, 4H, PPh2,), 7.71 – 
7.63 (m, 4H, PPh2,), 7.58 – 7.43 (m, 6H, PPh2,), 7.39 – 7.31 (m, 6H, PPh2,), 5.06 (d, 
2JHH = 
12.0 Hz, 2H, NH2, N
2), 3.59 (s, 2H, CH, Cy2), 3.54 (d, 2JHH = 12.0 Hz, 2H, NH2, N
2), 2.85 
(s, 1H, CH, Cy1), 2.24 (d, 2JHH = 15.0 Hz, 1H, CH2, Cy
4), 2.16 (s, 1H, CH2, Cy
4), 1.96 – 
1.87 (m, 2H, CH2, Cy
3), 1.56 (d, 2JHH = 15.1 Hz, 2H, CH2, Cy
3), 1.30 (s, 2H, NH2, N
1). 
31P{1H} NMR (162 MHz, CD3OD) (δ, ppm): 64.3 (s, 2P). 
13C{1H} NMR (126 MHz, 
CD3OD) (δ, ppm): 137.9 – 137.5 (m, PPh2,), 137.6 – 137.1 (m, PPh2,), 132.7 (t, J = 6.0 Hz, 
PPh2,), 131.3 (s, PPh2,), 131.1 (t, J = 6.0 Hz, PPh2,), 131.0 (s, PPh2,), 130.5 (t, |
3JPC + 
5JP’C| 
= 5 Hz, PPh2), 128.9 (t, J = 5.3 Hz, PPh2,), 44.7 (s, CH, Cy
2), 44.5 (s, CH, Cy1), 35.8 (s, 
CH2, Cy
4), 34.7 (s, CH2, Cy
3). HRMS (ESI): m/z calculated for C30H36ClN4P2Ru [M]
•+ = 
651.1147, found 651.1144. ESI mass spectrum exhibited the expected ruthenium/chlorine isotope 
pattern for 2.20. 
6.2.2.10 Synthesis of cis-[PtCl2(L2.12)] complex, 2.21 
A solution of L2.12 (59 mg, 0.11 mmol) in CH2Cl2 (1.5 mL) was 
added to a solution of [PtCl2(cod)] (38 mg, 0.10 mmol) in CH2Cl2 
(1.5 mL) and stirred at room temperature for 2 h. The solution 
was concentrated to 1 mL, and Et2O (15 mL) was added to precipitate the product which 
was filtered off and dried to give a yellow solid. Yield: 48 mg (63%). Crystals suitable for 
X-ray diffraction were grown by slow evaporation of a CH2Cl2 solution of the product. 
1H NMR (400 MHz, CDCl3) (δ, ppm): 8.20 (dd, 
3JHH = 6.5 Hz, 
4JHH = 3.5 Hz 2H), 7.96 
(m, 10H), 7.51 (m, 4H), 7.44 (m, 8H). 31P{1H} NMR (162 MHz, CDCl3) (δ, ppm): 21.0 
(s, 1JPPt = 3449 Hz). 
13C{1H} NMR (100 MHz, CDCl3) (δ, ppm): 162.0 – 161.1 (m), 136.2, 
130.4, 129.8, 127.0, 124.8, 122.3. HRMS (ESI): m/z calculated for C32H24ClN2P2Pt [M–
Cl]•+ = 728.0751, found 728.0742. 
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6.2.2.11 Synthesis of cis-[PtCl2(L2.13)] complex, 2.22 
A solution of L2.13 (30 mg, 0.050 mmol) in CH2Cl2 (1.5 mL) 
was added to a solution of [PtCl2(cod)] (19 mg, 0.050 mmol) 
in CH2Cl2 (1.5 mL) and stirred at room temperature for 2 h. 
The solution was concentrated to 1 mL, and Et2O (15 mL) 
was added to precipitate the product which was filtered off 
and dried to give a yellow solid. Yield: 22 mg (50%). Crystals suitable for X-ray diffraction 
were grown by diffusion of Et2O into a CH2Cl2 solution of the product. 
1H NMR (400 
MHz, CDCl3) (δ, ppm): 9.04 (dd, 
3JHH = 8.1, 
4JHH = 1.4 Hz, 2H), 8.59 (d, 
3JHH = 8.2 Hz, 
2H), 8.10 – 7.99 (m, 8H), 7.87 (m, 2H), 7.73 (m, 2H), 7.56 – 7.41 (m, 12H). 31P{1H} NMR 
(162 MHz, CDCl3) (δ, ppm): 21.6 (s, 
1JPPt = 3500 Hz). 
13C{1H} NMR (100 MHz, CDCl3) 
(δ, ppm): 161.3 – 161.0 (m), 139.2, 136.8, 135.0, 131.4, 130.3, 129.3, 128.9, 127.9, 127.8, 
125.1, 122.9. HRMS (ESI): m/z calculated for C40H28ClN2P2Pt [M–Cl]
•+ = 828.1064, 
found 828.1083. 
6.2.2.12 Synthesis of cis-[PtCl2(L2.11)] complex, 2.23 
A solution of L2.11 (16 mg, 0.030 mmol) in CH2Cl2 (1.0 mL) was 
added to a solution of [PtCl2(cod)] (10 mg, 0.030 mmol) in CH2Cl2 
(1.0 mL) and stirred at room temperature for 2 h. The solution was 
concentrated to 0.5 mL, and Et2O (10 mL) was added to precipitate 
the product which was filtered off and dried to give a yellow solid. 
Yield: 18 mg (82%). Spectroscopic data matched that previously reported.311 1H NMR 
(400 MHz, CDCl3) (δ, ppm): 7.80 – 7.68 (m, 9H), 7.53 – 7.48 (m, 2H), 7.47 – 7.40 (m, 
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6.3 Experimental procedures and characterising data for Chapter 3 – 
Fluorescent phosphine complex conjugates 
6.3.1 Synthesis of (Ph2PCH2)2NCH2COOH, L3.1 
Following an adapted literature procedure.198 A solution of Ph2PH 
(4.18 mL, 24.0 mmol) and paraformaldehyde (0.83 g, 27.6 mmol) in 
degassed EtOH (100 mL) was heated under reflux until the reaction 
mixture became a homogeneous solution (approx. 1 h). Glycine (0.90 
g, 11.9 mmol) was added, and the mixture heated under reflux for 18 h. The solvent was 
removed in vacuo to give the product as a white solid. Yield: 4.97 g (88%). Spectroscopic 
data matched that previously reported. 1H NMR (400 MHz, CDCl3) (δ, ppm): 7.40 – 7.28 
(m, 20H, PPh2), 3.68 (d, 
2JHP = 4.0 Hz, 4H, PCH2), 3.65 (s, 2H, COCH2). 
31P{1H} NMR 
(162 MHz, CDCl3) (δ, ppm): –26.6 (s, 2P). 
6.3.2 Synthesis of (Ph2PCH2)2NCH2-1-Pyr, L3.2 
NEt3 (1.20 mL, 8.50 mmol) was added to a solution 
of 1-pyrenylmethylamine hydrochloride (220 mg, 
0.83 mmol) in CH2Cl2 (5 mL). After stirring the 
mixture for 30 min to ensure complete 
deprotonation, this solution was added to a suspension of L3.1 (350 mg, 0.75 mmol) and 
HATU (314 mg, 0.83 mmol) in CH2Cl2 (20 mL). The flask was shielded from the light 
and stirred for 16 h before water (10 mL) was added. The aqueous layer was extracted 
with CH2Cl2 (3 × 20 mL), dried (MgSO4) and concentrated in vacuo. The compound was 
purified by silica column chromatography (30% EtOAc/hexane) to give a yellow solid. 
Yield: 75 mg (15%). 1H NMR (400 MHz, CDCl3) (δ, ppm): 8.20 (dd, 
3JHH = 7.6 Hz, 
4JHH 
= 1.8 Hz, 2H, CHPyr), 8.11 – 7.98 (m, 5H, CHPyr), 7.53 (d, 
3JHH = 7.8 Hz, 1H, CHPyr), 7.19 
(td, 3JHH = 7.1 Hz, 
4JHH = 1.5 Hz, 8H, PPh2), 7.13 (d, 
3JHH = 6.5 Hz, 4H, PPh2), 7.06 (td, 
3JHH = 7.1 Hz, 
4JHH = 1.4 Hz, 8H, PPh2), 6.71 (t, 
3JHH = 6.0 Hz, 1H, CHPyr), 4.71 (d, 
3JHH = 
6.0 Hz, 2H, NHCH2), 3.67 (s, 2H, COCH2), 3.52 (d, 
2JHP = 4.4 Hz, 4H, PCH2). 
31P{1H} 
NMR (162 MHz, CDCl3) (δ, ppm): –26.8 (s, 2P). 
13C{1H} NMR (100 MHz, CDCl3) (δ, 
ppm): 170.1 (s, CO), 136.7, 136.6, 133.2, 133.0, 131.4, 131.1, 131.0, 128.9, 128.6, 128.5, 
128.1, 127.5, 127.0, 126.1, 125.4, 125.3, 124.6, 123.2, 61.3 – 60.9 (m, COCH2), 60.2 – 59.8 
(m, PCH2), 40.9 (s, NHCH2). HRMS (ESI): m/z calculated for C45H39N2OP2 [M+H]
•+ = 
685.2538, found = 685.2534. 
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6.3.3 Synthesis of [RuCl(L3.1)(cis-tach)]Cl complex, 3.1 
A solution of [RuCl(DMSO-S)2(cis-tach)]Cl 2.1 (160 mg, 0.35 
mmol) and L3.1 (198 mg, 0.42 mmol) was heated under reflux in 
EtOH (50 mL) for 18 h. The solvent was removed, CH2Cl2 (1 
mL) was added and the complex was precipitated from Et2O 
(10 mL). The solid was then filtered off, washed with Et2O and 
dried in vacuo to give the product as a pale-yellow solid. Yield: 
260 mg (96%). 1H NMR (400 MHz, CD3OD) (δ, ppm): 7.96 
(m, 4H, PPh2), 7.82 (m, 4H, PPh2), 7.46 (m, 12H, PPh2), 4.26 (d, 
2JHH = 12.2 Hz, 2H, NH2, 
N2), 4.04 (d, 2JHH = 12.2 Hz, 2H, NH2, N
2), 3.70 – 3.62 (m, 2H, CH2, C5), 3.60 (s, 2H, 
CH2, C6), 3.55 – 3.44 (m, 4H; 2H, CH, Cy
2, 2H, CH2, C5), 2.65 (s, 1H, CH, Cy
1), 2.27 (d, 
2JHH = 15.6 Hz, 2H, CH2, Cy
4), 2.05 (d, 2JHH = 15.6 Hz, 2H, CH2, Cy
4), 1.78 (d, 2JHH = 15.2 
Hz, 2H, CH2, Cy
3), 1.65 (d, 2JHH = 15.3 Hz, 2H, CH2, Cy
3), 1.46 (s, 2H, NH2, N
1). 31P{1H} 
NMR (162 MHz, CD3OD) (δ, ppm): 40.4 (s, 2P). 
13C{1H} NMR (101 MHz, CD3OD) (δ, 
ppm): 173.3 (s, CO, C7), 135.9 (PPh2), 133.6 (PPh2), 131.5 (PPh2), 130.9 (PPh2), 130.2 
(PPh2), 129.7 (PPh2), 63.8 (vt, 
3JCP = 9 Hz, CH2, C6), 57.6 (vt, 
1JCP = 20 Hz, CH2, C5), 44.6 
(s, CH, Cy2), 44.2 (s, CH, Cy1), 35.4 (s, CH2, Cy
4), 34.2 (s, CH2, Cy
3). HRMS (ESI): m/z 
calculated for C34H42ClN4O2P2Ru [M]
•+ = 737.1516, found = 737.1523. 
6.3.4 Synthesis of [PtCl2(L3.2)] complex, 3.2 
A solution of L3.2 (21 mg, 0.050 mmol) in CH2Cl2 
(1.5 mL) was added dropwise to a solution of 
[PtCl2(cod)] (11 mg, 0.050 mmol) in CH2Cl2 (1.5 mL). 
After 1 h the volume was reduced to 1 mL and Et2O 
was added to precipitate the product which was 
filtered off and dried in vacuo. Yield: 10 mg (35%). 
1H NMR (400 MHz, CDCl3) (δ, ppm): 8.25 (d, 
3JHH = 7.6 Hz, 1H), 8.20 (d, 
3JHH = 7.5 Hz, 
1H), 8.16 – 8.00 (m, 4H), 7.95 (d, 3JHH = 9.2 Hz, 1H), 7.85 (d, 
3JHH = 9.3 Hz, 1H), 7.79 – 
7.66 (m, 8H), 7.55 (d, 3JHH = 7.8 Hz, 1H), 7.25 – 7.16 (m, 14H), 6.06 (t, 
3JHH = 5.9 Hz, 
1H), 4.70 (d, 3JHH = 5.9 Hz, 2H), 3.62 (m, 4H), 3.26 (s, 2H). 
31P{1H} NMR (162 MHz, 
CDCl3) (δ, ppm): –6.5 (s, 
1JPPt = 3416 Hz, 2P). 
13C{1H} NMR (100 MHz, CDCl3) (δ, ppm): 
170.2 (s, CO), 134.0, 131.7, 128.7, 128.6, 128.0. 127.7, 127.3, 126.5, 125.9, 125.6, 124.8, 
122.6, 66.1, 56.7, 41.0. HRMS (ESI): m/z calculated for C45H38N2OP2Pt [M–Cl]
•+ = 
914.1796, found = 914.1784.  
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6.3.5 Synthesis of [RuCl(L3.2)(cis-tach)]Cl complex, 3.3 
A solution of [RuCl(DMSO-S)2(cis-tach)]Cl 2.1 (28 mg, 0.050 
mmol) and L3.2 (62 mg, 0.090 mmol) was heated under reflux in 
EtOH (20 mL) for 48 h. The solvent was removed, CH2Cl2 (1 
mL) was added and the product was precipitated from Et2O (10 
mL). Yield: 48 mg (81%). 1H NMR (500 MHz, CD3OD) (δ, 
ppm): 8.29 (d, 3JHH = 9.3 Hz, 1H, CHPyr), 8.25 (d, 
3JHH = 7.6 Hz, 
1H, CHPyr), 8.12 (d, 
3JHH = 9.0 Hz, 1H, CHPyr), 8.08 – 8.04 (m, 
3H, CHPyr), 8.02 (t, 
3JHH = 7.5 Hz, 1H, CHPyr), 7.96 (d, 
3JHH = 7.8 
Hz, 1H, CHPyr), 7.84 (m, 4H, PPh2), 7.73 – 7.63 (m, 4H, PPh2), 
7.53 (d, 3JHH = 9.2 Hz, 1H, CHPyr), 7.49 (t, 
3JHH = 7.6 Hz, 4H, 
PPh2), 7.42 (t, 
3JHH = 7.5 Hz, 2H, PPh2), 7.18 (t, 
3JHH = 7.5 Hz, 2H, PPh2), 6.91 (t, 
3JHH = 
7.6 Hz, 3H, PPh2), 5.10 (s, 2H, CH2, C8), 4.15 (d, 
2JHH = 11.9 Hz, 2H, NH2, N
2), 3.96 (d, 
2JHH = 12.4 Hz, 2H, NH2, N
2), 3.54 – 3.46 (m, 2H, CH2, C5), 3.40 (s, 2H, CH, Cy
2), 3.32 
(s, 2H, CH2, C6), 3.05 (dt, 
2JHH = 13.4 Hz, 
4JHH = 2.9 Hz, 2H, CH2, C5), 2.57 (s, 1H, CH, 
Cy1), 2.19 (d, 2JHH = 15.1 Hz, 1H, CH2, Cy
4), 1.97 (d, 2JHH = 15.0 Hz, 1H, CH2, Cy
4), 1.70 
(d, 2JHH = 15.3 Hz, 2H, CH2, Cy
3), 1.56 (d, 2JHH = 15.3 Hz, 2H, CH2, Cy
3), 1.32 (s, 2H, 
NH2, N
1). 31P{1H} NMR (162 MHz, CD3OD) (δ, ppm): 41.6 (s, 2P). 
13C{1H} NMR (126 
MHz, CD3OD) (δ, ppm): 169.9 (s, CO, C7), 135.8 (PPh2), 133.7 (PPh2), 132.9, 132.7, 132.6, 
132.1, 131.2, 131.0, 130.3 (PPh2), 130.1, 129.5 – 129.3 (PPh2), 129.1, 128.5, 127.2, 126.5, 
126.4, 125.8, 124.4, 67.4 (t, 3JCP = 11.5 Hz, CH2, C6), 58.1 (vt, |
1JPC + 
3JPC’| = 85 Hz, CH2, 
C5), 44.6 (s, CH, Cy2), 44.1 (s, CH, Cy1), 42.3 (s, CH, C8), 35.3 (s, CH2, Cy
4), 34.2 (s, CH2, 
Cy3). HRMS (ESI): m/z calculated for C51H53ClN5O2P2Ru [M]
•+ = 950.2457, found = 
950.2465. 
6.3.6 Attempted synthesis of [RuCl(L3.2)(cis-tach)]Cl complex, 3.3  
NEt3 (0.30 mL, 2.0 mmol) was added to a solution of 1-pyrenylmethylamine 
hydrochloride (16 mg, 0.064 mmol) in CH2Cl2 (2 mL). After stirring the mixture for 30 
min to ensure complete deprotonation, this solution was added to a solution of 3.1 (31 
mg, 0.040 mmol), HATU (17 mg, 0.045 mmol), and DIPEA (10 µL, 0.060 mmol) in 
CH2Cl2 (20 mL). The flask was shielded from the light and stirred for 16 h before water 
(1 mL) was added. The aqueous layer was extracted with CH2Cl2 and Et2O was added. 
The precipitate contained trace amounts of 3.3 but was highly impure by 1H NMR 
spectroscopy.  
Chapter 6. Experimental 
181 
6.3.7 Attempted synthesis of complex, 3.4 
A solution of 3.1 (19 mg, 0.030 mmol) and DCC (6 mg, 0.031 mmol) in CH2Cl2 (5 mL) 
was stirred at room temperature for 10 min. After observation of a white precipitate, 
benzylamine (3.5 µL, 0.030 mmol) was added and the mixture stirred at room temperature 
for 18 h. The suspension was filtered, solvent concentrated in vacuo and Et2O (10 mL) was 
added. The precipitate contained trace amounts of 3.4 but was highly impure by 1H NMR 
spectroscopy. 
6.3.8 Attempted synthesis of complex, 3.5 
A solution of 3.1 (39 mg, 0.050 mmol) and DCC (12 mg, 0.062 mmol) in CH2Cl2 (10 mL) 
was stirred at room temperature for 10 min. After observation of a white precipitate, 7-
amino-4-methylcoumarin (11 mg, 0.060 mmol) was added and the mixture stirred at room 
temperature for 18 h. The suspension was filtered, solvent concentrated in vacuo and Et2O 
(10 mL) was added. The precipitate contained trace amounts of 3.5 but was highly impure 
by 1H NMR spectroscopy. 
6.3.9 Synthesis of [(η6-p-cym)RuCl2(PPh2(4-C6H4OH))] complex, 3.7 
Following an adapted literature procedure.171 A solution of [(η6-p-
cymene)RuCl2]2 (250 mg, 0.42 mmol) and PPh2(4-C6H4OH) (250 
mg, 0.90 mmol) in CH2Cl2 (10 mL) was stirred at room 
temperature for 18 h. The suspension was filtered, and the orange 
solid was washed with Et2O and dried in vacuo at 45 °C. Yield: 410 
mg (78%). 1H NMR (400 MHz, (CD3)2SO) (δ, ppm): 9.96 (s, 1H), 
7.77 – 7.66 (m, 4H), 7.62 – 7.52 (m, 2H), 7.46 – 7.32 (m, 6H), 6.78 (d, 3JHH = 6.9 Hz, 1H), 
5.30 (d, 3JHH = 6.2 Hz, 2H), 5.20 (d, 
3JHH = 5.4 Hz, 2H), 2.55 (hept, 
3JHH = 6.9 Hz, 1H), 
1.76 (s, 3H), 0.96 (d, 3JHH = 6.9 Hz, 6H). 
31P{1H} NMR (162 MHz, (CD3)2SO) (δ, ppm): 
23.5 (2, 1P).  
  
Chapter 6. Experimental 
182 
6.3.10 Synthesis of [(η6-p-cym)RuCl2(PPh2(4-C6H4OCO-Pyr))] complex, 3.8 
Following an adapted literature procedure.171 
Pyrene-1-carboxylic acid (100 mg, 0.42 mmol) 
and SOCl2 (2.0 mL, 17.0 mmol) were heated at 
80 °C for 4 h. Conversion to the acid chloride 
was monitored by IR spectroscopy before the 
volatiles were removed in vacuo and the yellow 
residue dissolved in CH2Cl2 (10 mL). This 
freshly prepared solution of pyrene-1-carbonyl chloride 3.6 was added to a solution of 3.7 
(140 mg, 0.25 mmol) in CH2Cl2 followed by NEt3 (0.04 mL, 0.3 mmol). The red solution 
was stirred at room temperature for 16 h and the volatiles were removed in vacuo. The 
residue was purified by silica column chromatography (0–10% MeOH/CH2Cl2). The red 
band was collected, concentrated in vacuo and the product precipitated from addition of 
Et2O. Yield: 50 mg (25%). 
1H NMR (500 MHz, CDCl3) (δ, ppm): 9.35 (d, 
2JHH = 9.5 Hz, 
1H), 8.85 (d, 2JHH = 8.1 Hz, 1H), 8.33 – 8.20 (m, 4H), 8.16 – 8.06 (m, 2H), 8.05 – 7.95 (m, 
2H), 7.94 – 7.86 (m, 3H), 7.47 – 7.32 (m, 10H), 5.24 (d, 3JHH = 6.0 Hz, 2H, C4-H), 5.05 
(d, 3JHH = 4.9 Hz, 2H, C3-H), 2.88 (hept, 
3JHH = 6.8 Hz, 1H, C6-H), 1.91 (s, 3H, C1-H), 
1.14 (d, 3JHH = 7.0 Hz, 6H, C7-H). 
31P{1H} NMR (162 MHz, CDCl3) (δ, ppm): 23.7 (s, 
1P). 13C{1H} NMR (126 MHz, CDCl3) (δ, ppm): 166.0 (C16), 152.8 (d, 
4JCP = 2.7 Hz, 
C15), 136.2 (d, 2JCP = 10.4 Hz, C13), 135.3 (CPyr), 134.4 (d, 
2JCP = 9.5 Hz, C9), 134.1 (d, 
1JCP = 45.2 Hz, C12), 132.2 (CPyr), 131.1 (CPyr), 131.1 (d, 
1JCP = 47.0 Hz, C8), 130.5 (d, 
4JCP 
= 2.6 Hz, C11), 130.4 (CPyr), 130.2 (CPyr), 129.2 (CPyr), 128.2 (d, 
3JCP = 9.9 Hz, C10), 127.3 
(CPyr), 126.9 (CPyr), 126.7 (CPyr), 126.7 (CPyr), 125.1 (CPyr), 124.8 (CPyr), 124.4 (CPyr), 124.2 
(CPyr), 121.8 (CPyr), 121.7 (d, 
3JCP = 10.6 Hz, C14), 111.4 (d, 
2JCP = 3.1 Hz, C5), 96.2 (C2), 
89.3 (d, 2JCP = 3.1 Hz, C3), 87.3 (d, 
2JCP = 5.5 Hz, C4), 30.4 (C6), 22.0 (C7), 17.9 (C1). 
HRMS (ESI): m/z calculated for C45H37O2PClRu [M–Cl]
•+ = 777.1263, found = 
777.1279. 
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6.4 Experimental procedures and characterising data for Chapter 4 – 
Photophysical properties of air-stable pyrenylphosphines 
6.4.1 Synthesis of diethyl 1-pyrenylphosphonate, 4.3 
The compound was prepared according to a literature 
procedure and spectroscopic data matched that reported.246 1H 
NMR (400 MHz, CDCl3) (δ, ppm): 8.86 (d, 
3JHH = 9.3 Hz, 1H, 
CH), 8.67 (dd, 3JHH = 14.3 Hz, 
4JHH = 7.9 Hz, 1H, CH), 8.33 – 8.16 (m, 5H, CH), 8.14 – 
8.02 (m, 2H, CH), 4.36 – 4.20 (m, 2H, CH2), 4.18 – 4.05 (m, 2H, CH2), 1.33 (t, 
3JHH = 7.1 
Hz, 6H, CH3). 
31P{1H} NMR (162 MHz, CDCl3) (δ, ppm): 20.5 (s, 1P). 
6.4.2 Synthesis of 1-pyrenylphosphine, L4.1 
A solution of TMSCl (0.51 mL, 4.05 mmol) in THF (10 mL) was 
cooled to –35 °C before LiAlH4 (0.175 g, 4.35 mmol) was added. 
The grey suspension was warmed to room temperature and 
stirred for 1.5 h. The suspension was cooled to –78 °C and a solution of 4.3 (0.51 g, 1.50 
mmol) in THF (5 mL) was added. The mixture was warmed to room temperature and 
stirred for 18 h. The reaction was quenched with H2O (0.5 mL), NaOH (15% w/w, 0.5 
mL) and H2O (0.5 mL). The precipitate was removed by filtration and the solvent 
removed in vacuo to give L4.1 as a white solid. Yield: 65 mg (19%). 
1H NMR (400 MHz, 
CDCl3) (δ, ppm): 8.41 (dd, 
3JHH = 9.1 Hz, 
4JHH = 1.9 Hz, 1H, CH), 8.25 – 8.15 (m, 4H, 
CH), 8.10 – 8.00 (m, 4H, CH), 4.45 (d, 1JHP = 204.1 Hz, 2H, PH2). 
13C{1H} NMR (101 
MHz, CDCl3) (δ, ppm): 133.9 (d, JCP = 11.4 Hz), 128.0, 128.0, 127.6, 126.3, 126.0, 125.8, 
125.7, 125.6, 124.5. 31P{1H} NMR (162 MHz, CDCl3) (δ, ppm) –132.2 (s, 1P). 
31P NMR 
(162 MHz, CDCl3) (δ, ppm) –132.2 (td, 
1JPH = 203 Hz, 
4JPH = 7 Hz). HRMS (MALDI): 
m/z calculated for C16H11P [M]
•+ = 234.0593, found = 234.0599. 
6.4.3 Synthesis of di(1-pyrenyl)phosphine oxide, 4.5 
Mg turnings (480 mg, 20.0 mmol) and one crystal of 
I2 were covered with THF. A solution of 1-
bromopyrene 4.2 (5.12 g, 18.2 mmol) in THF (50 mL) 
was added with heating to gentle reflux. In a second flask, NaH (185 mg, 7.7 mmol) in 
THF (20 mL) was cooled to 0 °C and (EtO)2POH (0.90 mL, 7.0 mmol) was added 
dropwise. This solution was cooled to –78 °C and the freshly prepared 1-
pyrenylmagnesium bromide was added dropwise via cannula. The solution was warmed 
to room temperature and stirred for 18 h. The reaction was quenched at 0 °C with sat. aq. 
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NH4Cl and concentrated in vacuo. The crude product was extracted with CH2Cl2, washed 
with brine, dried (MgSO4) and concentrated in vacuo. The mixture was triturated 
(MTBE/hexane, 3:1, 10 mL) to remove excess (EtO)2POH and the precipitate filtered 
off and dried to give 4.5 as a yellow solid. Yield: 490 mg (15%). 1H NMR (400 MHz, 
CDCl3) (δ, ppm): 9.39 (d, 
1JHP = 481.6 Hz, 1H, PH), 8.74 (d, 
3JHH = 9.2 Hz, 2H, CH), 8.48 
– 8.33 (m, 2H, CH), 8.31 – 8.13 (m, 7H, CH), 8.12 – 7.97 (m, 7H, CH). 31P{1H} NMR 
(162 MHz, CDCl3) (δ, ppm): 20.4 (s, 1P). 
31P NMR (162 MHz, CDCl3) (δ, ppm): 20.36 
(dt, 1JPH = 482 Hz, 
4JPH = 16 Hz). HRMS (ESI): m/z calculated for C32H19OP [M]
•+ = 
451.1251, found = 451.1242. 
6.4.4 Synthesis of (1-Pyr)2PNMe2, 4.6 
A solution of 1-bromopyrene 4.2 (1.13 g, 4.00 mmol) 
in Et2O (40 mL) was cooled to –78 °C and a solution 
of nBuLi (1.6 M in hexane) (2.75 mL, 4.40 mmol) was 
added dropwise. After 1 h stirring at 0 °C, (Me2N)PCl2 (0.23 mL, 2.0 mmol) was added 
dropwise and the mixture warmed to room temperature. After 2 h the solvent was 
removed in vacuo and LiCl was extracted into MeOH (30 mL). The remaining yellow solid 
was dried in vacuo. Yield: 650 mg (68%). 1H NMR (400 MHz, CDCl3) (δ, ppm): 8.62 (dd, 
3JHH = 9.2 Hz, 
4JHH = 3.9 Hz, 2H, CH), 8.20 (t, 
3JHH = 7.6 Hz, 4H, CH), 8.13 – 7.98 (m, 
9H, CH), 7.87 (dd, 3JHH = 7.9 Hz, 
4JHH = 4.1 Hz, 2H, CH), 2.90 (d, 
3JHP = 8.8 Hz, 6H, 
CH3). 
31P{1H} NMR (162 MHz, CDCl3) (δ, ppm): 53.8 (s, 1P). HRMS (ESI): m/z 
calculated for C32H19OP [M]
•+ = 477.1646, found [M+CH3]
•+= 492.1881. 
6.4.5 Synthesis of di(1-pyrenyl)phosphine, L4.2 
A solution of 1-bromopyrene 4.2 (1.20 g, 5.00 mmol) 
in THF (40 mL) was cooled to –78 °C and a solution 
of nBuLi (1.6 M in hexane) (3.44 mL, 5.50 mmol) was 
added dropwise. After 1 h (Me2N)PCl2 (0.29 mL, 2.5 mmol) was added and the solution 
warmed to room temperature for 2 h. The solution was cooled to –78 °C and a solution 
of HCl (2 M in Et2O) (2.50 mL, 5.00 mmol) was added dropwise. After 1 h, LiAlH4 (142 
mg, 3.8 mmol) and TMSCl (0.50 mL, 3.8 mmol) were added at –78 °C and the mixture 
was warmed to room temperature and stirred for 16 h. The solution was quenched with 
degassed water (1 mL) and filtered through silica. The solvent was removed in vacuo to 
give the product as a yellow solid. Yield: 820 mg (76% from 4.2). 1H NMR (400 MHz, 
C6D6) (δ, ppm): 8.81 (s, 1H), 8.10 – 7.51 (m, 10H, CH), 7.28 – 6.87 (m, 7H, CH), 6.20 (d, 
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1JPH = 223 Hz, 1H, PH). 
31P{1H} NMR (162 MHz, C6D6) (δ, ppm): –59.5 (s, 1P). 
31P 
NMR (162 MHz, C6D6) (δ, ppm) –59.5 (d, 
1JPH = 223 Hz). HRMS (MALDI): m/z 
calculated for C32H19P [M–H]
•+ = 433.1141, found = 433.1149.  
6.4.6 Synthesis of tri(1-pyrenyl)phosphine, L4.3 
A solution of nBuLi (1.6 M in hexane, 6.0 mL, 9.0 
mmol) was added to a solution of 1-bromopyrene 
4.2 (2.41 g, 8.57 mmol) in Et2O (80 mL) at –78 °C. 
The mixture was stirred for 1 h before PCl3 (0.25 
mL, 2.86 mmol) was added and warmed to room 
temperature. Volatiles were removed in vacuo and LiCl was extracted into MeOH. The 
solution was filtered, and the solvent removed in vacuo to give the product as a yellow 
solid. Yield: 1.50 g (83%). Spectroscopic data matched that previously reported.231 31P{1H} 
NMR (162 MHz, CDCl3) (δ, ppm): –30.6 (s, 1P). 
6.4.7 Synthesis of [RuCl2(η6-p-cym)(L4.1)] complex, 4.14 
A solution of [(η6-p-cymene)RuCl2]2 (40 mg, 0.070 mmol) and 
L4.1 (30 mg, 0.105 mmol) in CH2Cl2 (10 mL) was stirred at room 
temperature. After 1 h, the solvent was removed in vacuo to give 
the complex as a red solid. Yield: 42 mg (71%). Crystals suitable 
for X-ray diffraction were grown by evaporation of a CH2Cl2 
solution of the product. 1H NMR (400 MHz, CDCl3) (δ, ppm): 
8.58 (d, 3JHH = 9.1 Hz, 1H, CH), 8.41 – 8.28 (m, 4H, CH), 8.24 (dd, 
3JHH = 8.4 Hz, 
4JHH = 
3.3 Hz, 2H, CH), 8.18 – 8.09 (m, 2H, CH), 6.16 (d, 1JHP = 392 Hz, 2H, PH2), 5.24 (d, 
3JHH 
= 5.0 Hz, 2H, CH), 5.00 (d, 3JHH = 5.8 Hz, 2H, CH), 2.65 (hept, 
3JHH = 7.0 Hz, 1H, 
CH(CH3)2, 2.00 (s, 3H, CH3), 1.13 (d, 
3JHH = 6.9 Hz, 6H, CH(CH3)2). 
31P{1H} NMR (162 
MHz, CDCl3) (δ, ppm): –26.4 (s, 1P). 
31P NMR (162 MHz, CDCl3) (δ, ppm): –26.4 (td, 
1JPH = 392 Hz, 
3JPH = 13 Hz). 
13C{1H} NMR (101 MHz, CDCl3) (δ, ppm): 134.0, 131.3, 
130.8, 129.7, 127.3, 127.0, 126.9, 126.7, 125.6, 124.8, 124.2, 87.6 (d, JCP = 5.3 Hz), 86.7 (d, 
JCP = 3.8 Hz), 30.7, 22.2, 18.6. HRMS (ESI): m/z calculated for [M–Cl–HCl]
•+ = 
469.0659, found 469.0657. 
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6.4.8 Synthesis of [RuCl(η6-p-cym)(DPPP)] complex, 4.16 
Following an adapted literature procedure.253 A mixture of [(η6-p-
cymene)RuCl2]2 (31 mg, 0.050 mmol), DPPP (39 mg, 0.105 mmol), 
and NaOAc (16 mg, 0.200 mmol) in MeOH (10 mL) was stirred 
at room temperature for 1 h. The solvent was removed in vacuo and 
the residue was purified by silica column chromatography (50% 
petroleum ether/Et2O). The yellow band was collected and 
concentrated in vacuo to give the product as a yellow solid. Yield: 46 mg (70%). 1H NMR 
(400 MHz, CDCl3) (δ, ppm): 8.94 (s, 1H, CH), 8.21 – 8.11 (m, 6H, CH), 8.11 – 8.05 (m, 
2H, CH), 8.02 – 7.96 (m, 1H, CH), 7.49 – 7.40 (m, 3H, CH), 7.39 – 7.28 (m, 3H, CH), 
7.24 – 7.16 (m, 2H, CH), 6.03 – 5.90 (m, 2H, CH), 4.63 (ddt, 3JHP = 24.3 Hz, 
3JHH = 6.2 
Hz, 4JHH = 1.6 Hz, 2H, CH), 2.51 (hept, 
3JHH = 7.2 Hz, 1H, CH(CH3)2), 1.98 (s, 3H, CH3), 
1.08 (d, 3JHH = 6.9 Hz, 3H, CH(CH3)2), 0.75 (d, 
3JHH = 6.9 Hz, 3H, CH(CH3)2). 
31P{1H} 
NMR (162 MHz, CDCl3) (δ, ppm): 67.1 (s, 1P). HRMS (Nanospray): m/z calculated 
for C38H32PRu [M–Cl]
•+ = 621.1285, found 621.1292. 
6.4.9 Synthesis of [RuCl2(η6-p-cym)(L4.2)] complex, 4.17 
A solution of [(η6-p-cymene)RuCl2]2 (47 mg, 0.080 mmol) 
and L4.2 (70 mg, 0.155 mmol) in CH2Cl2 (10 mL) was 
stirred at room temperature. After 1 h the solvent was 
removed in vacuo to give the complex as a red solid. Yield: 
32 mg (31%). 1H NMR (400 MHz, CD2Cl2) (δ, ppm): 8.49 
– 8.43 (m, 3H, CH), 8.21 (d, 3JHH = 7.8 Hz, 4H, CH), 8.16 
– 8.04 (m, 6H, CH), 8.00 (d, 1JHP = 401 Hz, 1H, PH), 8.01 – 7.91 (m, 4H, CH), 5.48 (d, 
3JHH = 5.8 Hz, 2H, CH), 5.39 (d, 
3JHH = 5.8 Hz, 2H, CH), 2.49 (hept, 
3JHH = 7.0 Hz, 1H, 
CH(CH3)2), 1.99 (s, 3H, CH3), 0.80 (d, 
3JHH = 6.9 Hz, 6H, CH(CH3)2). 
31P{1H} NMR (162 
MHz, CD2Cl2) (δ, ppm): 5.2 (br. s, 1P). 
31P NMR (162 MHz, CD2Cl2) (δ, ppm): 5.2 (d, 
1JPH 
= 405 Hz). 13C{1H} NMR (101 MHz, CD2Cl2) (δ, ppm): 134.0 (d, JCP = 2.3 Hz), 133.9 (d, 
JCP = 15.4 Hz), 132.9 (d, JCP = 2.4 Hz), 131.6, 130.8, 129.8, 129.5, 127.8, 127.0, 126.8 (d, 
JCP = 3.4 Hz), 125.5 (d, JCP = 6.0 Hz), 125.4 (d, JCP = 7.0 Hz), 124.9, 124.8, 124.7, 108.8, 
98.7, 88.7 (d, JCP = 4.8 Hz), 86.8 (d, JCP = 5.2 Hz), 30.9, 21.9, 18.3. HRMS (ESI): m/z 
calculated for C42H32PRu [M–Cl–HCl]
•+ = 669.1285, found 669.1290. 
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6.4.10 Synthesis of [(DPPP)AuCl] complex, 4.22 
A solution of [(tht)AuCl] (32 mg, 0.110 mmol) and 1-
pyrenyldiphenylphosphine, DPPP (39 mg, 0.110 mmol) in CH2Cl2 
(10 mL) was stirred at room temperature. After 7 h, the product was 
precipitated from hexane, then filtered off and then dried in vacuo. 
Yield: 42 mg (68%). Spectroscopic data matched that previously 
reported.312 1H NMR (400 MHz, CDCl3) (δ, ppm): 8.72 (dd, 
3JHH = 
9.2 Hz, 4JHH = 1.5 Hz, 1H), 8.28 (dd, 
3JHH = 10.9 Hz, 
3JHH = 7.6 Hz, 2H), 8.20 (t, 
3JHH = 
8.3 Hz, 2H), 8.16 – 8.04 (m, 4H), 7.69 – 7.54 (m, 5H), 7.53 – 7.41 (m, 5H). 31P{1H} NMR 
(162 MHz, CDCl3) (δ, ppm): 27.5 (s, 1P). 
6.4.11 Synthesis of Ph2PCH2CH2P(Pyr)2, L4.4 
Mg turnings (54 mg, 2.2 mmol) and one crystal of 
I2 were stirred under nitrogen. THF (10 mL) was 
added and a solution of 1-bromopyrene (562 mg, 
2.00 mmol) in THF (5 mL) was added slowly to 
maintain reflux. The Grignard reagent was added 
to a solution of Ph2PCH2CH2PCl2 (315 mg, 1.00 
mmol) in THF (10 mL) dropwise at –78 °C. The yellow suspension was warmed to room 
temperature and stirred for 1 h. The reaction was quenched with degassed water (5 mL), 
the organic layer was separated, dried over MgSO4 and the product was precipitated by 
addition of EtOH. The product was filtered off and dried in vacuo to give L4.4 as a pale 
yellow solid. Yield: 170 mg (26%). 1H NMR (400 MHz, CDCl3) (δ, ppm): 8.96 (dd, 
3JHH 
= 9.2 Hz, 4JHH = 5.0 Hz, 2H), 8.18 (dt, 
3JHH = 8.0 Hz, 
4JHH = 4.2 Hz, 6H), 8.12 – 7.96 (m, 
11H), 7.79 (dd, 3JHH = 7.9 Hz, 
4JHH = 3.8 Hz, 2H), 7.35 – 7.20 (m, 7H), 2.54 (q, 
3JHH = 8.0 
Hz, 2H), 2.31 (q, 3JHH = 8.0 Hz, 2H).
31P{1H} NMR (162 MHz, CDCl3) (δ, ppm): –11.8 
(d, 3JPP = 36 Hz), –34.4 (d, 
3JPP = 36 Hz). 
13C{1H} NMR (101 MHz, CDCl3) (δ, ppm): 
138.2 (d, JCP = 13.6 Hz), 134.4 (d, JCP = 22.8 Hz), 133.0, 132.8, 131.8, 131.4, 131.0, 129.4, 
128.8, 128.6, 128.5, 128.2, 127.9, 127.4, 126.1, 125.6, 125.5, 125.2, 125.0, 24.7 – 24.2 (m, 
CH2), 24.2 – 23.7 (m, CH2). HRMS (MALDI): m/z calculated for C47H33P2 [M+H]
•+ = 
647.1979, found 647.1965. 
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6.4.12 Fluorescence quantum yield measurements, Φf 
Quantum yields were determined relative to quinine sulfate (λex = 350 nm) in 0.1 M H2SO4 
as a standard (Φf = 0.58).
216 Absorbance measurements were recorded on an Agilent Cary 
300 spectrophotometer against a solvent reference. Quantum yield measurements require 
the absorbance (optical density) of the solution at the absorption maxima to be < 0.1, 
thus appropriate sample concentrations were selected (2 – 20 µM). Limiting the 
absorbance to < 0.1 minimizes non-linear effects arising from inner filter (re-absorption) 
effects, which may otherwise skew the resulting quantum yield.313 Fluorescence 
measurements were recorded on a Perkin Elmer LS-45 fluorescence spectrometer in 
capped quartz cuvettes in deaerated solvent.  
Fluorescence quantum yields were calculated according to the following equation:  










m = gradient of the plot of integrated fluorescence intensity against absorbance, and 
η = refractive index of the solvent, taken as 1.343 for 0.1 M H2SO4 and 1.424 for CH2Cl2. 
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6.5 Experimental procedures and characterising data for Chapter 5 – 
Non-symmetric PCP metallacycles for alkylation catalysis 
6.5.1 Experimental procedures and characterising data for aminophosphines 
6.5.1.1 Synthesis of 1,3-(tBu2PNH)2(C6H4), L5.1 
Following an adapted literature procedure.131 A solution of 1,3-
diaminobenzene (324 mg, 3.00 mmol) in THF (30 mL) was cooled to 
0 °C and nBuLi (8.25 mL, 1.6 M in hexane, 6.60 mmol) was added. 
After stirring the mixture at room temperature for 1 h, the mixture 
was cooled to 0 °C and then tBu2PCl (1.25 mL, 6.60 mmol) was added. The solution was 
heated under reflux for 48 h, the volatiles were removed in vacuo and hexane was added 
to precipitate LiCl. The solution was then filtered, and the solvent removed in vacuo to 
give the product as an orange solid. Yield: 930 mg (78%). Spectroscopic data matched 
that previously reported. 1H NMR (400 MHz, CD2Cl2) (δ, ppm): 6.85 (t, 
3JHH = 8.0 Hz, 
1H, CH), 6.71 – 6.67 (m, 1H, CH), 6.35 – 6.30 (m, 2H, CH), 1.10 (d, 3JHP = 11.7 Hz, 36H, 
PC(CH3)3). 
31P{1H} NMR (162 MHz, CD2Cl2) (δ, ppm): 58.2 (s, 2P). 
6.5.1.2 Synthesis of 1-(tBu2PNH)-3-(tBu2PNHCH2)(C6H4), L5.2 
A solution of 3-aminobenzylamine (1.47 g, 12.0 mmol) in THF (150 
mL) was cooled to 0 °C and nBuLi (33.0 mL, 1.6 M in hexane, 26.4 
mmol) was added. After stirring the mixture at room temperature for 
1 h, the mixture was cooled to 0 °C and tBu2PCl (5.01 mL, 26.4 mmol) 
was added. The solution was heated under reflux for 48 h, the volatiles were removed in 
vacuo, and hexane was added before filtration and evaporation. The residue was then 
dissolved in hot hexane, filtered and the solvent removed in vacuo to give the product as 
an orange oil. Yield: 2.55 g (52%). 1H NMR (400 MHz, CDCl3) (δ, ppm): 7.10 (t, 
3JHH = 
7.7 Hz, 1H, CH), 7.00 (m, 1H, CH), 6.88 – 6.83 (m, 1H, CH), 6.74 (dt, 3JHH = 7.4 Hz, 
4JHH 
= 1.3 Hz, 1H, CH), 4.08 (d, 3JHP = 6.3 Hz, 2H, CH2), 1.13 (d, 
3JHP = 8.7 Hz, 18H, 
PC(CH3)3)), 1.10 (d, 
3JHP = 8.4 Hz, 18H, PC(CH3)3). 
31P{1H} NMR (162 MHz, CDCl3) (δ, 
ppm): 81.6 (s, 1P, CH2NHP
tBu2), 59.3 (s, 1P, NHP
tBu2). 
13C{1H} NMR (100 MHz, CDCl3) 
(δ, ppm): 149.5 (d, 2JCP = 16.7 Hz, CNH), 144.0 (d, 
3JCP = 9.6 Hz, CCH2), 129.1 (s, CH), 
117.6 (s, CH), 115.2 (d, 3JCP = 12.1 Hz, CH), 114.6 (d, 
3JCP = 11.3 Hz, CH), 55.2 (d, 
2JCP = 
30.1 Hz, CH2), 34.4 (d, 
1JCP = 18.8 Hz, C(CH3)3), 34.3 (d, 
1JCP = 19.4 Hz, C(CH3)3), 28.5 
(d, 2JCP = 14.6 Hz, C(CH3)3), 28.2 (d, 
2JCP = 15.1 Hz, C(CH3)3). HRMS (ESI): m/z 
calculated for C23H45N2P2 [M+H]
•+ = 411.3013, found 411.3037.  
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6.5.1.3 Synthesis of 1,3-(tBu2PNHCH2)2(C6H4), L5.3 
A solution of m-xylylenediamine (0.33 mL, 2.5 mmol) in THF (30 mL) 
was cooled to 0 °C and nBuLi (9.01 mL, 1.6 M in hexane, 7.25 mmol) 
was added. After stirring the mixture at room temperature for 3 h, the 
mixture was cooled to 0 °C and tBu2PCl (1.05 mL, 5.50 mmol) was 
added. The solution was heated under reflux for 48 h before the volatiles were removed 
in vacuo and hexane was added. The residue was then dissolved in hot hexane, filtered and 
the solvent removed in vacuo to give the product as a white solid. Yield: 670 mg (63%). 1H 
NMR (400 MHz, CDCl3) (δ, ppm): 7.33 (s, 1H, CH), 7.31 – 7.21 (m, 3H, CH), 4.15 (t, 
3JHP = 6.4 Hz, 4H, CH2), 1.11 (d, 
3JHP = 11.4 Hz, 36H, C(CH3)3). 
31P{1H} NMR (162 MHz, 
CDCl3) (δ, ppm): 81.6 (s, 2P). 
13C{1H} NMR (100 MHz, CDCl3) (δ, ppm): 143.0 (d, 
3JCP 
= 10.0 Hz, CCH2), 128.5 (s, CH), 127.0 (s, CH), 126.24 (s, CH), 55.23 (d, 
2JCP = 29.9 Hz, 
CH2), 34.42 (d, 
1JCP = 19.0 Hz, C(CH3)3), 28.51 (d, 
2JCP = 14.6 Hz, C(CH3)3). HRMS 
(Nanospray): m/z calculated for C24H47N2P2 [M]
•+ = 425.3214, found 425.3226. 
6.5.1.4 Synthesis of 1,3-(iPr2PNH)2(C6H4), L5.4 
Following an adapted literature procedure.144 A solution of 1,3-
diaminobenzene (433 mg, 4.00 mmol) and DMAP (977 mg, 8.00 
mmol) were combined in THF (40 mL). After stirring the mixture at 
room temperature for 10 min, iPr2PCl (1.27 mL, 8.00 mmol) was 
added. The solution immediately turned cloudy and was stirred at room temperature for 
2 h, the volatiles were removed in vacuo and the product was extracted into toluene. The 
solution was then filtered through Celite, and the solvent removed in vacuo to give the 
product as a white solid. Yield: 1.23 g (90%). Spectroscopic data matched that previously 
reported. 31P{1H} NMR (162 MHz, CD2Cl2) (δ, ppm): 46.0 (s, 2P). 
6.5.1.5 Synthesis of 1-(iPr2PNH)-3-(iPr2PNHCH2)(C6H4), L5.5 
A solution of 3-aminobenzylamine (977 mg, 8.00 mmol) and DMAP 
(1.96 g, 16.00 mmol) were combined in THF (60 mL). After stirring 
the mixture at room temperature for 10 min, iPr2PCl (2.55 mL, 16.00 
mmol) was added. The solution immediately turned cloudy and was 
stirred at room temperature for 2 h, the volatiles were removed in vacuo and the product 
was extracted into toluene. The solution was then filtered through Celite, and the solvent 
removed in vacuo to give the product as a white solid. Yield: 2.29 g (81%). 1H NMR (400 
MHz, CD2Cl2) (δ, ppm): 7.06 (t, 
3JHH = 7.8 Hz, 1H, CH), 6.98 (q, 
3JHH = 2.1 Hz, 1H, CH), 
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6.87 – 6.79 (m, 1H, CH), 6.69 (d, 3JHH = 7.5 Hz, 1H, CH), 4.02 (t, 
3JHH = 6.7 Hz, 1H, CH2), 
1.77 (hept, 3JHH = 7.0 Hz, 2H, PCH(CH3)2)), 1.66 (hept, 
3JHH = 7.0 Hz, 2H, PCH(CH3)2)), 
1.27 – 1.14 (m, 4H, PCH(CH3)2)), 1.13 – 1.01 (m, 20H, PCH(CH3)2)). 
31P{1H} NMR (162 
MHz, CD2Cl2) (δ, ppm): 67.9 (s, 1P, CH2NHP
iPr2), 49.1 (s, 1P, NHP
iPr2). 
13C{1H} NMR 
(100 MHz, CD2Cl2) (δ, ppm): 149.9 (d, 
2JCP = 15.9 Hz, CNH), 144.7 (d, 
3JCP = 7.7 Hz, 
CCH2), 129.4 (s, CH), 117.9 (s, CH), 115.4 (d, 
3JCP = 12.1 Hz, CH), 114.8 (d, 
3JCP = 11.6 
Hz, CH), 53.5 (d, 2JCP = 24.9 Hz, CH2), 27.3 (dd, 
1JCP = 12.0 Hz, CH(CH3)2), 19.6 (d, 
2JCP 
= 20.3 Hz, CH(CH3)2), 19.2 (d, 
2JCP = 20.0 Hz, CH(CH3)2), 17.9 (d, 
2JCP = 7.8 Hz, 
CH(CH3)2), 17.4 (d, 
2JCP = 7.9 Hz, CH(CH3)2). HRMS (ESI): m/z calculated for 
C19H37N2P2 [M+H]
•+ = 355.2426, found 355.2442. 
6.5.1.6 Synthesis of 1,3-(iPr2PNHCH2)2(C6H4), L5.6 
A solution of m-xylylenediamine (0.264 mL, 2.00 mmol) and DMAP 
(489 mg, 4.00 mmol) were combined in THF (20 mL). After stirring 
the mixture at room temperature for 10 min, iPr2PCl (0.637 mL, 4.00 
mmol) was added. The solution immediately turned cloudy and was 
stirred at room temperature for 2 h, the volatiles were removed in vacuo and the product 
was extracted into toluene. The solution was then filtered through Celite, and the solvent 
removed in vacuo to give the product as a white solid. Yield: 580 mg (79%). 1H NMR (400 
MHz, CD2Cl2) (δ, ppm): 7.33 – 7.30 (m, 1H, CH), 7.28 – 7.22 (m, 1H, CH), 7.22 – 7.16 
(m, 2H, CH), 4.10 (t, 3JHH = 7.0 Hz, 4H, CH2), 1.66 (hept, 
3JHH = 7.0 Hz, 4H, PCH(CH3)2)), 
1.13 – 0.98 (m, 24H, PCH(CH3)2)). 
31P{1H} NMR (162 MHz, CD2Cl2) (δ, ppm): 68.0 (s, 
2P). 13C{1H} NMR (100 MHz, CD2Cl2) (δ, ppm): 143.7 (d, 
3JCP = 7.8 Hz, CCH2), 128.7 
(s, CH), 127.1 (s, CH), 126.4 (s, CH), 53.5 (d, 2JCP = 25.0 Hz, CH2), 27.3 (d, 
1JCP = 12.2 
Hz, CH(CH3)2), 19.6 (d, 
2JCP = 20.1 Hz, CH(CH3)2), 17.9 (d, 
2JCP = 7.9 Hz, CH(CH3)2). 
HRMS (ESI): m/z calculated for C20H39N2P2 [M+H]
•+ = 369.2595, found 369.2595.  
6.5.1.7 Synthesis of 1,3-(Ph2PNH)2(C6H4), L5.7 
Following an adapted literature procedure.144 A solution of 1,3-
diaminobenzene (433 mg, 4.00 mmol) and DMAP (977 mg, 8.00 
mmol) were combined in THF (40 mL). After stirring the mixture at 
room temperature for 10 min, Ph2PCl (1.43 mL, 8.00 mmol) was 
added. The solution immediately turned cloudy and was stirred at room temperature for 
2 h, the volatiles were removed in vacuo and the product was extracted into toluene. The 
solution was then filtered through Celite, and the solvent removed in vacuo to give the 
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product as a white solid. Yield: 1.55 g (82%). Spectroscopic data matched that previously 
reported. 31P{1H} NMR (162 MHz, CD2Cl2) (δ, ppm): 24.8 (s, 2P). 
6.5.1.8 Synthesis of 1-(Ph2PNH)-3-(Ph2PNHCH2)(C6H4), L5.8 
A solution of 3-aminobenzylamine (733 mg, 6.00 mmol) and DMAP 
(1.47 g, 12.00 mmol) were combined in THF (60 mL). After stirring 
the mixture at room temperature for 10 min Ph2PCl (2.15 mL, 12.00 
mmol) was added. The solution immediately turned cloudy and was 
stirred at room temperature for 2 h, the volatiles were removed in vacuo and the product 
was extracted into toluene. The solution was then filtered through Celite, and the solvent 
removed in vacuo to give the product as a white solid. Yield: 2.47 g (84%). 1H NMR (400 
MHz, CD2Cl2) (δ, ppm): 7.50 – 7.41 (m, 8H, PPh2), 7.41 – 7.36 (m, 6H, PPh2), 7.36 – 7.30 
(m, 6H, PPh2), 7.11 (t, 
3JHH = 7.8 Hz, 1H, CH), 6.96 (q, 
3JHH = 2.1 Hz, 1H, CH), 6.89 (dt, 
3JHH = 8.0 Hz, 
5JHH = 2.2 Hz, 1H, CH), 6.73 (dt, 
3JHH = 7.6 Hz, 
5JHH = 1.3 Hz, 1H, CH), 
4.01 (app. t, 3JHH = 8.1 Hz, 2H, CH2). 
31P{1H} NMR (162 MHz, CD2Cl2) (δ, ppm): 42.7 
(s, 1P, CH2NHPPh2), 27.9 (s, 1P, NHPPh2). 
13C{1H} NMR (101 MHz, CD2Cl2) (δ, ppm): 
142.1 (d, 2JCP = 13.1 Hz, CNH), 140.8 (d, 
2JCP = 12.2 Hz, CCH2), 132.0 (s, CH), 131.8 (d, 
JCP = 1.7 Hz, CH), 131.5 (s, CH), 129.7 (s, CH), 129.2 – 128.9 (m, PPh2), 128.9 – 128.6 
(m, PPh2), 119.0 (s, CH), 115.5 (d, JCP = 13.0 Hz, CH), 115.0 (d, JCP = 13.2 Hz, CH), 50.7 
(d, 2JCP = 15.6 Hz, CH2). HRMS (ESI): m/z calculated for C31H29N2P2 [M+H]
•+ = 
491.1800, found 491.1790. 
6.5.1.9 Synthesis of 1,3-(Ph2PNHCH2)2(C6H4), L5.9 
A solution of m-xylylenediamine (0.264 mL, 2.00 mmol) and DMAP 
(489 mg, 4.00 mmol) were combined in THF (20 mL). After stirring 
the mixture at room temperature for 10 min, Ph2PCl (0.718 mL, 4.00 
mmol) was added. The solution immediately turned cloudy and was 
stirred at room temperature for 2 h, the volatiles were removed in vacuo and the product 
was extracted into toluene. The solution was then filtered through Celite, and the solvent 
removed in vacuo to give the product as a white solid. Yield: 550 mg (55%). 1H NMR (400 
MHz, CD2Cl2) (δ, ppm): 7.49 – 7.40 (m, 8H, PPh2), 7.39 – 7.30 (m, 12H, PPh2), 7.24 – 
7.19 (m, 1H, CH), 7.17 – 7.10 (m, 3H, CH), 4.12 – 3.97 (m, 4H, CH2). 
31P{1H} NMR 
(162 MHz, CD2Cl2) (δ, ppm): 42.7 (s, 2P). 
13C{1H} NMR (100 MHz, CD2Cl2) (δ, ppm): 
142.5 (d, 3JCP = 6.5 Hz, CCH2), 142.1 (d, 
3JCP = 13.1 Hz, CCH2), 131.9 (d, 
1JCP = 19.7 Hz, 
PPh2), 129.0 (s, CH), 128.9 (s, CH), 128.8 (d, 
3JCP = 6.3 Hz, CH), 127.3 (s, CH), 126.6 (s, 
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CH), 50.7 (d, 2JCP = 15.7 Hz, CH2). HRMS (ESI): m/z calculated for C32H31N2P2 [M+H]
•+ 
= 505.1962, found 505.1971.  
6.5.2 Experimental procedures and characterising data for PCP coordination 
compounds 
6.5.2.1 Synthesis of [(L5.1)PdCl] complex, 5.8 
A solution of L5.1 (150 mg, 0.40 mmol) and [PdCl2(cod)] (86 mg, 0.30 
mmol) in toluene (15 mL) was heated under reflux for 18 h. After in 
situ 31P{1H} NMR showed complete conversion to the target 
complex, the mixture was cooled, and volatiles removed in vacuo to 
give the product as a yellow solid. Yield: 156 mg (97%). Spectroscopic data matched that 
previously reported.314 1H NMR (400 MHz, CDCl3) (δ, ppm): 6.71 (tt, 
3JHH = 7.7 Hz, 
5JHH 
= 1.4 Hz, 1H, CH), 6.11 (d, 3JHH = 7.7 Hz, 2H, CH), 4.16 (s, 2H, NH), 1.41 (app. t, 
3JHP 
= 7.3 Hz, 36H, C(CH3)3). 
31P{1H} NMR (162 MHz, CDCl3) (δ, ppm): 119.5 (s, 2P). 
HRMS (ESI): m/z calculated for C22H41N2P2Pd [M–Cl]
•+ = 501.1780, found 501.1781. 
6.5.2.2 Synthesis of [(L5.2)PdCl] complex, 5.9 
A solution of L5.2 (111 mg, 0.27 mmol) and [PdCl2(NCPh)2] (58 mg, 
0.15 mmol) in CH2Cl2 (10 mL) was stirred for 1 h at room 
temperature. After in situ 31P{1H} NMR showed complete 
conversion to the target complex, hexane was added, the mixture 
was filtered, and the volatiles removed in vacuo to give the product as a yellow solid. Yield: 
70 mg (84%). Crystals suitable for X-ray diffraction were grown by evaporation of a 
CH2Cl2 solution of the product. 
1H NMR (400 MHz, CDCl3) (δ, ppm): 6.79 (t, 
3JHH = 7.5 
Hz, 1H, CH), 6.52 (d, 3JHH = 7.8 Hz, 1H, CH), 6.40 (d, 
3JHH = 7.2 Hz, 1H, CH), 4.09 (s, 
1H, NH), 3.94 (d, 3JHP = 19.4 Hz, 2H, CH2), 1.40 (app. t, 
3JHP = 14.6 Hz, 36H, C(CH3)3). 
31P{1H} NMR (162 MHz, CDCl3) (δ, ppm): 122.2 (d, 
2JPP = 406 Hz, NHP
tBu2), 89.7 (d, 
2JPP = 406 Hz, CH2NHP
tBu2). 
13C{1H} NMR (100 MHz, CDCl3) (δ, ppm): 142.0 (d, 
3JCP 
= 8.0 Hz, quat. C), 127.6 (s, quat. C), 126.1 (s, CH), 118.4 (s, CH), 109.4 (d, 3JCP = 14.3 
Hz, CH), 57.1 (d, 2JCP = 10.1 Hz, CH2), 38.7 (dd, 
1JCP = 10.9 Hz, 
3JCP = 4.7 Hz, C(CH3)3), 
38.3 (dd, 1JCP = 15.7 Hz, 
3JCP = 4.8 Hz, C(CH3)3), 30.0 (d, 
2JCP = 5.1 Hz, C(CH3)3), 28.9 (d, 
2JCP = 5.2 Hz, C(CH3)3). HRMS (ESI): m/z calculated for C23H44N2P2ClPd [M+H]
•+ = 
551.1703, found 551.1709.  
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6.5.2.3 Synthesis of [(L5.3)PdCl] complex, 5.10 
A solution of L5.3 (212 mg, 0.50 mmol) and [PdCl2(cod)2] (143 mg, 
0.50 mmol) in toluene (10 mL) was stirred for 18 h at 100 °C. After 
in situ 31P{1H} NMR showed complete conversion to the target 
complex, the solvent was removed in vacuo and the complex 
extracted into hexane. The hexane solution was then concentrated in vacuo and the 
precipitate was filtered off and dried to give the product as a pale-yellow solid. Yield: 142 
mg (50%). Crystals suitable for X-ray diffraction were grown by evaporation of a hexane 
solution of the product. 1H NMR (500 MHz, CD2Cl2) (δ, ppm): 6.87 (m, 1H, CH), 6.78 
(d, 3JHH = 7.2 Hz, 2H, CH), 4.13 – 3.99 (m, 4H, CH2), 1.60 (t, 
3JHP = 6.9 Hz, 18H, C(CH3)3), 
0.98 (t, 3JHP = 7.0 Hz, 18H, C(CH3)3). 
31P{1H} NMR (162 MHz, CD2Cl2) (δ, ppm): 89.9 
(s, 2P). 13C{1H} NMR (100 MHz, CD2Cl2) (δ, ppm): 144.5 (t, 
2JCP = 5.2 Hz, quat. C), 129.5 
(quat. C), 124.7 (CH), 124.7 (CH), 59.3 (t, 2JCP = 6.0 Hz, CH2), 29.9 (br. s, C(CH3)3), 29.6 
(t, 2JCP = 3.7 Hz, C(CH3)3). HRMS (ESI): m/z calculated for C24H44N2P2ClPd [M–H]
•+ = 
563.1703, found 563.1713.  
6.5.2.4 Synthesis of [(L5.1)Pd(TFA)] complex, 5.17 
 A solution of L5.1 (119 mg, 0.30 mmol) and [Pd(TFA)2] (100 
mg, 0.30 mmol) in THF (10 mL) was stirred for 4 h at room 
temperature. After in situ 31P{1H} NMR showed complete 
conversion to the target complex, the solvent was removed in 
vacuo and the complex extracted into hexane. The hexane solution was concentrated in 
vacuo and the precipitate was filtered off and dried to give the product as a yellow solid. 
Yield: 65 mg (35%). Spectroscopic data matched that previously reported.314 1H NMR 
(400 MHz, CD2Cl2) (δ, ppm): 6.73 (tt, 
3JHH = 7.8 Hz, 
5JHH  = 1.4 Hz, 1H, CH), 6.09 (d, 
3JHH = 7.8 Hz, 2H, CH), 4.15 (s, 2H, NH), 1.40 – 1.32 (m, 36H, C(CH3)3). 
31P{1H} NMR 
(162 MHz, CD2Cl2) (δ, ppm): 119.9 (s, 2P). HRMS (Nanospray): m/z calculated for 
C24H42F3N2O2P2Pd [M+H]
•+ = 615.1708, found 615.1713.  
6.5.2.5 Synthesis of [(L5.2)Pd(TFA)] complex, 5.18 
A solution of L5.2 (124 mg, 0.30 mmol) and [Pd(TFA)2] (100 
mg, 0.30 mmol) in THF (10 mL) was stirred for 4 h at room 
temperature. After in situ 31P{1H} NMR showed complete 
conversion to the target complex, the solvent was removed in 
vacuo and the complex extracted into hexane. The hexane solution was concentrated in 
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vacuo and the precipitate was filtered off and dried to give the product as a grey solid. Yield: 
142 mg (76%). 1H NMR (400 MHz, CD2Cl2) (δ, ppm): 6.84 – 6.76 (m, 1H, CH), 6.49 (dd, 
3JHH = 7.7 Hz, 
5JHH = 1.4 Hz, 1H, CH), 6.42 (ddd, 
3JHH = 7.3 Hz, 
4JHH = 2.3, 
5JHH = 1.4 
Hz, 1H, CH), 3.95 (d, 3JHP = 19.8 Hz, 2H, CH2), 1.34 (d, 
3JHP = 14.1 Hz, 18H, C(CH3)3), 
1.27 (d, 3JHP = 13.7 Hz, 18H, C(CH3)3). 
31P{1H} NMR (162 MHz, CD2Cl2) (δ, ppm): 125.9 
(d, 2JPP = 367 Hz, NHP
iPr2), 92.7 (d, 
2JPP = 367 Hz, CH2NHP
iPr2). 
13C{1H} NMR (101 
MHz, CD2Cl2) (δ, ppm): 159.0 (app. d, 
2JCP = 23.5 Hz), 142.9 (d, 
3JCP = 8.4 Hz, quat. C), 
127.6 (s, quat. C), 126.6 (s, CH), 118.7 (s, CH), 109.4 (d, 3JCP = 14.3 Hz, CH), 57.4 (d, 
2JCP 
= 10.8 Hz, CH2), 38.7 (dd, 
1JCP = 10.9 Hz, 
3JCP = 4.7 Hz, C(CH3)3), 38.3 (dd, 
1JCP = 15.7 
Hz, 3JCP = 4.8 Hz, C(CH3)3), 29.2 (d, 
2JCP = 5.7 Hz, C(CH3)3), 28.6 (d, 
2JCP = 6.1 Hz, 
C(CH3)3). HRMS (Nanospray): m/z calculated for C25H42F3N2O2P2Pd [M–H]
•+ = 
627.1708, found 627.1703. m/z calculated for C24H43N2P2Pd [M–TFA]
•+ = 515.1936, 
found 515.1991.  
6.5.2.6 Synthesis of [(L5.3)Pd(TFA)] complex, 5.19 
A solution of L5.3 (127 mg, 0.30 mmol) and [Pd(TFA)2] (100 
mg, 0.30 mmol) in THF (10 mL) was stirred for 4 h at room 
temperature. After in situ 31P{1H} NMR showed complete 
conversion to the target complex, the solvent was removed 
in vacuo and the complex extracted into hexane. The hexane solution was concentrated in 
vacuo and the precipitate was filtered off and dried to give the product as a yellow solid. 
Yield: 95 mg (49%). 1H NMR (400 MHz, CD2Cl2) (δ, ppm): 6.90 (dd, 
3JHP = 7.7 Hz, 
3JHP 
= 6.7 Hz, 1H, CH), 6.78 (d, 3JHP = 7.2 Hz, 2H, CH), 4.25 – 4.04 (m, 4H, CH2), 1.37 (app. 
t (1:1:1), 18H, C(CH3)3), 0.92 (app. t (1:1:1), 18H, C(CH3)3). 
31P{1H} NMR (162 MHz, 
CD2Cl2) (δ, ppm): 92.7 (s, 2P). 
13C{1H} NMR (100 MHz, CD2Cl2) (δ, ppm): 144.5 (t, 
2JCP 
= 5.2 Hz, quat. C), 129.5 (quat. C), 124.7 (CH), 124.7 (CH), 59.3 (t, 2JCP = 6.0 Hz, CH2), 
29.9 (br. s, C(CH3)3), 29.6 (t, 
2JCP = 3.7 Hz, C(CH3)3). HRMS (Nanospray): m/z 
calculated for C24H45N2P2Pd [M–TFA]
•+ = 529.2093, found 529.2096. 
6.5.2.7 Synthesis of [(L5.5)Pd(TFA)] complex, 5.21 
A solution of L5.5 (106 mg, 0.30 mmol) in THF (2.5 mL) was 
added to a suspension of [Pd(TFA)2] (100 mg, 0.30 mmol) in 
THF (2.5 mL) and stirred for 20 min at room temperature. 
After in situ 31P{1H} NMR showed complete conversion to 
the target complex, the solvent was removed in vacuo and the complex extracted into 
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hexane. The hexane solution was concentrated in vacuo and the precipitate was filtered off 
and dried to give the product as a yellow solid. Yield: 115 mg (67%). 1H NMR (400 MHz, 
CD2Cl2) (δ, ppm): 6.80 (td, 
3JHH = 7.5 Hz, 
5JHH = 1.9 Hz, 1H, CH), 6.53 (dd, 
3JHH = 7.7 Hz, 
5JHH = 1.4 Hz, 1H, CH), 6.44 (dt, 
3JHH = 7.3 Hz, 
5JHH = 1.9 Hz, 1H, CH), 3.91 (d, 
3JHP = 
19.9 Hz, 2H, CH2), 2.38 – 2.27 (m, 2H, CH(CH3)2), 2.16 – 2.05 (m, 2H, CH(CH3)2), 1.34 
– 1.13 (m, 20H, CH(CH3)2), 1.04 (m, 4H, CH(CH3)2). 
31P{1H} NMR (162 MHz, CD2Cl2) 
(δ, ppm): 118.5 (d, 2JPP = 388 Hz, NHP
iPr2), 89.4 (d, 
2JPP = 388 Hz, CH2NHP
iPr2). 
13C{1H} 
NMR (100 MHz, CD2Cl2) (δ, ppm): 160.8 (q, JCF = 34.9 Hz, CO), 158.9 (d, JCP = 26.0 Hz, 
quat. C), 142.1 (dd, JCP = 11.5, 1.4 Hz, quat. C), 126.0 (s, CH), 118.4 (d, JCP = 1.2 Hz, CH), 
109.2 (d, JCP = 15.0 Hz, CH), 56.7 (d, 
2JCP = 11.4 Hz, CH2), 27.9 (dd, JCP = 19.9, 4.5 Hz, 
CH(CH3)2), 25.8 (dd, JCP = 24.5, 4.4 Hz, CH(CH3)2), 17.8 (dd, JCP = 11.0, 6.7 Hz, 
CH(CH3)2), 16.8 (dt, JCP = 20.4, 1.5 Hz, CH(CH3)2). HRMS (Nanospray): m/z calculated 
for C21H34N2O2F3P2Pd [M–H]
•+ = 571.1082, found 571.1075. 
6.5.2.8 Synthesis of [(L5.8)Pd(TFA)] complex, 5.24 
A solution of L5.8 (147 mg, 0.30 mmol) in THF (2.5 mL) was 
added to a suspension of [Pd(TFA)2] (100 mg, 0.30 mmol) in 
THF (2.5 mL) and stirred for 20 min at room temperature. 
After in situ 31P{1H} NMR showed complete conversion to 
the target complex, the solvent was removed in vacuo and the complex precipitated by 
addition of hexane. The precipitate was filtered off and dried to give the product as an 
orange solid. Yield: 188 mg (88%). 1H NMR (500 MHz, CD2Cl2) (δ, ppm): 7.58 – 7.30 
(m, 20H, PPh2), 6.91 (td, 
3JHH = 7.5 Hz, 
5JHH = 2.1 Hz, 1H, CH), 6.69 – 6.61 (m, 2H, CH), 
4.10 (d, 3JHP = 24.1 Hz, 2H, CH2). 
31P{1H} NMR (162 MHz, CD2Cl2) (δ, ppm): 88.5 (d, 
2JPP = 447 Hz, NHPPh2), 63.2 (d, 
2JPP = 447 Hz, CH2NHPPh2). 
13C{1H} NMR (126 MHz, 
CD2Cl2) (δ, ppm): 133.0 (d, JCP = 1.6 Hz, quat. C), 132.9 (quat C.), 131.6 (d, JCP = 2.5 Hz, 
quat C.), 129.1 (dd, JCP = 10.6 Hz, JCP = 5.7 Hz, CH), 111.1 (d, JCP = 16.6 Hz, CH), 107.7 
(s, CH), 54.8 (d, JCP = 12.7 Hz, CH2). HRMS (Nanospray): m/z calculated for 
C31H27N2P2Pd [M–TFA]
•+ = 595.0684, found 595.0685. 
6.5.2.9 Reaction of L5.5-L5.6 and L5.8-L5.9 with [PdCl2(cod)] or [PdCl2(NCPh)2] 
A solution of aminophosphine ligand (0.30 mmol) in THF (2.5 mL) was added to a 
solution of [PdCl2(cod)] or [PdCl2(NCPh)2] (0.30 mmol) in THF (2.5 mL) and heated 
under reflux. The mixtures quickly produced a highly insoluble orange precipitate. An in 
situ 31P{1H} NMR analysis of the soluble material did show formation of traces of the 
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target complexes, however pure materials could not be isolated. The Pd–Cl containing 
polymeric materials were not used further.  
6.5.3 Experimental procedure for allylic alkylation catalysis 
To a suspension of NaH (26 mg, 1.1 mmol) in THF (5 mL) was added dimethyl malonate 
(114 µL, 1.00 mmol). The mixture was stirred for 10 min and then transferred to a Schlenk 
tube with a stir bar containing the preformed Pd catalyst (0.03 mmol, 5 mol%) and 
cinnamyl acetate (83 µL, 0.50 mmol) in THF (5 mL). The tube was then stirred for the 
prescribed time at the temperature indicated. An aliquot was quenched by filtration 
through a silica plug and analysed by GC-MS using dodecane as an internal standard.  
6.5.4 Experimental procedures and characterising data for all-carbon pincer 
ligands and precursors 
6.5.4.1 Synthesis of 1,3-(CH2CH2OH)2(C6H4), 5.5 
Following an adapted literature procedure. A slurry of 
LiAlH4 (2.93 g, 77.3 mmol) in THF (50 mL) was heated 
under reflux for 30 mins. A solution of 1,3-C6H4(CH2CO2H)2 5.4 (5.00 g, 25.8 mmol) in 
THF (200 mL) was slowly added to the LiAlH4  mixture to maintain reflux. After 3 h, the 
mixture was quenched by the slow addition of ice-cold water (50 mL). The mixture was 
extracted with EtOAc (3 × 100 mL) and the combined organics were washed with water 
and then brine, then dried (MgSO4), filtered and concentrated in vacuo. Purification by 
silica column chromatography (0–50% EtOAc/hexane) to give the product as a white 
solid. Yield: 3.75 g (88%). Spectroscopic data matched that previously reported. 1H NMR 
(400 MHz, CD3OD) (δ, ppm): 7.20 (dd, 
3JHH = 8.1 Hz, 
4JHH = 6.9 Hz, 1H, CH), 7.12 – 
7.08 (m, 1H, CH), 7.06 (dd, 3JHH = 7.5 Hz, 
4JHH = 1.8 Hz, 2H, CH), 3.74 (t, 
3JHH = 7.1 Hz, 
4H, CH2), 2.79 (t, 
3JHH = 7.1 Hz, 4H, CH2). 
6.5.4.2 Synthesis of 1,3-(CH2CH2OTs)2(C6H4), 5.6 
Following an adapted literature procedure.315 To a 
solution of TsCl (629 mg, 3.30 mmol), DMAP (37 mg, 
0.30 mmol) and NEt3 (0.84 mL, 6.00 mmol) in CH2Cl2 (20 mL) at 0 °C was added a 
solution of 5.5 (250 mg, 1.50 mmol) in CH2Cl2 (8 mL). The mixture was warmed to room 
temperature and stirred for 18 h. The solution was then washed with sat. aq. NaHCO3 
and water. The combined aqueous layers were extracted with CH2Cl2, dried (Na2SO4), 
filtered and concentrated in vacuo. Purification by silica column chromatography (20% 
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EtOAc/hexane) to give the product as a pale-yellow oil. Yield: 472 mg (66%). 1H NMR 
(400 MHz, CDCl3) (δ, ppm): 7.76 – 7.64 (m, 4H, CH), 7.33 – 7.27 (m, 4H, CH), 7.15 (t, 
3JHH = 7.6 Hz, 1H, CH), 6.98 (dd, 
3JHH = 7.5 Hz, 
4JHH = 1.8 Hz, 2H, CH), 6.85 (s, 1H, 
CH), 4.18 (t, 3JHH = 7.0 Hz, 4H, CH2), 2.89 (t, 
3JHH = 7.1 Hz, 4H, CH2O), 2.43 (s, 6H, 
CH3). 
13C{1H} NMR (100 MHz, CDCl3) (δ, ppm): 144.9 (s, CH), 136.7 (s, CH), 133.1 (s, 
CH), 130.0 (s, CH), 129.6 (s, CH), 129.0 (s, CH), 128.0 (s, CH), 127.6 (s, CH), 70.5 (s, 
C6H4CH2), 35.3 (s, CH2O), 21.8 (s, CH3). 
6.5.4.3 Synthesis of 1,3-(CH2CH2PtBu2(BH3))2(C6H4), 5.7 
A solution of nBuLi (0.82 mL, 1.6 M in hexane, 1.30 
mmol) was added to tBu2PH(BH3) (160 mg, 1.00 mmol) 
in THF (20 mL) at –78 °C. After 30 min at room 
temperature the mixture was cooled to –78 °C and a solution of 5.6 (237 mg, 0.50 mmol) 
in THF (5 mL) was added and the mixture was heated under reflux for 1 h. After in situ 
31P{1H} NMR showed complete conversion to the borane protected product, the mixture 
was then filtered through a small pad of Celite in air. The volatiles were removed in vacuo 
to give the product as a white solid. Yield: 210 mg (93%). 1H NMR (400 MHz, CDCl3) 
(δ, ppm): 7.74 – 7.64 (m, 1H, CH), 7.12 – 7.03 (m, 2H, CH), 7.01 – 6.93 (m, 1H, CH), 
3.03 – 2.82 (m, 4H, CH2), 2.00 – 1.77 (m, 4H, CH2), 1.30 (d, 
3JHP = 12.4 Hz, 36H, C(CH3)3). 
31P{1H} NMR (162 MHz, CDCl3) (δ, ppm): 44.5 (br. s, 2P). HRMS (ESI): m/z calculated 
for C26H54B2P2 [M]
•+ =450.3887, found 456.3267.  
6.5.4.4 Attempted synthesis of 1,3-(CH2CH2PtBu2)2(C6H4), L5.10 
A solution of 5.7 (45 mg, 0.10 mmol) and DABCO 
(112 mg, 1.00 mmol) in hexane (10 mL) was heated 
under reflux for 18 h. After in situ 31P{1H} NMR showed complete conversion to the 
deprotected phosphine, the mixture was then filtered to remove the DABCO·BH3 
precipitate. The volatiles were removed in vacuo to give the product as a white solid. Yield: 
194 mg (93%). 31P{1H} NMR (162 MHz, CDCl3) (δ, ppm): 29.5 (s, 2P). 
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6.6 Computational details 
Calculations were performed using the Gaussian 09 (D.01) software package.264 Structures 
L4.1-L4.3, 4.5, 4.14, and 4.17 were optimised in the gas phase at the B3LYP/6-
31G(d)/LANL2DZ level of theory.269 TD-DFT was used to calculate the UV-visible 
absorption properties the CAM-B3LYP/6-31G(d)/LANL2DZ level of theory using a 
polarisable continuum model for CH2Cl2 (ε = 9.1) as solvent.
271 
6.7 X-ray crystallography 
The X-ray data presented in this thesis were collected by Dr Hazel Sparkes or Dr Natalie 
Pridmore at 100 K on a Bruker APEX II CCD diffractometer using Mo-Kα radiation (λ 
= 0.71073 Å). Intensities were integrated in SAINT316 and absorption corrections based 
on equivalent reflections were applied using SADABS.317 The structure was solved using 
ShelXT318 all of the structures were refined by full matrix least squares against F2 in 
ShelXL318,319 using Olex2320. Crystal structure and refinement data are given in Table 6.1.  
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Table 6.1. Crystal data.  
Identification code L2.11 [2.18]PF6 [2.20]Cl 
Empirical formula C36H26P2S3  C38H39ClF6N5P3Ru C32H44Cl2N4O2P2Ru  
Formula weight 616.69  909.17 750.62  
Temperature/K 100(2)  100(2) 100(2)  
Crystal system monoclinic  monoclinic orthorhombic  
Space group P21/c  P21/n Pbca  
a/Å 13.4695(7)  13.9014(6) 18.9394(4)  
b/Å 15.2008(9)  19.6282(9) 17.9554(4)  
c/Å 15.1890(9)  14.2188(6) 19.7240(4)  
α/° 90  90 90  
β/° 105.8130(10)  98.3870(10) 90  
γ/° 90  90 90  
Volume/Å3 2992.2(3)  3838.2(3) 6707.4(2)  
Z 4  4 8  
ρcalcg/cm
3 1.369  1.573 1.487  
μ/mm-1 0.380  0.669 0.758  
F(000) 1280.0  1848.0 3104.0  
Crystal size/mm3 0.406 × 0.269 × 0.192  0.392 × 0.288 × 0.14 0.414 × 0.367 × 0.134  
Radiation MoKα (λ = 0.71073)  MoKα (λ = 0.71073) MoKα (λ = 0.71073)  
2θ range for data 
collection/° 
3.866 to 56.04  3.562 to 55.748 3.746 to 55.962  
Index ranges 
-11 ≤ h ≤ 17,  
-19 ≤ k ≤ 20,  
-20 ≤ l ≤ 19  
-16 ≤ h ≤ 18, 
-25 ≤ k ≤ 25, 
-18 ≤ l ≤ 11 
-24 ≤ h ≤ 24,  
-22 ≤ k ≤ 23,  
-26 ≤ l ≤ 26  
Reflections collected 27175  34855 56675  
Rint / Rsigma 
7201 [Rint = 0.0617, 
Rsigma = 0.0603]  
0.0518 / 0.0516 
8062 [Rint = 0.0770, 
Rsigma = 0.0469]  
Data/restraints/parameters 7201/90/383  9143/132/560 8062/30/434  
Goodness-of-fit on F2 1.014  1.015 1.001  
Final R indexes [I>=2σ (I)] 
R1 = 0.0427,  
wR2 = 0.0854  
R1 = 0.0350, 
wR2 = 0.0695 
R1 = 0.0337,  
wR2 = 0.0676  
Final R indexes [all data] 
R1 = 0.0725,  
wR2 = 0.0970  
R1 = 0.0534, 
wR2 = 0.0762 
R1 = 0.0606,  
wR2 = 0.0771  
Largest diff. peak/hole /  
e Å-3 
0.43/-0.38  0.49/-0.55 0.83/-0.61  
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Table 6.1. Crystal data (cont.).  
Identification code 2.21 2.22 4.14 
Empirical formula C32H24Cl2N2P2Pt  C42H32Cl6N2P2Pt  C27H25Cl4PRu  
Formula weight 764.46  1034.42  623.31  
Temperature/K 100(2)  100(2)  100(2)  
Crystal system monoclinic  monoclinic  triclinic  
Space group P21/c  C2/c  P-1  
a/Å 10.4297(5)  17.4468(2)  11.5602(5)  
b/Å 14.3210(8)  14.3479(2)  16.3474(9)  
c/Å 19.6325(12)  17.6226(2)  16.9829(9)  
α/° 90  90  63.114(3)  
β/° 101.369(3)  114.3260(10)  71.058(3)  
γ/° 90  90  70.557(3)  
Volume/Å3 2874.8(3)  4019.72(9)  2640.8(2)  
Z 4  4  4  
ρcalcg/cm
3 1.766  1.709  1.568  
μ/mm-1 5.204  4.003  1.074  
F(000) 1488.0  2032.0  1256.0  
Crystal size/mm3 0.394 × 0.297 × 0.166  0.367 × 0.269 × 0.169  0.408 × 0.262 × 0.087  
Radiation MoKα (λ = 0.71073)  MoKα (λ = 0.71073)  MoKα (λ = 0.71073)  
2θ range for data 
collection/° 
4.232 to 55.908  3.824 to 55.782  2.748 to 50.7  
Index ranges 
-13 ≤ h ≤ 13,  
-18 ≤ k ≤ 18,  
-23 ≤ l ≤ 25  
-22 ≤ h ≤ 17,  
-18 ≤ k ≤ 18,  
-23 ≤ l ≤ 23  
-13 ≤ h ≤ 13,  
-19 ≤ k ≤ 18,  
-20 ≤ l ≤ 20  
Reflections collected 25595  18355  40153  
Rint / Rsigma 
6884 [Rint = 0.0261, 
Rsigma = 0.0243]  
4799 [Rint = 0.0301, 
Rsigma = 0.0298]  
9664 [Rint = 0.0966, 
Rsigma = 0.0921]  
Data/restraints/parameters 6884/0/352  4799/0/240  9664/1790/901  
Goodness-of-fit on F2 1.041  1.048  1.010  
Final R indexes [I>=2σ (I)] 
R1 = 0.0183,  
wR2 = 0.0381  
R1 = 0.0216,  
wR2 = 0.0442  
R1 = 0.0546,  
wR2 = 0.1170  
Final R indexes [all data] 
R1 = 0.0217,  
wR2 = 0.0389  
R1 = 0.0291,  
wR2 = 0.0466  
R1 = 0.1044,  
wR2 = 0.1385  
Largest diff. peak/hole /  
e Å-3 
0.53/-0.59  0.83/-0.77  0.82/-1.15  
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Table 6.1. Crystal data (cont.).  
Identification code 5.9 5.10  
Empirical formula C23H43ClN2P2Pd  C24H45ClN2P2Pd   
Formula weight 551.38  565.41   
Temperature/K 100.0  99.89   
Crystal system trigonal  monoclinic   
Space group P-3  P21/c   
a/Å 20.4582(5)  14.8440(3)   
b/Å 20.4582(5)  16.4594(4)   
c/Å 11.8658(3)  11.1260(3)   
α/° 90  90   
β/° 90  100.759(2)   
γ/° 120  90   
Volume/Å3 4300.9(2)  2670.56(11)   
Z 6  4   
ρcalcg/cm
3 1.277  1.406   
μ/mm-1 0.863  0.929   
F(000) 1728.0  1184.0   
Crystal size/mm3 0.422 × 0.34 × 0.114  0.384 × 0.227 × 0.076   
Radiation MoKα (λ = 0.71073)  MoKα (λ = 0.71073)   
2θ range for data 
collection/° 
3.432 to 60.282  3.732 to 54.898   
Index ranges 
-24 ≤ h ≤ 28,  
-28 ≤ k ≤ 28,  
-16 ≤ l ≤ 16  
-19 ≤ h ≤ 19,  
-21 ≤ k ≤ 16,  
-14 ≤ l ≤ 14  
 
Reflections collected 97401  45241   
Rint / Rsigma 
8483 [Rint = 0.0425, 
Rsigma = 0.0193]  
6097 [Rint = 0.0532, 
Rsigma = 0.0314]  
 
Data/restraints/parameters 8483/0/393  6097/0/291   
Goodness-of-fit on F2 1.028  1.033   
Final R indexes [I>=2σ (I)] 
R1 = 0.0225,  
wR2 = 0.0576  
R1 = 0.0250,  
wR2 = 0.0508  
 
Final R indexes [all data] 
R1 = 0.0266,  
wR2 = 0.0593  
R1 = 0.0370,  
wR2 = 0.0542  
 
Largest diff. peak/hole /  
e Å-3 
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